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Abstract 
Distinct characteristics, including decreased dependence on mitochondrial 
respiration and high levels of oxygen radicals, provide opportunities for cancer 
targeting. We have shown the compound pancratistatin (PST) to selectively 
induce apoptosis in cancers by mitochondrial targeting. However, its low 
availability in nature was limiting its preclinical development. Various PST 
analogues were synthesized to circumvent this limitation. In this dissertation, 
these analogues were screened and several had comparable or greater anti-
cancer activity compared to PST. The analogue, SVTH-7, demonstrated the most 
potent anti-cancer activity, followed by SVTH-6 and -5 in vitro and in vivo. These 
compounds had greater efficacy than PST, 7-deoxyPST analogues, and multiple 
standard chemotherapeutics, and were found to induce apoptosis in cancer cells 
by acting on cancer cell mitochondria. Furthermore, the anti-cancer effects of 
PST analogues were enhanced when used with agents known to target cancer 
cell mitochondria and oxidative vulnerabilities, including tamoxifen, curcumin, and 
piperlongumine. Interestingly, functional complex II and III of the electron 
transport chain were required for SVTH-7 to inflict its pro-apoptotic effects on 
cancer cells, suggesting exploitation of a mitochondrial vulnerability by SVTH-7. 
Therefore, these findings demonstrate a novel approach to treat cancer by 
exploiting cancer cell mitochondria with PST analogues alone or in combination 
with other compounds. These PST analogues have high therapeutic potential 
and this work will lay the groundwork for the identification and characterization of 
distinct mitochondrial features of cancer cells. 
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Cancer 
 Cancer is a disease characterized by uncontrolled growth and proliferation 
of cells of the affected organism, which in turn can disrupt normal functioning of 
tissues and organs  (Fearon 1997). In 2012, it was a leading cause of death in 
the world claiming 8.2 million lives with an estimated 14.1 million new cases; 
most common cancers diagnosed include lung with 1.82 million cases, breast 
with 1.67 million, and colorectal with 1.36 million (Ferlay et al. 2014).  
 Mounting evidence suggests that tumorigenesis, or the development of 
cancer, is a process of successive accumulation of genetic alterations that 
results in progressive transformation of cells to a neoplastic phenotype (Renan 
1993; FOULDS 1954; Bergers et al. 1998). Undergoing Darwinian evolution, 
advantageous genetic modifications for growth and survival in cells are selected 
and propagated. Selected genetic changes disrupt regulatory circuits that 
normally regulate cell homeostasis and proliferation and give rise to acquired 
capabilities, which are proposed to be mutually observed in most and possibly all 
types of cancer (Hanahan & Weinberg 2000). These hallmarks of cancer include: 
self-sufficiency in growth signals, evasion of growth suppressors, sustained 
angiogenesis, infinite replicative potential, tissue invasion and metastasis, 
reprogramming of energy metabolism, escape from immune destruction, and 
resistance to apoptosis (Hanahan & Weinberg 2000; Hanahan & Weinberg 
2011). This dissertation will heavily focus on apoptosis evasion, and explore 
various tactics to overcome defects in cell death programming in cancer cells. 
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Apoptosis 
Apoptosis or type I programmed cell death is a naturally occurring 
physiological phenomenon of the body (Green & Reed 1998). This process is 
characterized by membrane blebbing, chromatin condensation, DNA 
fragmentation, and the formation of membrane bound cell fragments called 
apoptotic bodies (Kerr et al. 1972; Fink & Cookson 2005). Furthermore, the 
characteristic flipping of phosphatidylserine from the inner to outer leaflet of the 
plasma membrane during apoptosis facilitates recognition and subsequent 
engulfment of apoptotic bodies by phagocytes (Fadok et al. 1998). Thus, 
apoptosis is a mechanism that allows cells to perish in a controlled manner 
without affecting cells in neighbouring environments (Kerr et al. 1972; Wyllie et 
al. 1980). In contrast, necrosis is a form of cell death characterized by cell 
swelling, plasma membrane rupture, and lysis that can lead to inflammation (Fink 
& Cookson 2005).  
 
Extrinsic and Intrinsic Apoptosis 
The two main modalities of apoptosis include the extrinsic and intrinsic 
pathways, which are distinguished by the location of initiation; the extrinsic 
pathway requires an external stimulus while the intrinsic pathway is triggered by 
an intracellular stress (Fulda & Debatin 2006). Extrinsic and intrinsic apoptosis 
are summarized in Figure 1.1. These two pathways can involve a family of 
cysteine proteases known as caspases.  
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Figure 1.1 Summary of Extrinsic and Intrinsic Apoptosis 
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When a death-promoting stimulus is absent, these proteases exist as inactive 
zymogens. Upon activation of apoptosis, these precursors are proteolytically 
cleaved to their active forms (Degterev et al. 2003). Caspases can be further 
classified as initiator or executioner caspases. Initiator caspases, which include 
caspase-2, -8, -9, and -10, are autoproteolytically cleaved upon activation of 
apoptosis by an external or intracellular stimulus and relay this apoptotic signal to 
executioner caspases. Executioner caspases include caspase-3, -6, and -7, 
which are cleaved and activated by initiator caspases. Once active, executioner 
caspases  cleave a multitude of proteins involved in various cellular functions, 
including structural stability and survival, to exert their lethal effects on cells 
(Fischer et al. 2003). One such protein is inhibitor of caspase-activated DNase 
(ICAD), which inhibits caspase-activated DNase (CAD). Upon executioner 
caspase cleaveage of ICAD, CAD is no longer inhibited and free to translocate to 
the nucleus, where it fragments DNA (Enari et al. 1998).  
The extrinsic pathway of apoptosis is a receptor mediated process in 
which a death ligand binds to its corresponding death receptor. A number of 
death receptors exist and include CD95/Fas/Apo1, TNFR1, TNFR2, DR3/Wsl-
1/Tramp, DR4/TRAIL-R1, DR5/TRAIL-R2/TRICK2/Killer, and DR6 (Degterev et 
al. 2003). Upon ligand binding, the receptor oligomerizes and associates with 
proteins in the cytosol to form the death-inducing signalling complex (DISC) 
(Ashkenazi & Dixit 1998). This complex is composed of the intracellular domain 
of the death receptor, the Fas associated death domain (FADD) adaptor protein, 
and procaspase-8/10. Once assembled, procaspase-8/10 is cleaved to caspase-
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8/10. Caspase-8/10 activates caspase-3, -6, and/or -7, which then execute 
apoptosis. Caspase-8/10 can also cleave the protein Bid, yielding truncated Bid 
(tBid), which promotes oliogomerization of pro-apoptotic Bax protein and 
mitochondrial membrane potential collapse and subsequent apoptotic execution 
(Kim et al. 2009; Roucou et al. 2002). Thus, there is crosstalk between the 
extrinsic and intrinsic pathway of apoptosis. 
In contrast to the extrinsic pathway of apoptosis, the intrinsic pathway is 
elicited by internal stress, such as DNA damage and oxidative stress (Fulda & 
Debatin 2006). Following this initial stress, mitochondrial permeabilization is 
induced, causing apoptogenic factor release from the mitochondrial 
intermembrane space to the cytosol. This release can subsequently lead to direct 
or indirect execution of apoptosis (Debatin et al. 2002).   
 
Apoptogenic Factors  
The apoptogenic factor cytochrome c (Cyto c) normally plays an active 
role in mitochondrial oxidative phosphorylation, facilitating the transfer of 
electrons between complex III and IV of the electron transport chain (Ow et al. 
2008). However, once released into the cytosol, it assembles with apoptotic 
peptidase activating factor 1 (Apaf1) and procaspase-9, forming the apoptosome 
complex. The formation of this complex promotes the cleavage of procaspase-9 
into active caspase-9 (Li et al. 1997), which subsequently activates caspase-
3/6/7 (Enari et al. 1998). In contrast to this caspase-dependent induction of 
apoptosis, which indirectly triggers apoptosis through the successive activation of 
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initiator and executioner caspases, the apoptogenic factors apoptosis inducing 
factor (AIF) and endonuclease G (EndoG) can translocate to the nucleus to 
fragment  DNA and execute apoptosis (Earnshaw 1999).  
Additional apoptogenic factors are also housed and released upon 
mitochondrial membrane permeabilization. Second mitochondrial activator of 
caspases (SMAC)/direct IAP binding protein with low pI (DIABLO) release into 
the cytosol promotes Cyto c mediated apoptosis by binding and inhibiting 
inhibitor of apoptosis (IAP) proteins (Srinivasula et al. 2001). One such protein is 
XIAP, which acts to inhibit caspase-3, -7, and -9 (Scott et al. 2005; Srinivasula et 
al. 2001). HtrA/Omi serves as a chaperon and serine protease in the 
mitochondrial intermembrane space to degrade or facilitate proper folding of 
mitochondrial proteins (Vande Walle et al. 2008). Like SMAC/DIABLO, the serine 
protease HtrA2/Omi abolishes function of IAP proteins once released from the 
mitochondria, but through proteolytic degradation as opposed to allosteric 
inhibition (Yang et al. 2003; Srinivasula et al. 2003). Adenylate kinase 2 (AK2) 
acts to catalyze the interconversion of adenine nucleotides and maintain cellular 
energy homeostasis by relaying AMP levels to metabolic sensors (Dzeja & Terzic 
2009). Upon release from the mitochondria, AK2 was found to form  a complex 
with FADD and caspase-10, leading to activation of this initiator caspase and 
subsequent execution of apoptosis (Lee et al. 2007). Thus, the intrinsic pathway 
of apoptosis can facilitate crosstalk to the extrinsic pathway upon mitochondrial 
membrane permeabilization. 
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The Bcl-2 Family of Proteins 
Mitochondrial outer membrane permeabilization is governed by the Bcl-2 
family of proteins. Members of this family share at least one or more of the four 
Bcl-2 homology (BH) domains, which include BH1, BH2, BH3 and BH4, and can 
be either anti-apoptotic or pro-apoptotic by discouraging or promoting 
mitochondrial outer membrane permeabilization, respectively (Strasser 2005; 
Youle & Strasser 2008).  BH1 and BH2 are present in all anti-apoptotic proteins, 
which include Bcl-2, Bcl-XL, Bcl-W, A1, Mcl-1 and Boo/Diva. The BH3 domain 
allows these proteins to dimerize with other members of the Bcl-2 family and is 
crucial for pro-apoptotic activity. Thus, this domain is present in all pro-apoptotic 
members of the Bcl-2 family of proteins, which include Bax, Bok, Bcl-Xs, Bak, 
Bcl-GL, Bfk, Bad, Bik, Bid, Hrk, Bim, Noxa, Puma, and Bmf (Strasser 2005; Youle 
& Strasser 2008). The overall proportion of pro-apoptotic Bcl-2 family proteins to 
anti-apoptotic Bcl-2 family proteins present within the cell will dictate the stability 
of the mitochondrial outer membrane and cell fate (Green & Reed 1998; Tait & 
Green 2010). An increase in expression of pro-apoptotic Bcl-2 proteins by a 
death stimulus can be facilitated by the p53 tumor suppressor, which has been 
shown to transcriptively activate Bax, Puma, Noxa, and Bid directly (Hemann & 
Lowe 2006). With insufficient anti-apoptotic proteins present to suppress the 
activity of pro-apoptotic proteins, the balance of Bcl-2 family of proteins is tipped 
in favor of apoptosis and mitochondrial outer membrane permeabilization occurs. 
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Mitochondrial Membrane Permeabilization 
Two different mechanisms for the permeabilization of the mitochondrial 
outer membrane have been presented  (Bouchier-Hayes et al. 2005). One 
involves the formation of pores composed of pro-apoptotic Bcl-2 family proteins 
on the mitochondrial outer membrane that allow cytotoxic proteins to be expelled 
from the mitochondrial intermembrane space (Kuwana et al. 2002). However, 
evidence supporting this mechanism is derived from cell-free system 
experiments that lack the intricacies of in vitro and in vivo models.  
Alternatively, mitochondria can be permeabilized via the permeability 
transition pore (PTP) which spans the inner and outer mitochondrial membranes 
(Brenner & Grimm 2006). The three principle proteins of the permeability 
transition pore are voltage-dependent anion channel (VDAC) in the mitochondrial 
outer membrane, adenine nucleotide translocase (ANT) in the inner 
mitochondrial membrane, and cyclophilin D in the matrix (Kroemer et al. 2007). 
When the gate keeper protein cyclophilin D associates with ANT, it promotes 
PTP formation and opening, allowing an influx of water and solutes into the 
mitochondrial matrix (Schinzel et al. 2005; Bernardi 1999). Consequences of this 
influx include mitochondrial swelling, mitochondrial outer membrane rupture, 
release of apoptogenic factors from the mitochondrial intermembrane space, 
collapse of mitochondrial membrane potential (MMP), and uncoupling of 
oxidative phosphorylation (Bouchier-Hayes et al. 2005). Bax and Bak have been 
shown to facilitate this process and the release of apoptogenic factors by 
associating with VDAC (Shimizu et al. 1999; Narita et al. 1998). However, this 
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promotion of PTP opening can be prevented by the glycolytic enzyme, 
hexokinase, which has been demonstrated to associate with VDAC and prevent 
Bax binding to VDAC (Pastorino et al. 2002).  
Interestingly, an isoform of hexokinase, hexokinase II, is overexpressed in 
a variety of tumor cells, which acts to satisfy the energetic needs of these highly 
glycolytic cells. In addition to fueling energy production, hexokinase II also plays 
a role in apoptosis evasion in cancer cells by binding to VDAC, and thus, 
preventing prop-apoptotic Bcl-2 proteins from interacting with VDAC and 
subsequent PTP opening (Pedersen et al. 2002).  Consequently, inhibition of 
hexokinase II may provide therapeutic benefit as seen with the hexokinase II 
inhibitor 3-bromopyruvate in vitro; this inhibitor triggered hexokinase II 
dissociation from the mitochondria, mitochondrial release of AIF, and apoptosis 
(Chen et al. 2009). Like the overexpression of hexokinase II, a multitude of 
cellular modifications have been observed in cancer cells, which function to 
circumvent apoptosis programming and fuel proliferation in cancer cells. In the 
next few sections, some of these distinct features in cancer cells will be explored 
as well as potential opportunities for therapeutic intervention. 
 
Evasion of Apoptosis by Cancer Cells 
Apoptosis can occur physiologically during embryogenesis or as a 
safeguard against DNA damage (Kerr et al. 1972; Wyllie et al. 1980). Under such 
normal circumstances, this process is tightly regulated. However, apoptosis and 
its associated programming can be pathologically altered in various disease 
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states (Brown & Attardi 2005). As mentioned previously, a hallmark or acquired 
trait of cancer cells is their ability to evade apoptosis (Hanahan & Weinberg 
2000). As with other acquired advantages of cancer cells, the ability to cheat 
death is the result of various genetic alterations through mutations or epigenetic 
modifications (Berdasco & Esteller 2010). Through these changes, neoplastic 
cells evolve a number of tactics to survive. The loss of TP53 tumor suppressor 
function is the most common method observed in cancer cells. 
 
The p53 Tumor Supressor 
The TP53 gene, which encodes the p53 protein, has been reported to be 
mutated or deleted in over 50 percent of human tumors (Hollstein et al. 1991). 
The p53 protein serves as a transcription factor for many genes responsible for 
DNA repair, cell cycle arrest, and apoptosis in response to a number or cellular 
stresses (Zilfou & Lowe 2009). In absence of cellular stress, inactivity of p53 is 
maintained by MDM2, which inhibits p53 transcriptional activity and marks p53 
for degradation via ubiquitination (Toledo & Wahl 2006). 
In response to hypoxia, oncogene activation, or DNA damage, p53 can 
promote apoptosis via transactivation of pro-apoptotic proteins such as Bax, 
Puma, and Noxa or induce senescence by transactivation of the p21 protein 
(Zilfou & Lowe 2009). p53 also acts as a transcription factor for extrinsic 
apoptosis death receptors 4 and 5, and thus, it can promote this cell death 
pathway (Ashkenazi & Dixit 1998). However, if such p53 safeguard mechanisms 
fail, potentially harmful mutations can persist and propagate, potentiating the 
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development of cancer. Therefore, it is not surprising that mutations in p53 are 
the most common type of mutation in human cancers, and if p53 is functional, 
MDM2 is commonly overexpressed to abolish its death promoting functions 
(Hollstein et al. 1991; Toledo & Wahl 2006).  
As p53 plays vital roles in initiating apoptosis, functional reactivation of 
mutant p53 presents as an attractive approach to cancer therapy. Mutant p53 
rescue has been explored by pharmacological manipulation via small molecules 
with some success in vitro and in vivo (Bullock & Fersht 2001; Bykov et al. 2009; 
Bykov & Wiman 2014). One lead compound, APR-246, was found to restore 
wildtype conformation in mutant p53, induce apoptosis in cancer cells, and inhibit 
the growth of tumors in mouse models (Bykov et al. 2002). As such, APR-246 
was advanced to a Phase I/II clinical trial with promising findings (Lehmann et al. 
2012); p53 target gene expression, cell cycle arrest,  and apoptosis  was 
observed in tumor cells from treated patients. Moreover, in cancers with wildtype 
p53 and overexpressed MDM2, small molecule inhibition of MDM2 has been 
explored with preclincal success (Zhao et al. 2015; Shangary & Wang 2009). 
 
Metabolic Reprogramming in Cancer Cells 
A distinct metabolic phenotype is observed in cancer cells, in which 
glycolysis dominates as the main source of energy production rather than ATP 
production in mitochondria, a phenomenon known as the Warburg effect 
(Warburg, 1956). In turn, this glycolytic phenotype and alteration of mitochondria 
provides a proliferative advantage and an acquired resistance to apoptosis 
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(DeBerardinis et al. 2008; Gogvadze et al. 2008; Gogvadze et al. 2010; Plas & 
Thompson 2002; Vander Heiden et al. 2009; Pastorino et al. 2002; Chen et al. 
2010; Green & Kroemer 2004; Casellas et al. 2002).  Therefore, exploitation of 
these distinct features in cancer cells may provide novel strategies for cancer 
therapy. 
As with hexokinase II, cancer cells have elevated levels of various 
proteins that function to promote glycolysis and/or discourage mitochondrial 
oxidative phosphorylation. As a result, this decreases the likelihood of oxidative 
stress-induced apoptosis by limiting use of the electron transport chain, a 
prominent generator of reactive oxygen species (Rohlena et al. 2013). Thus, 
reversal of this shift in metabolic phenotype could be an effective therapeutic 
tactic.  Pyruvate dehydrogenase (PDH) is a mitochondrial gate-keeping enzyme, 
which converts pyruvate to acetyl-CoA, permitting it to enter the Krebs cycle. 
PDH kinase (PDK) inhibits PDH and subsequent glucose oxidation in the 
mitochondria via phosphorylation. Common events involved in cancer 
progression, including loss of p53 (Contractor & Harris 2012) and hypoxia-
inducible factor 1α (HIF1α) activation (Kim et al. 2006), can result in increased 
PDK expression. Thus, this aberrant expression of PDK presents itself as a 
potentially lucrative target in cancer cells. The small molecule dichloroacetate 
(DCA) is a well known inhibitor of PDK and has been used for many years as a 
therapeutic for lactic acidosis associated with inherited mitochondrial diseases 
(Bowker-Kinley et al. 1998; Knoechel et al. 2006; Stacpoole 1989). Interestingly, 
DCA-mediated inhibition of PDK has been shown to shift the metabolism of 
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pyruvate from lactate generation and glycolysis to mitochondria-based glucose 
oxidation (Bonnet et al. 2007). This shift in metabolic phenotype towards 
oxidative phosphorylation was accompanied by decreases in MMP, increases in 
mitochondrial H2O2, and activation of voltage-gated K
+ channels in cancer cells. 
These cellular events lead to apoptosis induction and decreased proliferation of 
cancer cells in vitro as well as inhibition of tumor growth in vivo, in absence of 
any apparent toxicity (Bonnet et al. 2007). Pre-clinical and clinical work has 
shown that DCA alone may be effective against glioblastoma multiforme (Bonnet 
et al. 2007; Michelakis et al. 2010). Furthermore, as DCA releases cancer cells 
from an apoptosis resistant state, it may serve as a potent sensitizer of cancer 
cells to other chemotherapeutics. Despite these findings, effective in vitro 
concentrations of DCA are high and may not translate to a feasible dosage for 
patient consumption as a monotherapy (Bonnet et al. 2007). 
 
Reactive Oxygen Species (ROS) Scavengers & Generators 
 It has been shown that cancer cells have higher basal levels of ROS 
(Szatrowski & Nathan 1991; Trachootham et al. 2006) and that high 
concentrations of ROS can be a driving force behind tumor progression (Petros 
et al. 2005). In the development of cancer, mutations of genes encoding 
mitochondrial electron transport chain (ETC) components can yield an increase 
in ROS generation (Wallace 2005). Disruptions in the ETC can lead to the 
improper transfer of a single electron to an O2 molecule, forming a superoxide 
radical. Superoxide radicals are quickly converted to H2O2, by superoxide 
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dismutase, which can in turn diffuse to the nucleus and cause DNA damage and 
exacerbate genomic instability in cancer cells (Petros et al. 2005).  However, 
when in excess, ROS levels can lead to DNA, protein, and cell membrane 
damage, ultimately resulting in cell death. In response to higher ROS levels, 
malignancies have been shown to overexpress ROS scavengers, including 
thioredoxin reductase-1 (Yoo et al. 2006), manganese-containing superoxide 
dismutase (MnSOD) (Hu et al. 2005) and glutathione S-transferase pi 1 (GSTP1) 
(Raj et al. 2011). This suggests an increased dependency on antioxidative 
enzymes by cancer cells to survive. Thus, agents targeting ROS scavengers, as 
with the GSPT1 targeting compound piperlongumine (Raj et al. 2011), or 
increasing ROS levels directly with various mitochondrial targeting agents may 
allow for selective cancer targeting (Ralph et al. 2006). Furthermore, a 
combination of complementary chemotherapeutics, such as those targeting ROS 
scavengers and those raising ROS levels, may be an effective therapeutic 
strategy (Schumacker 2006). This selective killing of cancer cells with small 
molecules targeting the cellular ROS stress response has been dubbed 
"oxycution"  and is an emerging field in cancer therapeutics (Burgess 2011; Raj 
et al. 2011). Mitochondria, in the context of cancer, will be the subject of the 
following section, as they are the main generators of ROS. 
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Cancer Cell Mitochondria and Mitocans 
Cancer mitochondria feature several distinct differences, in comparison to 
non-transformed cells, which may permit for cancer specific targeting (Gogvadze 
et al. 2008; Chen et al. 2010). The glycolytic phenotype of cancer cells creates 
an acidic cytosolic environment, contributing to mitochondria hyperpolarization. 
Invasiveness and apoptotic resistance has been associated with 
hyperpolarization of mitochondria (Heerdt et al. 2006). This feature may allow 
selective targeting of cancer cells. Anti-cancer agents may be devised such that 
they are processed into a positively charged molecule that can be selectively 
taken up into the highly negative internal environment of the mitochondrial matrix, 
which is the result of hyperpolarization. Similar to hexokinase II, various 
antiapoptotic proteins of the Bcl-2 family of proteins are highly expressed in 
cancer cells, which discourage mitochondrial membrane permeabilization (Green 
& Kroemer 2004; Casellas et al. 2002; Mathupala et al. 1997). Furthermore, as 
cancer cells are more susceptible to ROS insult, targeting ETC components 
could be an effective therapeutic tactic (Rohlena et al. 2013). Collectively, these 
cancer cell mitochondria-specific features provide a basis for targeting cancer 
cell mitochondria, and thus, cancer cells selectively.  
Compounds that specifically target cancer cell mitochondria to induce 
mitochondrial dysfunction and apoptosis have been classified as mitocans (Chen 
et al. 2010; Ralph et al. 2006). These comprise of ETC inhibitors, mitochondrial 
PTP activators, mimetics of pro-apoptotic Bcl-2 proteins, and inhibitors of anti-
apoptotic Bcl-2 proteins (Rohlena et al. 2013; Yip & Reed 2008; Adams & Cory 
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2007). These compounds are generally well tolerated by non-cancerous cells 
and are effective anti-cancer agents, as a monotherapy or as chemosensitizers 
(Neuzil et al. 2013).  
 
Vitamin E Analogues 
 With growing interest in mitocans as selective anti-cancer agents, vitamin 
E analogues have been studied intensively. In particular, α-Tocopheryl succinate 
is able to selectively induce apoptosis in cancer cells by targeting mitochondria 
as shown in both in vitro and in vivo models (Zhao et al. 2009). This anti-cancer 
activity has been attributed to its ability to target complex II of the mitochondrial 
ETC at the ubiquinone binding site, causing ROS generation and mitochondrial 
dysfunction (Dong et al. 2008; Dong et al. 2009). Liposomal-based formulations 
and vitamin E analogues are being developed to optimize its therapeutic benefits 
(Dong et al. 2009; Neuzil et al.; Zhao et al. 2009). 
 
Taxol 
 Taxol, a common tubulin stabilizing chemotherapeutic isolated from the 
bark of the Pacific yew tree, was also found to target the mitochondria by 
interacting with the anti-apoptotic protein Bcl-2 (Ferlini et al. 2009). Furthermore, 
additional studies using isolated mitochondria demonstrated the ability of Taxol to 
promote free radical formation and mitochondrial membrane permeabilization, as 
indicated by the release of Cyto c (Varbiro et al. 2001). However, despite the 
ability of Taxol to target mitochondria, its side effects produced by its tubulin 
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targeting actions still remain problematic (Ferlini et al. 2009; Jordan & Wilson 
2004). Using this drug at as a chemosensitizer at lower doses, taking advantage 
of its mitochondria targeting abilities, could limit its harmful effects at higher 
doses (Ferlini et al. 2009). 
 
Pancratistatin and Narciclasine  
 The Amaryllidaceae family of plants has been used in traditional medicine 
for the treatment of various diseases including cancer (Kornienko & Evidente 
2008). One such plant is the Hymenocallis littoralis plant. To identify, 
characterize, and scientifically validate compounds responsible for these health 
benefits, components from the Hymenocallis littoralis plant were extracted and 
analyzed. Consequently, the natural compound pancratistatin (PST) (Figure 1.2), 
was first extracted and characterized in 1984 from this plant (Pettit et al. 1984; 
Pettit et al. 2004). Our laboratory has shown PST to induce apoptosis in 
numerous cancer types including leukemia, breast cancer, human 
neuroblastoma, colorectal cancer, glioblastoma, prostate cancer, and melanoma 
cells without adverse effects to normal cells (Kekre et al. 2005; McLachlan et al. 
2005; Siedlakowski et al. 2008; Griffin et al. 2010; Griffin, Karnik, et al. 2011; 
Griffin, McNulty, et al. 2011; Chatterjee et al. 2010). PST treatment was shown to 
target cancer cell mitochondria; it caused dissipation of MMP, ROS generation at 
early time points, and induction of apoptogenic factor release (McLachlan et al. 
2005; Siedlakowski et al. 2008; Griffin, Karnik, et al. 2011).  
 
 21 
 
 
Figure 1.2. Structure of Pancratistatin (PST) and Narciclasine with the 
Proposed Minimum Anti-Cancer Pharmacophore 
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Additionally, a synergistic anti-cancer effect was observed when PST was utilized 
with tamoxifen in human breast cancer cells, with no effect on normal breast 
fibroblast cells (Siedlakowski et al. 2008).  
Tamoxifen is commonly used to treat estrogen receptor positive breast 
cancers (Baum 2005). It is understood that tamoxifen antagonizes the estrogen 
receptor to elicit its anti-cancer effects. However, other studies have provided 
evidence of additional targeting by tamoxifen autonomous of the estrogen 
receptor (Mandlekar & Kong 2001; Moreira et al. 2006). In particular, it has been 
demonstrated that tamoxifen interacts with Complex I of the mitochondrial 
respiratory chain at the flavin mononucleotide site (Moreira et al. 2006). The anti-
cancer synergism with PST was found to be a result of mitochondrial targeting 
irrespective of the estrogen receptor (Siedlakowski et al. 2008). Similar findings 
were found in melanoma cells, as tamoxifen was demonstrated to sensitize the 
mitochondria of these cancer cells to dysfunction and permeabilization by PST 
(Chatterjee et al. 2010). 
Another Amaryllidaceae alkaloid, narciclasine (Figure 1.2), is extracted 
from the Narcissus tazetta plant, a species of daffodil and a known modulator of 
plant growth (Kornienko & Evidente 2008). It is very similar in structure compared 
to PST, only lacking the hydroxyl group at the C-1 position. Narciclasine  exhibits 
anti-cancer properties comparable to PST. Similarly, narciclasine has been 
shown to activate the intrinsic pathway of apoptosis, dependent on Cyto c 
release and caspase-9 activation in MCF7 breast cancer cells (Dumont et al. 
2007). In contrast, the pro-apoptotic effects of narciclasine in PC-3 prostate 
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carcinoma cells was dependent on Fas and DR4 death receptor-mediated 
activation of caspase-8 (Dumont et al. 2007).   
 
Synthetic Analogues of Pancratistatin 
 Despite having potent activity against a wide range of cancers, preclinical 
work on both PST and narciclasine has been hindered by the low availability of 
these compounds from their natural source. To circumvent this issue, various 
analogues of PST have been synthesized and subjected to structure activity 
relationship (SAR) analyses (Griffin et al. 2007; McNulty et al. 2008). 
Consequently, these studies have assisted in elucidating the minimum anti-
cancer pharmacophore (Figure 1.2). These analogues, however, featured poorer 
anti-cancer activity when compared to natural PST.  
 More recently, 7-deoxypancratistatin (7-deoxyPST) analogues were 
synthesized and screened for anti-cancer activity (Collins et al. 2010); these 
included JCTH-1, JCTH-2, JCTH-3, and JCTH-4 (Figure 1.3). Our preliminary 
work has shown JCTH-4 to have comparable anti-cancer activity compared to 
natural PST while JCTH-3 had limited activity (Collins et al. 2010). JCTH-1 and -
2, however, had very minimal anti-cancer activity. This was the first time a PST 
analogue with the C-7 hydroxyl group absent was found to have substantial anti-
cancer activity.  Subsequently, additional PST analogues were designed and 
synthesized in an effort to find chemical modifications to maximize anti-cancer 
activity.   
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Figure 1.3. Structure of 7-deoxyPST and PST Analogues 
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Analogues with the full proposed anti-cancer pharmacophore of PST and related 
alkaloids were made, which incorporated the hydroxyl group at the C-7 position 
(Vshyvenko et al. 2011). These included SVTH-5 and -6, the C-7 hydroxylated 
equivalents of JCTH-3 and -4, respectively, and the novel analogue SVTH-7 
(Figure 3). This dissertation will collectively evaluate and characterize the anti-
cancer activity of these novel 7-deoxyPST and PST analogues to assess their 
therapeutic potential. 
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Objectives 
 The evaluation of anti-cancer activity of synthetic 7-deoxyPST and PST 
analogues will be completed in this body of work, which include JCTH-1, JCTH-2, 
JCTH-3, JCTH-4, SVTH-5, SVTH-6, and SVTH-7. SAR analyses and 
characterization of anti-cancer activity will be carried out as outlined by the 
objectives listed below:  
 1. Evaluate 7-deoxyPST and PST analogues for selective anti-cancer 
 activity in various two- and three-dimensional culture models of cancerous 
 and non-cancerous cells  
 2. Evaluate the anti-cancer activity of these analogues in vivo 
 3. Characterize the mechanism of selective anti-cancer activity exhibited 
 by these 7-deoxyPST and PST analogues 
 4. Evaluate the efficacy of these analogues in combination with other anti-
 cancer agents 
The outcomes of this study will potentially identify novel compounds with 
therapeutic potential alone and in combination with other anti-cancer agents. 
Moreover, distinct features between cancer and non-cancerous cells may be 
identified and characterized. Such findings would provide a basis for better 
understanding cancer etiology that can be exploited to improve or design new 
therapeutic strategies. 
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ANT  adenine nucleotide translocase  
CK  creatine kinase 
CRC  colorectal cancer  
CypD  cyclophilin D 
Cyto c  cytochrome c 
ER  estrogen receptor   
IC50  half-maximal inhibitory concentration 
JCTH-1 JC-TH-acid-1  
JCTH-4  JC-TH-acetate-4 
HK   hexokinase  
LC3  microtubule-associated protein 1 light chain 3 
MDC  monodansylcadaverine 
MMP  mitochondrial membrane potential  
MRC  mitochondrial respiratory chain  
mtDNA mitochondrial DNA  
NFF  normal human fetal fibroblast  
PBR  peripheral benzodiazepine receptor  
PQ  paraquat  
PST  pancratistatin  
PTP  permeability transition pore  
RFU  relative fluorescence units 
ROS  reactive oxygen species  
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SDHA  succinate dehydrogenase subunit A  
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TMRM tetramethylrhodamine methyl ester  
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Summary 
 The natural compound Pancratistatin (PST), isolated from the 
Hymenocallis littoralis plant, specifically induces apoptosis in many cancer cell 
lines. Unlike many other chemotherapeutics, PST is not genotoxic and has 
minimal adverse effects on non-cancerous cells. However, its availability for 
preclinical and clinical work is limited due to its low availability in its natural 
source and difficulties in its chemical synthesis. Several synthetic analogues of 7-
deoxypancratistatin with different modifications at C1 were synthesized and 
screened for apoptosis inducing activity in human colorectal cancer (CRC) cells. 
We found that a C1 acetoxymethyl derivative of 7-deoxypancratistatin, JC-TH-
acetate-4 (JCTH-4), was effective in inducing apoptosis in both p53 positive 
(HCT-116) and p53 negative (HT-29) human CRC cell lines, demonstrating 
similar efficacy to that of natural PST. JCTH-4 was able to decrease 
mitochondrial membrane potential (MMP), increase levels of reactive oxygen 
species in isolated mitochondria, cause release of the apoptogenic factor 
cytochrome c (Cyto c) from isolated mitochondria, and induce autophagy in HCT-
116 and HT-29 cells. Interestingly, when JCTH-4 was administered with 
tamoxifen (TAM), there was an enhanced effect in apoptosis induction, reactive 
oxygen species (ROS) production and Cyto c release by isolated mitochondria, 
and autophagic induction by CRC cells. Minimal toxicity was exhibited by a 
normal human fetal fibroblast (NFF) and a normal colon fibroblast (CCD-18Co) 
cell line. Hence, JCTH-4 is a novel compound capable of selectively inducing 
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apoptosis and autophagy in CRC cells alone and in combination with TAM and 
may serve as a safer and more effective alternative to current cancer therapies.  
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Introduction 
Globally, colorectal cancer (CRC) accounts for 9.4 % of all newly 
diagnosed cancers (Parkin et al. 2005). In 2009, CRC was the third most 
common cancer responsible for 49,920 deaths in the USA (Murphy & Ryan 
2010). Current treatments include surgery, radiotherapy, and chemotherapy. 
Most chemotherapeutics however, are genotoxic in nature and cause adverse 
effects in non-cancerous cells. More recent efforts have achieved improved rates 
of survival with metastatic CRC, using combination therapy of various drugs, 
such as administration of oxaliplatin or irinotecan with flouoruracil (de Gramont et 
al. 2000; Douillard et al. 2000; Maindrault-Goebel et al. 1999; André et al. 1999). 
Despite these efforts, CRC remains as one of the most prominent and 
aggressive forms of cancer. 
Many cancers develop as a result of defects in the apoptosis or 
programmed cell death pathway (Borst & Rottenberg 2004). In the intrinsic 
pathway of apoptosis, various pro-apoptotic proteins act to permeabilize the 
mitochondria, dissipate mitochondrial membrane potential (MMP), and cause 
release of apoptogenic factors, such as cytochrome c (Cyto c), from the 
mitochondrial intermembrane space into the cytosol (Earnshaw 1999).  Once in 
the cytosol, apoptogenic factors can directly or indirectly execute apoptosis. As 
most cancers possess malfunctions in this pathway, much effort has been put 
into restoring or selectively activating this pathway for cancer therapy. 
Pancratistatin (PST), a natural compound from the Hymenocallis littoralis 
plant, specifically induces apoptosis in numerous cancer cell lines (Kekre et al. 
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2005; McLachlan et al. 2005). Contrasting with many chemotherapeutic agents, 
PST is non-genotoxic and does not exhibit adverse effects in non-cancerous 
cells (Kekre et al. 2005; McLachlan et al. 2005). Nonetheless, the availability of 
PST for preclinical and clinical work is limited as it is only present in its natural 
source in very low quantities and there have been great difficulties associated 
with its chemical synthesis. We have synthesized and tested several synthetic 
derivatives of 7-deoxypancratistatin and have found a C1 acetoxymethyl 
derivative, JC-TH-acetate-4 (JCTH-4), which has similar efficacy and selective 
apoptosis inducing activity to that of PST (Collins et al. 2010). 
Tamoxifen (TAM) is commonly administered to estrogen receptor (ER) 
positive breast cancer patients (Baum 2005). In such cases, TAM binds the ER 
to induce apoptosis by preventing estrogen binding, which normally activates 
pro-survival signalling pathways. However, other studies have provided evidence 
of estrogen receptor independent mechanisms of apoptotic induction by TAM 
(Mandlekar & Kong 2001; Moreira et al. 2006). More specifically, TAM has been 
shown to interact with the flavin mononucleotide site of Complex I of the 
mitochondrial respiratory chain (MRC) (Moreira et al. 2006). Interestingly, our 
past work also indicates PST to act on a mitochondrial target (McLachlan et al. 
2005). We have previously exploited this mitochondrial targeting and 
demonstrated a sensitization by TAM to PST-induced apoptosis in ER positive 
and negative breast cancer and melanoma cell lines (Siedlakowski et al. 2008; 
Chatterjee et al. 2010). Another recent report has also shown enhancement of 
cytotoxic effects of nelfinavir, an HIV drug, by TAM in an ER independent manner 
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in breast cancer cells (Brüning et al. 2010). As TAM has exhibited capabilities in 
enhancing the cytotoxicity of certain anti-cancer agents in cancer cells, we 
wanted to evaluate the combinatory effects of TAM and JCTH-4. 
This study analyzes the combinatory treatment of TAM and JCTH-4 in 
both p53 positive HCT-116 and p53 negative HT-29 human CRC cell lines. Our 
results show JCTH-4 to be effective in inducing apoptosis and autophagy in both 
cell lines through mitochondrial targeting. Interestingly, when JCTH-4 was 
administered with TAM, there was an enhancement in the aforementioned effects 
in both cell lines. Minimal toxicity by JCTH-4 alone and with TAM was exhibited 
in a normal human fetal fibroblast (NFF) and a normal colon fibroblast (CCD-
18Co) cell line. Thus, this study presents a therapeutic window in combination 
therapy using a novel synthetic analogue of PST with a clinically available drug to 
rival current cancer therapies. 
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Materials and Methods 
Cell Culture 
 The human CRC cells lines HT-29 and HCT 116 (ATCC, CCL-218 & CCL-
247, Manassas, VA, USA) were grown and cultured with McCoy’s Medium 5a 
(Gibco BRL, VWR, Mississauga, ON, Canada) supplemented with 2 mM L-
glutamine, 10 % fetal bovine serum (FBS) and 10 mg/ml gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada). The apparently normal human fetal fibroblast 
(NFF) cell line (Coriell Institute for Medical Research, AG04431B, Camden, NJ, 
USA) was grown in Dulbecco’s Modified Eagle’s Medium, High Glucose (Thermo 
Scientific, Waltham, MA, USA) supplemented with 15 % (v/v) FBS and 10 mg/mL 
gentamycin (Gibco BRL, VWR, Mississauga, ON, Canada). The normal colon 
fibroblast (CCD-18Co) cell line (ATCC, CRL-1459, Manassas, VA, USA) was 
cultured with Eagle’s Minimal Essential Medium supplemented with 10 % (v/v) 
FBS and 10 mg/mL gentamycin (Gibco BRL, VWR, Mississauga, ON, Canada). 
All cells were grown at 37˚ C and 5 % CO2.  
 
Cell Treatment 
 Cells were grown to 60–70 % confluence and treated with pancratistatin 
(PST), tamoxifen (TAM) citrate salt (Sigma-Aldrich, T9262, Mississauga, ON, 
Canada), JC-TH-acetate-4 (JCTH-4), JC-TH-acid-1 (JCTH-1), and other 
synthetic 7-deoxypancratistatin analogues at the indicated concentrations and 
time points. The C-1 analogues were produced by chemoenzymatic synthesis 
from bromobenzene as previously described (Collins et al. 2010). 
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Nuclear Staining 
 Following treatment and incubation with the aforementioned drugs, nuclei 
were stained with Hoechst 33342 dye (Molecular Probes, Eugene, OR, USA). 
Post drug treatment and incubation, cells were incubated with 10 µM Hoechst 
33342 dye for 5 minutes. Images were captured at 400x magnification on a Leica 
DM IRB inverted fluorescence microscope (Wetzlar, Germany).  
 
Annexin V Binding Assay 
 Subsequent to drug treatment and incubation, the Annexin V binding 
assay was performed to confirm apoptotic induction. Post drug treatment and 
incubation, cells were washed twice using phosphate buffer saline (PBS) and 
resuspended and incubated in Annexin V binding buffer (10 mM HEPES, 10 mM 
NaOH, 140 mM NaCl, 1 mM CaCl2, pH 7.6) with Annexin V AlexaFluor-488 
(1:50) (Sigma-Aldrich, Mississauga, ON, Canada) for 15 minutes. Images were 
captured at 400x magnification on a Leica DM IRB inverted fluorescence 
microscope (Wetzlar, Germany).  
 
WST-1 Assay for Cell Viability 
 The WST-1 based colorimetric assay for cell viability, an indicator of active 
cell metabolism, was conducted according to the manufacturer’s protocol (Roche 
Applied Science, Indianapolis, IN, USA). 96-well clear bottom tissue culture 
plates were seeded with approximately 2.0 x 103 HT-29 or HCT 116 cells/well, 
5.0 x 103 NFF cells/well, or 4.0 x 103 CCD-18Co cells/well and treated with 
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JCTH-4 and TAM at the indicated concentrations and durations. Subsequent to 
drug treatment and incubation, the WST-1 reagent, which is cleaved to formazan 
by cellular enzymes, was added to each well and incubated for 4 hours at 37˚ C. 
The metabolic product formazan was quantified by taking absorbance readings 
at 450 nm on a Wallac Victor3 TM 1420 Multilabel Counter (PerkinElmer, 
Woodbridge, ON, Canada). Absorbance readings were expressed as 
percentages of the untreated control groups. 
 
Tetramethylrhodamine Methyl Ester (TMRM) Staining 
 Tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, VWR, 
Mississauga, ON, Canada) was used to detect MMP. Cells were grown on 
coverslips and treated with the indicated doses of drugs for the indicated 
durations.  Following drug incubation, cells were incubated with 200 nM TMRM 
for 45 minutes at 37˚ C. Images were captured at 400x magnification on a Leica 
DM IRB inverted fluorescence microscope (Wetzlar, Germany). 
 
Mitochondrial Isolation  
 Mitochondria were isolated from untreated HT-29 and HCT 116 cells as 
per a previously published protocol (Siedlakowski et al. 2008). In brief, cells were 
washed two times with cold PBS and resuspended in hypotonic buffer (1 mM 
EDTA, 5 mM Tris–HCl, 210 mM mannitol, 70 mM sucrose, 10 μM Leu-pep and 
Pep-A, 100 μM PMSF). Cells were homogenized manually and subsequently 
centrifuged at 600 x g for 5 minutes at 4˚ C. The resulting supernatant was 
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centrifuged at 15,000 x g for 15 minutes at 4˚ C. Subsequently, the cytosolic 
supernatant was discarded and the mitochondrial pellet was resuspended in cold 
reaction buffer (2.5 mM malate, 10 mM succinate, 10 μM Leu-pep and Pep-A, 
100 μM PMSF in PBS). 
 
Amplex Red Assay 
 The levels of ROS produced were quantified with Amplex Red (Molecular 
Probes, Eugene, OR, USA). Equal amounts of isolated mitochondria suspended 
in cold reaction buffer were loaded into an opaque 96-well plate (20 µg of 
protein/well) with the indicated concentrations of drugs. Paraquat (PQ) (Sigma-
Aldrich, Mississauga, ON, Canada) was used as a positive control at 250 µM. In 
each well, Amplex Red reagent was added to a final concentration of 50 µM and 
horseradish peroxidase (HRP) (Sigma-Aldrich, Mississauga, ON, Canada) was 
added in the ratio of 6 U/200 µL.  Plates were read at Ex. 560 nm and Em. 590 
nm on a spectrofluorometer (SpectraMax Gemini XS, Molecular Devices, 
Sunnyvale, CA, USA) in 10 minute intervals for 4 hours. Fluorescence readings 
were expressed as relative fluorescence units (RFU).  
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Cellular Lysate Preparation 
 CRC cells were treated for 72 hours with the indicated concentrations of 
JCTH-4 and TAM. Treated cells were mechanically homogenized in cold 
hypotonic buffer (10 mM Tris HCl at pH 7.2, 5 mM KCl, 1 mM MgCl2, 1 mM 
EGTA, 1% Triton-X-100; 10 μM Leu-pep and Pep-A, 100 μM PMSF). Cell lysates 
were stored at -20˚ C until use. 
 
Western Blot Analyses 
 Protein samples (mitochondrial pellets, post mitochondrial supernatants, 
or cell lysates) were subjected to SDS-PAGE. Electrophoresed samples were 
transferred to a nitrocellulose membrane and were blocked with a 5% w/v milk 
TBST (Tris-Buffered Saline Tween-20) solution for 1 hour. Membranes were 
probed with an anti-cytochrome c antibody (1:1000) (Abcam, ab13575, 
Cambridge, MA, USA), an anti-succinate dehydrogenase subunit A antibody 
(1:1000) (Santa Cruz Biotechnology, Inc., sc-59687, Paso Robles, CA, USA), an 
anti-LC3 antibody (1:500) (Novus Biologicals, NB100-2220, Littleton, CO, USA), 
or an anti-β-Actin antibody (1:1000) overnight at 4˚ C. Subsequently, membranes 
were subjected to one 15 minute and two 5 minute washes in TBST and were 
incubated with an anti-mouse (1:2000) or an anti-rabbit (1:2000) horseradish 
peroxidase-conjugated secondary antibody (1:2000) (Abcam, ab6728, ab6802, 
Cambridge, MA, USA) for 1 hour at 25˚ C. Following three consecutive 5 minute 
washes in TBST, bands were visualized with enhanced chemiluminescence 
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reagent (Sigma-Aldrich, CPS160, Mississauga, ON, Canada). Densitometry 
analyses were performed using ImageJ software. 
 
Z-VAD-FMK Caspase Inhibition 
 To determine the dependence of caspases in apoptosis induction, the 
broad spectrum caspase inhibitor Z-VAD-FMK was used. Approximately 2.0 x 
103 HCT 116 cells were seeded in 96-well clear bottom tissue culture plates. 
After 24 hours, cells were treated with 1 µM JCTH-4 alone and with 25 µM and 
50 µM Z-VAD-FMK. Following 72 hours, the WST-1 reagent was added to each 
well and incubated for 4 hours at 37˚ C. Plates were read at 450 nm on a Wallac 
Victor3 TM 1420 Multilabel Counter (PerkinElmer, Woodbridge, ON, Canada). 
Absorbance readings were expressed as a percentage of untreated control cell 
groups. 
 
Monodansylcadaverine (MDC) Staining 
 Monodansylcadaverine (MDC) (Sigma-Aldrich, Mississauga, ON, Canada) 
staining was used to detect autophagic vacuoles. Cells were grown on coverslips 
and treated with the indicated doses of drugs for the indicated durations.  
Following drug incubation, cells were incubated with 0.1 mM MDC for 15 min. 
Images were captured at 400x magnification on a Leica DM IRB inverted 
fluorescence microscope (Wetzlar, Germany).  
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Long-term  Analysis on Growth Rate 
 To evaluate the long term effects of JCTH-4 and TAM on growth rate, cells 
were treated for 72 hours at the indicated concentrations of drugs. Following drug 
incubation, cells were trypsinized and 2 plates per experimental group were 
seeded with approximately 5.0 x 105 live cells, quantified with Trypan Blue 
exclusion dye, in drug-free media. Subsequently, cells were trypsinized and the 
number of live cells was quantified using Trypan Blue exclusion dye after 48 and 
96 hours using 1 plate of cells per time point per experimental group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56 
 
Results 
JCTH-4 Effectively Induces Apoptosis in Human CRC Cells 
Natural PST (Figure 2.1A) has been shown to induce apoptosis 
selectively in cancer cells (Siedlakowski et al. 2008; Chatterjee et al. 2010; Griffin 
et al. 2011). As there are insufficient quantities of PST available for preclinical 
and clinical work, various synthetic analogues of PST were synthesized and 
screened for similar specific apoptosis inducing activity on both p53 positive 
HCT-116 and p53 negative HT-29 human CRC cell lines. As seen with Hoechst 
dye, 1 µM natural PST after 96 hours yielded condensed, brightly stained nuclei 
accompanied by apoptotic bodies, indicative of apoptosis in HT-29 and HCT 116 
cells (Figure 2.1B).  Interestingly, one of the synthetic compounds, JCTH-4, 
induced apoptosis with comparable efficacy to that of PST in both cell lines, while 
many other synthetic analogues (data not shown) of PST such as JCTH-1 did not 
(Figure 2.2A & B).  
The effect of JCTH-4 on both the HT-29 and HCT 116 cell lines was 
quantified using a WST-1 based colorimetric assay for cell viability, an indicator 
of active cell metabolism. JCTH-4 was able to reduce cell viability in both cell 
lines in a time and dose dependent manner and exhibited approximate half-
maximal inhibitory concentration (IC50) values of 1 µM and 0.25 µM in HT-29 and 
HCT 116 cells respectively after 96 hours (Figure 2.3A & B). Notably, JCTH-4 
demonstrated selectivity to CRC cell lines as non-cancerous normal human fetal 
fibroblasts (NFF) and normal colon fibroblasts (CCD-18Co) were significantly 
less sensitive compared to both CRC cells lines after 72 hours (Figure 2.3C). 
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Figure 2.1. PST induces apoptosis in CRC cells and structural comparison 
to its synthetic 7-deoxy analogues. (A) Chemical structure of pancratistatin 
(PST). (B) Nuclear morphology of HCT 116 and HT-29 cells stained with Hoechst 
dye treated with 1 µM PST and the solvent control (Me2SO) after 96 hours. Scale 
bar= 15 µm. (C) Chemical structure of JC-TH-acetate-4 (JCTH-4). (D) Chemical 
structure of JC-TH-acid-1 (JCTH-1). 
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Figure 2.2. JCTH-4 induces apoptosis in CRC cells. Nuclear morphology of 
(A) HT-29 and (B) HCT 116 cells stained with Hoechst dye treated with the 
indicated concentrations of JCTH-1 and JCTH-4 after 96 hours. Control groups 
were treated with solvent (Me2SO). Scale bar= 15 µm. 
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Figure 2.3. JCTH-4 decreases viability of CRC cells in a time and dose-
dependent manner. (A) 96-well plates were seeded with HT-29 cells and 
treated with JCTH-4 at concentrations ranging from 0.1 µM to 2 µM for 24, 48, 
72, and 96 hours. Subsequent to drug treatment and incubation, the WST-1 
reagent was added to each well, absorbance readings were taken at 450 nm, 
and expressed at a percentage of the control (Me2SO). Statistics were performed 
using GraphPad Prism version 5.0. Values are expressed as mean ± SD from 
quadruplicates of 3 experiments. *p<0.005 versus control. (B) As performed with 
HT-29 cells, the WST-1 reagent was used to access viability of HCT 116 cells 
with the same concentrations of JCTH-4 and durations as previously described.  
Values are expressed as mean ± SD from quadruplicates of 3 independent 
experiments. *p<0.05, **p<0.005, ***p<0.0005 versus control. (C) The WST-1 
reagent was used to evaluate viability of NFF and CCD-18Co cells with the 
aforementioned concentrations of JCTH-4 after 72 hours. Values are expressed 
as mean ± SD from quadruplicates of 3 independent experiments. Viability of HT-
29 and HCT 116 cells presented correspond to 72 hours of treatment with JCTH-
4. *p<0.01 versus HT-29; #p<0.01, ##p<0.005 versus HCT 116. 
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TAM Enhances the Apoptotic Efficacy of JCTH-4 in CRC Cells 
We have previously shown PST and TAM to synergistically induce 
apoptosis in ER positive and negative breast cancer and melanoma cells 
(Siedlakowski et al. 2008; Chatterjee et al. 2010). To investigate the potential of 
JCTH-4 to replicate the combinatorial effects of PST and TAM, we treated HT-29 
and HCT 116 cells with JCTH-4 and TAM. Enhanced induction of apoptosis of 
JCTH-4 was observed when treated with TAM as exhibited by Hoechst staining 
(Figure 2.4A & B). No evident apoptosis induction was exhibited in CCD-18Co 
cells by JCTH-4 alone and in combination with TAM (Figure 2.4C). 
The WST-1 based colorimetric assay was used to quantify cell viability. 
This confirmed a greater decrease in viability of HCT 116 cells using 0.5 µM 
JCTH-4 with 5 µM and 10 µM TAM compared to 0.5 µM JCTH-4 alone, and a 
more prominent decrease in viability using 1 µM JCTH-4 with 10 µM TAM 
compared to 1 µM JCTH-4 alone after 72 hours (Figure 2.5A). After 72 hours, 
the 1 µM JCTH-4 and 10 µM TAM combinational treatment was significantly less 
toxic to NFF (Figure 2.5B) and CCD-18Co (Figure 2.5C) cells. 
Phosphatidylserine externalization, a biochemical marker of apoptosis, 
was detected by Annexin V binding to confirm apoptotic induction. JCTH-4 
caused phosphatidylserine externalization indicated by the green fluorescence, 
confirming the induction of apoptosis   (Figure 2.6A & B).  Such apoptotic 
induction was not exhibited in NFF cells (Figure 2.6C). Thus, combinational 
treatment of JCTH-4 and TAM demonstrates cytotoxic selectivity towards CRC 
cell lines. 
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Figure 2.4. TAM enhances apoptosis-inducing activity of JCTH-4 selectively 
in CRC cells. Nuclear morphology of (A) HT-29, (B) HCT 116, and (C) CCD-
18Co cells treated with the indicated concentrations of TAM and JCTH-4 for 96 
hours stained with Hoechst dye. Control groups were treated with solvent 
(Me2SO). Scale bar= 15 µm. 
 
 
 
 
  
 62 
 
 
Figure 2.5 TAM enhances viability decrease in CRC cells by JCTH-4. (A) As 
previously described, the WST-1 reagent was used to measure viability of HCT 
116 cells treated with the indicated concentrations of TAM and JCTH-4 for 72 
hours.  Absorbance readings were taken at 450 nm and expressed as a 
percentage of the control (Me2SO). Statistics were performed using GraphPad 
Prism version 5.0. Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments. *p<0.05, **p<0.005, ***p<0.0001 versus control; 
#p<0.05, ##p<0.005 versus 0.5 µM JCTH-4; †p<0.05 versus 1 µm JCTH-4. (B) 
The WST-1 reagent was used to measure viability of NFF cells treated with the 
indicated concentrations of TAM of JCTH-4 for 72 hours.  Values are expressed 
as mean ± SD from quadruplicates of 3 independent experiments. *p<0.005 
versus 10 µM TAM + 1 µM JCTH-4 combinational treatment on HCT 116 cells 
(Figure 5A). (C) The WST-1 reagent was used to measure viability of CCD-18Co 
cells treated with the indicated concentrations of TAM of JCTH-4 for 72 hours.  
Values are expressed as mean ± SD from quadruplicates of 3 independent 
experiments. *p<0.005 versus 10 µM TAM + 1 µM JCTH-4 combinational 
treatment on HCT 116 cells (Figure 5A). 
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Figure 2.6. JCTH-4 induces phosphatidylserine externalization alone and in 
combination with TAM in CRC cells. Annexin V binding to externalized 
phosphatidylserine was monitored to confirm apoptotic induction in (A) HT-29, 
(B) HCT 116, and (C) NFF cells treated with JCTH-4 and TAM for 72 hours at the 
indicated concentrations. Control groups were treated with solvent (Me2SO). 
Images were taken at 400x magnification on a fluorescent microscope. Scale 
bar= 15 µm.  
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JCTH-4 and TAM Target the Mitochondria in HT-29 and HCT 116 Cells 
Although TAM is well characterized as an ER antagonist in the treatment 
of ER positive breast cancers, there have been studies which indicate that TAM 
can induce apoptosis independently of the estrogen receptor via mitochondrial 
targeting (Moreira et al. 2006). Moreover, we have previously provided evidence 
supporting the mitochondria as a target of PST and have shown TAM to 
strengthen the ability of PST to dissipate MMP and increase in ROS production 
(Siedlakowski et al. 2008; Chatterjee et al. 2010).  
To access the ability of JCTH-4 to dissipate MMP both alone and in 
combination with TAM, HT-29 and HCT 116 cells were treated for 96 hours and 
stained with tetramethylrhodamine methyl ester (TMRM). Both 1 µM JCTH-4 and 
10 µM TAM alone were able to dissipate MMP in both cell lines indicated by the 
decrease in positive TMRM staining; however, when used together, there was a 
greater dissipation in MMP (Figure 2.7A & B). No evident dissipation in MMP 
was observed in CCD-18Co cells by JCTH-4 and TAM alone and in combination 
(Figure 2.7C). 
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Figure 2.7. JCTH-4 and TAM dissipate MMP in CRC cells. (A) HT-29, (B) HCT 
116, and (C) CCD-18Co cells were grown on coverslips and treated with the 
indicated concentrations of drugs for 96 hours and subsequently stained with 
TMRM to detect MMP. Control groups were treated with solvent (Me2SO).  
Images were captured at 400x magnification on a fluorescence microscope. 
Scale bar= 15 µm. 
 
 
 
 
 66 
 
Increases in reactive oxygen species (ROS) production in mitochondria 
have been associated with both the cause and effect of mitochondrial membrane 
permeabilization, and the release of apoptogenic factors (Madesh & Hajnóczky 
2001; Simon et al. 2000; Batandier et al. 2004). To access the ability of JCTH-4 
and TAM to increase generation of ROS in mitochondria directly, isolated 
mitochondria from HT-29 and HCT 116 cells were treated with 1 µM JCTH-4 and 
10 µM TAM alone and in combination.  ROS generation was monitored with 
Amplex Red dye over 4 hours in 10 minute intervals. Paraquat (PQ), a known 
inducer of mitochondrial ROS generation, was used as a positive control at 250 
µM (Cochemé & Murphy 2008). In both cell lines, JCTH-4 and TAM alone caused 
a significant increase in ROS production compared to control and with the 
combinational treatment the increase was significantly greater than either JCTH-
4 or TAM alone in HT-29 and HCT 116 cells (Figure 2.8A & B). 
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Figure 2.8. JCTH-4 and TAM increase ROS generation in isolated 
mitochondria from CRC cells. Isolated mitochondria from (A) HT-29 and (B) 
HCT 116 cells were treated directly with JCTH-4 and TAM at the indicated 
concentrations and ROS was measured with Amplex Red substrate in presence 
of horseradish peroxidase (HRP). The control groups were treated with solvent 
(Me2SO). Paraquat (PQ) was used at 250 µM as a positive control in both cell 
lines. Fluorescence readings were taken in 10 minute intervals for 4 hours at Ex. 
560 nm and Em. 590 nm and expressed as relative fluorescence units (RFU). 
Statistics were performed using GraphPad Prism version 5.0. Image is 
representative of 3 independent experiments demonstrating similar trends. 
Values are expressed as mean ± SD of quadruplicates of 1 independent 
experiment. *p<0.05 versus control; #p<0.05 versus 1 µM JCTH-4; †p<0.05 
against 10 µM TAM. 
 
 
 68 
 
The release of apoptogenic factors such as Cyto c from the mitochondria 
following mitochondrial membrane permeabilization is important for apoptosis 
signalling and execution (Green & Reed 1998). To assess the ability of both 
JCTH-4 and TAM to directly trigger release of Cyto c, isolated mitochondria from 
HT-29 cells were treated with the indicated concentrations of JCTH-4 and TAM 
for 2 hours. Post treatment, the samples were centrifuged and western blot 
analyses were performed for Cyto c on the supernatants and succinate 
dehydrogenase subunit A (SDHA) on the mitochondrial pellets. Both JCTH-4 and 
TAM alone were able to cause release of Cyto c but the effect was greatly 
enhanced with the combinatorial treatment, significantly releasing more Cyto c 
than both treatments alone (Figure 2.9). Collectively these results are supportive 
of a mitochondrial target for both JCTH-4 and TAM. 
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Figure 2.9. JCTH-4 and TAM cause release of apoptogenic factor Cyto c 
from isolated mitochondria in CRC cells. Isolated mitochondrial from HT-29 
cells were directly treated with JCTH-4 and TAM at the indicated concentrations 
for 2 hours. The control group was treated with solvent (Me2SO). Following drug 
incubation, samples were resuspended and centrifuged 15,000 x g for 15 
minutes at 4˚ C.  Subsequently, western blot analyses were performed for Cyto c 
on the resultant supernatants and SDHA on the resultant mitochondrial pellets 
resuspended in reaction buffer. Densitometric analyses were performed using 
ImageJ software. Statistics were performed using GraphPad Prism version 5.0. 
Values are expressed as mean ± SD. *p<0.005, **p<0.0005 versus control; 
#p<0.005 versus 1 µM JCTH-4; †p<0.0005 versus 10 µM TAM. 
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JCTH-4 Induces Apoptosis in a Caspase-Independent Manner 
Caspases are proteases well known for their participation in apoptosis 
signalling (Stennicke & Salvesen 1999). However, there are other pathways 
which are independent of these proteases. To determine the dependence on 
caspases in JCTH-4 induced apoptosis, HCT 116 cells were treated with JCTH-4 
alone and in combination with the broad spectrum caspase inhibitor Z-VAD-FMK 
at 25 µM and 50µM. Using the WST-1 based colorimetric assay to access cell 
viability, there was no statistically significant difference observed in cell viability 
between the JCTH-4 treatment alone and the JCTH-4 treatment in combination 
with Z-VAD-FMK at both 25 µM and 50 µM, indicative of caspase independence 
in JCTH-4 induced apoptosis (Figure 2.10). 
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Figure 2.10. JCTH-4 induces apoptosis in CRC cells independent of 
caspases. To determine the dependence on caspases in the induction of 
apoptosis by JCTH-4, HCT 116 cells were treated with JCTH-4 alone and in 
combination with the broad spectrum caspase inhibitor Z-VAD-FMK at the 
indicated concentrations. After 72 hours, the WST-1 reagent was used to 
evaluate cell viability as previously described. Absorbance readings were taken 
at 450 nm and expressed as a percentage of the control (Me2SO). Statistics were 
performed using GraphPad Prism version 5.0. Values are expressed as mean ± 
SD from quadruplicates of 3 independent experiments. *p<0.005 versus control. 
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JCTH-4 Induces Autophagy in HT-29 and HCT 116 Cells 
Autophagy, a process in which cells break down their own constituents, 
can be induced by various forms of cellular stress such as hypoxia, reactive 
oxygen species, protein aggregates, nutrient deprivation, growth factor 
deprivation, damaged organelles, and mutant proteins (Kroemer et al. 2010). 
During this process, cytosolic material is taken up by autophagosomes, which 
are double-membraned vesicles that fuse to lysosomes to form autolysosomes. 
Subsequent to autolysosome formation, intra-autophagosomal contents are 
broken down by lysosomal enzymes (Kroemer et al. 2010).  To access the 
induction of autophagy, HT-29 and HCT 116 cells were treated with 1 µM JCTH-
4 and 10 µM TAM alone and in combination for 72 hours and stained with 
monodansylcadaverine (MDC) (Figure 2.11A & B). Bright punctate MDC 
staining was observed in JCTH-4 and in TAM treated HT-29 and HCT 116 cells, 
indicative of autophagosomes.  Interestingly, the combinatory treatment yielded 
the greatest induction of autophagosome formation, as indicated by the high 
intensity punctate MDC staining. However, after 72 hours of treatment of CCD-
18Co cells, minimal MDC staining was observed with JCTH-4, and bright 
punctate staining was observed with TAM (Figure 2.11C). With the 
combinational treatment of JCTH-4 and TAM, CCD-18Co cells exhibited MDC 
staining intensity similar to that of TAM alone.  
Upon autophagic induction, microtubule-associated protein 1 light chain 3 
(LC3) localized in the cytosol, LC3-I, is conjugated to phosphatidylethanolamine, 
resulting in the lipidated protein LC3-II that is recruited to autophagosomal 
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membranes (Kroemer et al. 2010). Consequently, detection of LC3-II has been 
used as a marker of autophagic induction. To confirm the induction of autophagy, 
western blot analyses were performed using an anti-LC3 antibody on cell lysates 
from HT-29 and HCT 116 cells treated with the indicated concentrations of 
JCTH-4 and TAM for 72 hours. Results confirmed that JCTH-4 induced 
autophagy in both CRC cell lines (Figure 2.11D & E). Furthermore, the addition 
of TAM to JCTH-4 treatment enhanced the conversion of LC3-I to LC3-II. 
Therefore, these results indicate that JCTH-4 alone and in combination with 
TAM, triggers autophagic induction in CRC cell lines. 
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Figure 2.11. JCTH-4 and TAM induce autophagy in CRC cells. Cells were 
grown on coverslips and treated with JCTH-4 and TAM at the indicated 
concentrations. The control group was treated with solvent (Me2SO). After 72 
hours, (A) HT-29, (B) HCT 116, and (C) NFF cells were stained with MDC to 
detect autophagic vacuoles. Images were captured at 400x magnification on a 
fluorescence microscope. Scale bar= 15 µm. Western blot analyses were 
performed for LC3-II and β-Actin on cell lysates of CRC cells treated for 72 hours 
with the indicated concentrations of JCTH-4 and TAM. Densitometric analyses 
were performed using ImageJ software. Statistics were performed using 
GraphPad Prism version 5.0. Values are expressed as mean ± SD. (D) HT-29: 
*p<0.0005 versus control; #p<0.005 versus 1 µM JCTH-4; †p<0.005 versus 10 
µM TAM. (E) HCT 116: *p<0.0005 versus control; #p<0.05 versus 1 µM JCTH-4; 
†p<0.005 versus 10 µM TAM. 
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Long-Term Effect on Human CRC Cells Post Exposure to JCTH-4 and TAM  
CRC is notorious for its aggressive nature, thus, the resilience of HT-29 
and HCT 116 cells after exposure to 1 µM JCTH-4 and 10 µM TAM alone and in 
combination was examined. After the HT-29 and HCT 116 cells were initially 
exposed to the aforementioned treatments for 72 hours, approximately 5.0 x 105 
live cells were seeded in drug-free media and the number of live cells was 
monitored over an additional 96 hours using Trypan Blue exclusion dye. As 
determined by quantifying the number of live cells, the cells initially treated with 1 
µM JCTH-4 exhibited a significantly smaller growth rate in both the HT-29 and 
HCT 116 cells in drug-free media compared to the control group (Figure 2.12A & 
B). The growth rate following drug removal after initial treatment was 
synergistically reduced in the combination treatment group compared to both 1 
µM JCTH-4 and 10 µM TAM alone in HT-29 and HCT 116 cells; however, the 
initial treatment of 10 µM TAM alone caused an increase in the growth rate in 
HCT 116 cells and had no significant effect on the growth rate in HT-29 cells 
after media replacement (Figure 2.12A & B).  
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Figure 2.12. Initial JCTH-4 treatment reduces resilience of CRC cells after 
drug removal. (A) Subsequent to 72 hours of treatment with JCTH-4 and TAM 
at the indicated concentrations, approximately 5.0 x 105 live HT-29 cells were 
seeded in drug-free media and the number of live cells were counted after 48 
and 96 hours using Trypan Blue exclusion dye. Statistics were performed using 
GraphPad Prism version 5.0. Values are expressed as mean ± SD (n=3). 
*p<0.005, **p<0.0005 versus control (Me2SO); #p<0.05 versus 1 µM JCTH-4; 
†p<0.05 versus 10 µM TAM. (B) The aforementioned procedure was performed 
with HCT 116 cells. Statistics were performed using GraphPad Prism version 5.0. 
Values are expressed as mean ± SD (n=3). **p<0.01, **p<0.005 versus control 
(Me2SO); #p<0.05 versus 1 µM JCTH-4; †p<0.05 versus 10 µM TAM. 
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Discussion 
There has been great difficulty in synthesizing PST (Figure 2.1A). Many 
synthetic analogues of PST have been synthesized but demonstrated minimal 
anti-cancer activity (McNulty et al. 2008).  For the first time, we have 
demonstrated substantial cancer specific apoptosis inducing activity using a 
novel synthetic derivative of PST, JCTH-4, with comparable efficacy to that of 
PST, in both p53 positive HCT-116 and p53 negative HT-29 human CRC cell 
lines.  In both CRC cell lines, this C1 acetoxymethyl derivative of 7-
deoxypancratistatin was able to effectively induce apoptosis at 1µM (Figure 2.2A 
& B). NFF and CCD-18Co cells were significantly less sensitive to JCTH-4 than 
the CRC cells both alone (Figure 2.3C) and in combination with TAM (Figure 
2.5A-C). Moreover, JCTH-4 alone and in combination with TAM did not yield any 
evident induction of apoptosis in NFF cells observed by Hoechst and Annexin V 
assays (Figure 2.6C). 
The various synthetic analogues of 7-deoxypancratistatin tested in this 
report are identical in structure with the exception of a varying functional group at 
C1 (Figure 2.1C & D). Specific anti-cancer activity was found only in JCTH-4 and 
not in the other synthetic analogues, such as JCTH-1. This suggests a critically 
specific binding of JCTH-4 to some particular protein domain or enzymatic pocket 
of a key cellular protein by the functional group at C1. Furthermore, this study 
demonstrates an active compound in the PST series lacking the C7 hydroxyl 
group, previously reported to mildly contribute to apoptotic activity, demonstrating 
the unimportance of this group to the structural minimum pharmacophore for 
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cancer specific cytotoxicity (McNulty et al. 2008). The minimum pharmacophore 
essential for specific anti-cancer activity suggests a specific target and mode of 
action of JCTH-4, as opposed to the non-specific binding to various cellular 
targets exhibited by many current chemotherapeutics. This report provides 
evidence of specific mitochondrial targeting. 
The classification of mitocans collectively includes anti-cancer agents 
which directly or indirectly target mitochondrial functioning (Chen et al. 2010). 
Both PST and JCTH-4 fall under this classification. Our previous reports provide 
evidence of mitochondrial targeting by PST (McLachlan et al. 2005; Siedlakowski 
et al. 2008). Similarly, this report presents data indicative of mitochondrial 
targeting by JCTH-4 in CRC cell lines. JCTH-4 was able to dissipate MMP 
(Figure 2.7A & B), increase generation of reactive oxygen species in isolated 
mitochondria (Figure 2.8A & B), and cause release the apoptogenic factor Cyto 
c from isolated mitochondria (Figure 2.9) in both HCT-116 and HT-29 cells. 
Furthermore, the broad spectrum caspase inhibitor Z-VAD-FMK was unable to 
prevent JCTH-4-induced apoptosis (Figure 2.10). This supports the action of 
JCTH-4 at the level of mitochondrial destabilization, upstream of executioner 
caspase activation, to cause release of various apoptogenic factors involved in 
both caspase dependent and independent pathways of apoptotic induction.   
As the Bcl-2 family of proteins serves crucial regulatory roles in apoptosis, 
there has been a growing interest in the development of small molecules capable 
of directly binding to and modifying the activity of Bcl-2 proteins, such as the pro-
apoptotic protein Bax (Leber et al. 2010). However, we have evidence to rule out 
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such direct binding to Bax specifically by PST and JCTH-4. We have previously 
stably transfected and expressed anti-Bax single-domain antibodies (sdAbs) in 
human neuroblastoma cells (SH-SY5Y) capable of blocking Bax function 
(Gueorguieva et al. 2006). These sdAbs however, were unable to prevent PST-
induced apoptosis in the SH-SY5Y cells (Griffin et al. 2011). Moreover, the tumor 
suppressor p53 functions as a transcription factor for the pro-apoptotic proteins 
Bax, Noxa, and PUMA and also indirectly activates Bim, which all act to 
permeabilize the mitochondrial membrane to induce apoptosis (Miyashita & Reed 
1995; Oda et al. 2000; Nakano & Vousden 2001; Puthalakath & Strasser 2002). 
In many aggressive cancers however, p53 is often mutated giving rise to 
resistance to many chemotherapeutics. Interestingly, both PST and JCTH-4 
effectively induced apoptosis in both p53 positive and p53 negative human CRC 
cell lines. This suggests these compounds are capable of bypassing 
malfunctions in p53 and in a manner independent of p53 downstream proteins 
such as Bax.  
In treating ER positive breast cancer, TAM is well known as an ER 
antagonist. In such circumstances, TAM interferes with estrogen binding to the 
ER which inhibits various signalling cascades resulting in apoptosis. The ER 
receptor was also found to be expressed in CRC. The CRC cell lines HT-29 and 
HCT 116 are both positive for ER beta and in HT-29 cells in particular, previous 
work has proven TAM to be effective in inhibiting cell proliferation and inducing 
apoptosis (Fang et al. 2009; Janakiram et al. 2009). Independent of the ER, 
former studies have suggested TAM to act on the Complex I of the electron 
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transport chain at the flavin mononucleotide site. Accordingly, we have 
demonstrated TAM to increase ROS generation (Figure 2.8A & B) and cause 
release of Cyto c (Figure 2.9) in isolated mitochondria from both HT-29 and HCT 
116 cells. As a proof-of-concept of mitochondrial targeting in both TAM and 
JCTH-4, combinatory treatment with these compounds yielded greater increase 
in ROS production (Figure 2.8A & B) and greater release of Cyto c (Figure 2.9) 
in isolated mitochondria from HT-29 and HCT 116 cells than either of these 
compounds alone. Consequently, the enhanced mitochondrial targeting in these 
cell lines is most likely responsible for the greater apoptotic induction (Figure 
2.4A & B) and MMP dissipation (Figure 2.7A & B) with the combinatory 
treatment of TAM with JCTH-4. Furthermore, when these treatments were 
removed after 72 hours of incubation, the HT-29 and HCT 116 cells initially 
treated with both 1 µM JCTH-4 and 10 µM TAM exhibited a synergistically 
reduced growth rate compared to both 1 µM JCTH-4 and 10 µM TAM alone in 
drug-free media (Figure 2.12A & B). Notably, the CRC cells initially treated with 
1 µM JCTH-4 alone grew much slower than the control group in drug-free media. 
However, 10 µM TAM alone had no significant effect on growth rate post-drug 
incubation in HT-29 cells and caused an increase in growth rate in HCT 116 cells 
after drug removal. Although previous work has shown TAM to exert moderate 
cytotoxicity against CRC cells at higher doses, TAM treatment alone at 10 µM 
appears to be ineffective and potentially detrimental in treating CRC unless 
utilized with JCTH-4 (Fang et al. 2009). 
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Consistent with the findings in this report, our previous work has shown 
TAM to sensitize ER positive and negative breast cancer and melanoma cell 
lines to PST-induced cell death via mitochondrial targeting independent of 
estrogen receptors (Siedlakowski et al. 2008; Chatterjee et al. 2010). As we have 
shown specific mitochondrial targeting in cancer cells with PST and JCTH-4, 
there are numerous factors that may render cancer cells vulnerable to such 
targeting. Most cancer cells rely predominantly on glycolysis as the main source 
of energy production regardless of the abundance of oxygen present in the 
surrounding environment (Warburg, 1956). Furthermore, studies have proven 
cancer cells to exhibit higher levels of ROS which have been attributed to 
mitochondrial DNA (mtDNA) mutations in multiple types of cancers (Szatrowski & 
Nathan 1991; Carew et al. 2003; Indo et al.; Ishikawa et al. 2008). MRC 
complexes are encoded in mtDNA, and thus, mutations in these genes could 
give rise to errors in electron transport and subsequent electron leakage and 
superoxide generation (Adam-Vizi & Chinopoulos 2006; Brandon et al. 2006). 
Moreover, cancer cells possess elevated mitochondrial transmembrane potential, 
which can act to supplement the generation of ROS by the MRC (Chen et al. 
2010). Increased levels of ROS have also been linked to the establishment of 
aggressive and advanced malignancies (Patel et al. 2007; Kumar et al. 2008). 
However, if the levels of ROS surpass the antioxidant capabilities of the cell, 
cytotoxicity and cell death may result (Fruehauf & Meyskens 2007). Thus, it is 
possible for cancer cells to be more sensitive to compounds that abolish cellular 
antioxidant activity or promote ROS production.  
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The permeability transition pore (PTP) is a complex spanning the 
mitochondrial membranes and is proposed to be composed of multiple proteins 
including adenine nucleotide translocase (ANT), voltage-dependent anion 
channel (VDAC), and cyclophilin D (CypD). Under normal physiological 
conditions, small molecules are permitted in and out of the mitochondria via the 
PTP to maintain mitochondrial homeostasis. In the presence of apoptotic stimuli, 
the PTP can give rise to dissipation of MMP, ATP depletion, and expulsion of 
apoptogenic factors resulting in apoptosis (Berridge et al. 2009). Proteins 
associated with the PTP, which play roles in regulation of its opening, are 
peripheral benzodiazepine receptor (PBR), creatine kinase (CK), and hexokinase 
(HK) (Halestrap 2009). In various types of cancer, PBR, HKII, and CK have all 
been reported to be over-expressed (Corsi et al. 2008; Meffert et al. 2005; 
Palmieri et al. 2009). Additionally, ANT, VDAC, and CypD are more abundant in 
malignant tissues (Kim et al. 2006; Pedersen 2008; Chen et al. 2009). 
Consequently, these mitochondrial abnormalities may serve as specific targets 
that can be exploited by PST and JCTH-4 to specifically induce apoptosis in 
cancer cells. 
Autophagy exists as a stress response, allowing cells to survive under 
harsh environments (Kroemer et al. 2010). However, extensive degradation of 
intracellular contents by this process can lead to autophagic cell death (Dalby et 
al. 2010).   Recently, induction of autophagy has been implicated in both killing 
cancer cells, via autophagic cell death, as well as protecting cancer cells against 
chemotherapy (Dalby et al. 2010).  Interestingly, TAM has been shown to induce 
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autophagy in various cancer cell types (Dalby et al. 2010).  We found strong 
autophagic induction in CRC (Figure 2.11A, B, D, E) and NFF (Figure 2.11C) 
cells treated with TAM but found minimal cell death (Figure 2.11A-C). This may 
indicate that autophagic induction by TAM is a protective response in CRC and 
NFF cells.  We also observed that JCTH-4 induced autophagy in CRC cells 
(Figure 2.11A, B, D, E) with significant induction of apoptosis (Figure 2.6A & B). 
Activation of autophagy in NFF cells however, appeared to be very minimal by 
JCTH-4 (Figure 2.11C). As described previously, JCTH-4 causes mitochondrial 
dysfunction that leads to apoptosis; however, in response to mitochondrial 
dysfunction and oxidative stress, these CRC cells may trigger autophagy as a 
default mechanism. When JCTH-4 and TAM are used together, there was an 
enhanced induction of autophagy in CRC cells (Figure 2.11A, B, D, E). More 
interestingly, the protective autophagic response induced by TAM becomes lethal 
in the presence of JCTH-4, causing autophagic/apoptotic cell death (Figure 2.4 
A & B, 2.5A, 2.6A & B, 2.11A, B, D, E). However, since mitochondria are 
permeabilized, the CRC cells ultimately undergo apoptosis.  Such pathological 
autophagic processes were not observed in the NFF cell line as shown with MDC 
and bright field pictures (Figure 2.11C). As TAM has been established to target 
complex I of the MRC, it can be hypothesized that such targeting can lead to the 
generation of oxidative stress which is insufficient to destabilize the mitochondria 
but sufficient to produce a protective autophagic response (Moreira et al. 2006). 
Nevertheless, such oxidative stress generated by TAM may act to sensitize 
cancer cell mitochondria to JCTH-4-induced dysfunction and permeabilization, 
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ultimately yielding apoptosis. As both TAM and JCTH-4 are able to generate 
oxidative stress (Figure 2.8A & B), the combinatorial production of such stress 
by both compounds may give rise to extensive activation of the autophagic 
pathway to ultimately yield a detrimental response.  
In conclusion, we present a novel derivative of PST, JCTH-4, created by 
de novo synthesis, capable of specifically inducing apoptosis in human CRC cell 
lines via mitochondrial targeting.  As a synthetic derivative of PST demonstrating 
similar efficacy and specificity towards cancer cells has been discovered, 
previous limitations on PST, including its low availability in its natural source and 
difficulties in its chemical synthesis, have been overcome. Moreover, TAM was 
able to enhance the efficacy of JCTH-4 and induce a pathological autophagic 
response in CRC cells in the presence of JCTH-4. Therefore, the novel synthetic 
compound JCTH-4 may serve as a safer and more effective alternative, both 
alone and in combination with TAM, to the chemotherapeutics currently available. 
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Summary 
 The natural compound pancratistatin (PST) is a non-genotoxic inducer of 
apoptosis in a variety of cancers.  Nonetheless, PST is not readily synthesized 
and is present in very low quantities in its natural source to be applied clinically. 
We have previously synthesized and evaluated several synthetic analogues of 7-
deoxypancratistatin, and found that JC-TH-acetate-4 (JCTH-4), a C-1 
acetoxymethyl analogue, possessed similar apoptosis inducing activity compared 
to PST. In this study, osteosarcoma (OS) cells (Saos-2, U-2 OS) were 
substantially susceptible to JCTH-4-induced apoptosis through mitochondrial 
targeting; JCTH-4 induced collapse of mitochondrial membrane potential (MMP), 
increased reactive oxygen species (ROS) production in isolated mitochondria, 
and caused release of apoptosis inducing factor (AIF) and endonuclease G 
(EndoG) from isolated mitochondria. Furthermore, JCTH-4 selectively induced 
autophagy in OS cells.  Additionally, we investigated the combinatory effect of 
JCTH-4 with the natural compound curcumin (CC), a compound found in turmeric 
spice, previously shown to possess antiproliferative properties. CC alone had no 
observable effect on OS cells. However, when present with JCTH-4, CC was 
able to enhance the cytotoxicity of JCTH-4 selectively in OS cells. Cytotoxicity by 
JCTH-4 alone and in combination with CC was not observed in normal human 
osteoblasts (HOb) and normal human fetal fibroblasts (NFF).  Therefore, this 
report illustrates a new window in combination therapy, utilizing a novel synthetic 
analogue of PST with the natural compound CC, for the treatment of OS. 
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Introduction 
For many centuries, a plethora of natural products have been used in 
traditional medicine for the treatment of numerous ailments.  One such product 
includes the Curcuma longa herb (Ravindran et al. 2009). Traditionally, this herb 
has been used to treat anorexia, rheumatism, sinusitis, hepatic disorders, and 
inflammation (Singh 2007). More recently, a component of this herb, the 
compound curcumin (CC) also referred to as (1E,6E)-1,7-bis(4-hydroxy-3-
methoxyphenyl)-1,6-heptadiene-3,5-dione or diferuloylmethane, has been 
recognized for its antiproliferative properties in treating cancer (Ravindran et al. 
2009). In particular, CC has been shown to regulate expression of genes 
implicated in cell proliferation, metastasis, chemotherapy resistance, and 
angiogenesis (Ravindran et al. 2009; Kuttan et al. 1985). The anti-neoplastic 
properties of CC are exhibited in many types of malignancies including 
osteosarcoma (OS) (Ravindran et al. 2009; Walters et al. 2008).  
OS, a primary malignant bone tumor, is an extremely aggressive form of 
cancer associated with poor prognosis (Arndt & Crist 1999). It occurs most 
commonly in the developing bones of children and adolescents and is often 
accompanied by lung metastases and subsequent respiratory failure (Marina et 
al. 2004).  Current treatment strategies include surgery and radiation therapy with 
adjuvant chemotherapy with agents such as doxorubicin, cisplatin, methotrexate, 
etoposide, and ifosfamide at high doses (Marina et al. 2004). Despite the use of 
these chemotherapeutics, the 5-year survival rate for patients with metastatic OS 
is only 20% (Marina et al. 2004). Furthermore, toxicity has been associated with 
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the use of these drugs and chemoresistance frequently develops in this 
aggressive cancer; thus, more selective and effective chemotherapeutics are 
needed for OS (Bielack et al. 2002; Baum et al.; Smith et al. 1991; Meistrich et al. 
1989; Goorin et al. 1991).  
Previously, we have shown the natural compound pancratistatin (PST), 
isolated from the Hymenocallis littoralis plant, to induce cytotoxicity in a number 
of malignant cell lines at concentrations below 1 µM and reduce the volume of 
human prostate and colon tumor xenografts (Kekre et al. 2005; McLachlan et al. 
2005; Siedlakowski et al. 2008; Chatterjee et al. 2010; Griffin, Karnik, et al. 2011; 
Griffin, McNulty, et al. 2011). Contrasting from many approved 
chemotherapeutics in use, non-cancerous cell lines are markedly less sensitive 
to PST (Kekre et al. 2005; McLachlan et al. 2005; Siedlakowski et al. 2008; 
Chatterjee et al. 2010; Griffin, Karnik, et al. 2011; Griffin, McNulty, et al. 2011). 
PST however, is present in only parts per million quantities in its natural source 
and there have been many difficulties associated with its chemical synthesis; 
therefore, the major bottleneck of this compound has been its low availability for 
preclinical and clinical work. We have recently synthesized and screened 7-
deoxypancratistatin derivatives and have identified a C-1 acetoxymethyl 
analogue, JC-TH-acetate-4 (JCTH-4), with comparable efficacy and specificity to 
PST against several cancer cell lines (Collins et al. 2010).  
 Evasion of apoptosis, or type I programmed cell death, as a result of 
abnormalities in pathways leading to apoptosis plays a major role in the 
development of cancer; therefore, much effort has been made to manipulate and 
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restore apoptosis as a way to treat cancer (Borst & Rottenberg 2004; Liu et al. 
2011). Apoptosis can be activated in response to a death ligand binding to its 
corresponding death receptor or in response an internal stress stimulus such as 
DNA damage (Reed 2000). In response to such internal stress, various 
proapoptotic proteins are upregulated and translocated to the mitochondria 
where they induce mitochondrial membrane permeabilization, collapse of 
mitochondrial membrane potential (MMP), and release of apoptogenic factors 
which subsequently execute apoptosis directly or indirectly (Earnshaw 1999). 
Execution of this pathway yields nuclear and cellular condensation, membrane 
blebbing, and formation of apoptotic bodies which are phagocytosed by 
phagocytes or neighbouring cells (Reed 2000). As well as apoptosis, much focus 
has been put on the implications of other cell death pathways in cancer therapy 
(Kroemer et al. 2010; Levine 2007).  
Autophagy has been recognized as a cellular pro-survival response to 
various forms of sublethal cellular stress such as DNA damage, deficiencies in 
growth factors and nutrients, protein aggregates, reactive oxygen species, 
hypoxia, pathogens, and defective organelles (Kroemer et al. 2010). Once this 
pathway is activated, cytoplasmic material is sequestered by double-membraned 
vesicles known as autophagosomes. These autophagosomes fuse with 
lysosomes to form autolysosomes which degrade the contained cytoplasmic 
contents (Levine 2007).  Extensive activation of autophagy however, can result in 
a pro-death response leading to autophagic cell death, classified as type II 
programmed cell death (Gozuacik & Kimchi 2004).  
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In this report, we demonstrate JCTH-4 to be a potent inducer of apoptosis 
and autophagy in OS cells (Saos-2, U-2 OS) via mitochondrial targeting. 
Furthermore, CC was able to potentiate the cytotoxic effects of JCTH-4 in Saos-2 
and U-2 OS cells. The normal human fetal fibroblast (NFF) and normal human 
osteoblast (HOb) cell lines utilized in this study were drastically less sensitive to 
JCTH-4 alone and in combination with CC, presenting a potential therapeutic 
window for this aggressive malignancy.  
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Materials and Methods 
Cell Culture 
An OS cell line, Saos-2 (American Type Culture Collection, Cat. No. HTB-
85, Manassas, VA, USA), was grown in McCoy’s 5A Medium Modified (Sigma-
Aldrich Canada, Mississauga, ON, Canada) supplemented with 15% (v/v) fetal 
bovine serum (FBS) standard (Thermo Scientific, Waltham, MA, USA) and 10 
mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). An additional 
OS cell line, U-2 OS (American Type Culture Collection, Cat. No. HTB-96, 
Manassas, VA, USA), was grown in McCoy’s 5A Medium Modified (Sigma-
Aldrich Canada, Mississauga, ON, Canada) supplemented with 10% (v/v) FBS 
standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada). Apparently NFF cells (Coriell 
Institute for Medical Research, Cat. No. AG04431B, Camden, NJ, USA) were 
cultured in Dulbecco’s Modified Eagle’s Medium, High Glucose (Thermo 
Scientific, Waltham, MA, USA) supplemented with 15% (v/v) FBS standard 
(Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada). HOb cells (Cell Applications, Inc., Cat. No. 
406-05a, San Diego, CA, USA) were cultured in Osteoblast Growth Medium (Cell 
Applications, Inc., Cat. No. 417-500, San Diego, CA, USA). All cells were grown 
at 37˚ C and 5 % CO2. 
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Cell Treatment 
After culturing cells to 60–70 % confluence, they were treated with CC 
(Sigma-Aldrich Canada, Cat. No. C7727, Mississauga, ON, Canada), tamoxifen 
(TAM) citrate salt (Sigma-Aldrich, Cat. No. T9262, Mississauga, ON, Canada), 
the broad spectrum caspase inhibitor Z-VAD-FMK (EMD Chemicals, Gibbstown, 
NJ, USA), and JCTH-4 (((1S, 2S, 3R, 4S, 4aR, 11bR)-2, 3, 4-Trihydroxy-6-oxo-1, 
2, 3, 4, 4a, 5, 6, 11b-octahydro-[1,3]dioxolo[4,5-j]phenanthridin-1-yl)methyl 
Acetate) at the indicated doses and durations. As per a previously published 
protocol, JCTH-4 was produced by chemoenzymatic synthesis from 
bromobenzene (Collins et al. 2010). All stock solutions of drugs were made with 
dimethylsulfoxide (Me2SO).  
 
Nuclear Staining 
Post treatment and incubation with the aforementioned drugs, Hoechst 
33342 dye (Molecular Probes, Eugene, OR, USA) was used to stain the nuclei. 
Cells were incubated with 10 µM Hoechst 33342 dye for 5 minutes and images 
were taken at 400x magnification on a Leica DM IRB inverted fluorescence 
microscope (Wetzlar, Germany).  
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Annexin V Binding Assay 
The Annexin V binding assay was performed to verify the induction of 
apoptosis. Following drug treatment, cells were washed two times using 
phosphate buffer saline (PBS), resuspended in Annexin V binding buffer (10 mM 
HEPES, 10 mM NaOH, 140 mM NaCl, 1 mM CaCl2, pH 7.6), and incubated with 
Annexin V AlexaFluor-488 (1:50) (Sigma-Aldrich Canada, Mississauga, ON, 
Canada) for 15 minutes. Micrographs were taken at 400x magnification on a 
Leica DM IRB inverted fluorescence microscope (Wetzlar, Germany).  
 
WST-1 Assay for Cell Viability 
The WST-1 based colorimetric assay was performed according to the 
manufacturer’s protocol (Roche Applied Science, Indianapolis, IN, USA) to 
quantify cell viability as a function of active cell metabolism. 96-well clear bottom 
tissue culture plates were seeded with approximately 6.0 x 103 Saos-2 cells/well, 
7.5 x 103 U-2 OS cells/well, 5.0 x 103 NFF cells/well, or 4.0 x 103 HOb cells/well 
and treated with JCTH-4 and CC at the indicated concentrations and for the 
indicated durations. Following treatment, the WST-1 reagent, which is processed 
to formazan by cellular enzymes, was added to each well and incubated for 4 
hours at 37˚ C. Absorbance readings were taken at 450 nm on a Wallac Victor3 
TM 1420 Multilabel Counter (PerkinElmer, Woodbridge, ON, Canada) to quantify 
the formazan product and were expressed as percentages of the solvent control 
groups (Me2SO). 
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Tetramethylrhodamine Methyl Ester (TMRM) Staining 
TMRM (Gibco BRL, VWR, Mississauga, ON, Canada) was used as an 
indicator for MMP. Cells were grown on coverslips and treated with the indicated 
concentrations of JCTH-4 and CC for the indicated durations.  Subsequent to 
drug treatment, cells were incubated with 200 nM TMRM for 45 minutes at 37˚ C. 
Micrographs were taken at 400x magnification on a Leica DM IRB inverted 
fluorescence microscope (Wetzlar, Germany). 
 
Mitochondrial Isolation  
Mitochondria were isolated from untreated Saos-2 and U-2 OS cells. 
These cells were washed two times with cold PBS, resuspended in hypotonic 
buffer (1 mM EDTA, 5 mM Tris–HCl, 210 mM mannitol, 70 mM sucrose, 10 μM 
Leu-pep, 10 μM Pep-A, and 100 μM PMSF), manually homogenized, and 
subsequently centrifuged at 600 x g for 5 minutes at 4˚ C. The supernatant was 
centrifuged at 15,000 x g for 15 minutes at 4˚ C. The resulting cytosolic 
supernatant was discarded and the mitochondrial pellet was resuspended in cold 
reaction buffer (2.5 mM malate, 10 mM succinate, 10 μM Leu-pep, 10 μM Pep-A, 
and 100 μM PMSF in PBS). 
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Amplex Red Assay 
Generation of reactive oxygen species (ROS) was quantified with Amplex 
Red (Molecular Probes, Eugene, OR, USA). Opaque 96-well plates were equally 
loaded with isolated mitochondria suspended in cold reaction buffer, with 20 µg 
of protein/well. The Bio-Rad protein assay (Bio-Rad Laboratories, Hercules, CA 
USA) was used for protein quantification as per manufacturer’s protocol. Isolated 
mitochondria were incubated with the indicated concentrations of drugs, Amplex 
Red reagent at a final concentration of 50 µM, and horseradish peroxidase 
(Sigma-Aldrich Canada, Mississauga, ON, Canada) in the ratio of 6 U/200 µL.  
Paraquat (PQ) (Sigma-Aldrich Canada, Mississauga, ON, Canada) was used as 
a positive control at 250 µM. Fluorescence readings were acquired after 2 hours 
of incubation at Ex. 560 nm and Em. 590 nm on a spectrofluorometer 
(SpectraMax Gemini XS, Molecular Devices, Sunnyvale, CA, USA). 
Fluorescence readings were expressed as relative fluorescence units (RFU).  
 
Treatment of Isolated Mitochondria & Evaluation of Apoptogenic Factor Release 
Mitochondria isolated from Saos-2 and U-2 OS cells were directly treated 
with JCTH-4 and CC at the indicated concentrations for 2 hours in cold reaction 
buffer (2.5 mM malate, 10 mM succinate, 10 μM Leu-pep, 10 μM Pep-A, and 100 
μM PMSF in PBS). The control group was treated with solvent (Me2SO). After 
treatment, mitochondrial samples were vortexed and centrifuged at 15,000 x g for 
15 minutes at 4˚C.  The resultant supernatant and mitochondrial pellet 
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(resuspended in cold reaction buffer) samples were subjected to western blot 
analyses to monitor for mitochondrial release or retention of apoptogenic factors. 
  
Cellular Lysate Preparation 
Cells were treated for 72 hours with the indicated concentrations of JCTH-
4, CC, and TAM, and subsequently homogenized manually in cold hypotonic 
buffer (10 mM Tris HCl at pH 7.2, 5 mM KCl, 1 mM MgCl2, 1 mM EGTA, 1% 
Triton-X-100; 10 μM Leu-pep, 10 μM Pep-A, and 100 μM PMSF). Cell lysates 
were stored at -20˚ C until use. 
 
Western Blot Analyses  
SDS-PAGE was performed on the protein samples. Electrophoresed 
proteins were transferred to a nitrocellulose membrane. For 1 hour, membranes 
were blocked with a 5% w/v milk TBST (Tris-Buffered Saline with Tween-20) 
solution. The membranes were probed with various primary antibodies overnight 
at 4˚ C for microtubule-associated protein1 light chain 3 (LC3) raised in rabbit 
(1:500) (Novus Biologicals, Cat. No. NB100-2220, Littleton, CO, USA), β-Actin 
raised in mouse (1:1000) (Santa Cruz Biotechnology, Inc., Cat. No. sc-81178, 
Paso Robles, CA, USA), apoptosis inducing factor (AIF) raised in rabbit (1:1000) 
(Abcam, Cat. No. ab1998, Cambridge, MA, USA), endonuclease G (EndoG) 
raised in rabbit (1:1000) (Abcam, Cat. No. ab9647, Cambridge, MA, USA), and 
succinate dehydrogenase subunit A (SDHA) raised in mouse (1:1000) (Santa 
Cruz Biotechnology, Cat. No. sc-59687, Paso Robles, CA, USA). Following 
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primary antibody incubation, membranes were washed once for 15 minutes and 
twice for 5 minutes with TBST and were incubated with an anti-mouse (1:2000) 
or an anti-rabbit (1:2000) horseradish peroxidase-conjugated secondary antibody 
(Abcam, Cat. No. ab6728 & ab6802, Cambridge, MA, USA) for 1 hour at 25˚ C. 
After secondary antibody incubation, the membranes were washed three times 
for 5 minutes in TBST. Bands were visualized with enhanced chemiluminescence 
reagent (Sigma-Aldrich Canada, Cat. No. CPS160, Mississauga, ON, Canada) 
and densitometry analyses were performed using ImageJ software. 
 
Monodansylcadaverine (MDC) Staining 
MDC (Sigma-Aldrich Canada, Mississauga, ON, Canada) was used to 
detect autophagic vacuoles. Cells were grown on coverslips and treated with 
TAM, JCTH-4, and CC at the indicated concentrations and for the indicated 
durations.  After treatment, cells were incubated with 0.1 mM MDC for 15 
minutes. Using a Leica DM IRB inverted fluorescence microscope (Wetzlar, 
Germany), micrographs were taken at 400x magnification. 
 
Propidium Iodide (PI) Staining 
PI (Sigma-Aldrich Canada, Mississauga, ON, Canada) was used to detect 
cell lysis.  Cells were incubated with 1μg/mL PI for 10 minutes and images were 
taken at 400x magnification on a Leica DM IRB inverted fluorescence 
microscope (Wetzlar, Germany).  
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Results 
JCTH-4 causes selective cytotoxicity in OS cells in a time and dose-dependent 
manner  
As we have previously found PST (Figure 3.1A) to be effective in 
producing cytotoxicity selectively in various cancer cell lines, we evaluated the 
activity of JCTH-4 (Figure 3.1B) in the OS cell lines Saos-2 and U-2 OS using 
the WST-1 based colorimetric assay for cell viability. JCTH-4 decreased cell 
viability in a time and dose dependent manner and had a half-maximal inhibitory 
concentration (IC50) value of 0.25 µM after 48 hours in both Saos-2 and U-2 OS 
cells (Figure 3.2A & B). Importantly, JCTH-4 was selective to OS cells as HOb 
and NFF cells were drastically less sensitive to this compound (Figure 3.2C). 
 
CC potentiates the cytotoxicity of JCTH-4 selectively in OS cells 
 The natural compound CC has been shown to possess anti-cancer 
properties as well as the ability to enhance the efficacy of various 
chemotherapeutics (Patel & Majumdar 2009; Epelbaum et al. 2010). Thus, we 
evaluated the combinatorial effects of CC and JCTH-4 in OS cells. CC alone at 5 
µM had no significant effect on Saos-2 (96 hours) and U-2 OS cells (72 hours); 
however, when used in combination, CC was able to selectively potentiate the 
effect of JCTH-4 in these OS cell lines as HOb and NFF cells were markedly less 
sensitive to this combinatorial insult (Figure 3.3A-D).  
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Figure 3.1. Comparison of chemical structures. Structures of (A) 
Pancratistatin (PST) and (B) JC-TH-acetate-4 (JCTH-4).  
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Figure 3.2. JCTH-4 causes selective cytotoxicity in OS cells in a time and 
dose-dependent manner.  Effect of JCTH-4 on cellular viability of OS cells was 
determined by the WST-1 based colorimetric assay.  (A) Saos-2 and (B) U-2 OS 
cells were treated with JCTH-4 and the WST-1 reagent was used to quantify cell 
viability. Absorbance was read at 450 nm and expressed as a percent of the 
control (Me2SO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments. *p<0.05, **p<0.01, ***p<0.001 versus solvent control 
(Me2SO). (C) Effect on cellular viability of HOb and NFF cells treated with JCTH-
4 compared to Saos-2 and U-2 OS cells after 72 hours.  The WST-1 reagent was 
used to quantify cellular viability. Absorbance was read at 450 nm and expressed 
as a percent of the solvent control (Me2SO). Values are expressed as mean ± SD 
from quadruplicates of 3 independent experiments. *p<0.005 versus Saos-2 
cells; #p<0.005 versus U-2 OS cells.  
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Figure 3.3. CC potentiates the cytotoxicity of JCTH-4 selectively in OS cells. 
Effect of JCTH-4 & CC in combination on cellular viability of OS cells was 
determined by the WST-1 based colorimetric assay.  (A) Saos-2 (96 hours), (B) 
U-2 OS (72 hours), (C) HOb (72 hours), and (D) NFF (72 hours) cells were 
treated with JCTH-4 and CC and the WST-1 reagent was used to quantify 
cellular viability. Absorbance was read at 450 nm and expressed as a percent of 
the solvent control (Me2SO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments. *p<0.05, **p<0.01, versus solvent 
control (Me2SO); †p<0.001 versus 0.25 μM JCTH-4; ††p<0.01 versus 0.5 μM 
JCTH-4; #p<0.001 versus 5 μM CC; @p<0.001 versus 0.25 μM JCTH-4 + 5 μM 
CC treatment with Saos-2 cells (Figure 3A); &p<0.01 versus 0.5 μM JCTH-4 + 5 
μM CC treatment with U-2 OS cells (Figure 3B). 
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JCTH-4 alone & in combination with CC induces apoptosis in OS cells 
Nuclear and cellular morphology was monitored in Saos-2 and U-2 OS 
cells treated with JCTH-4 and CC at the indicated concentrations for 96 and 72 
hours respectively. As depicted by Hoechst staining, JCTH-4 produced brightly 
stained, condensed nuclei, and apoptotic bodies while corresponding phase 
micrographs revealed cell condensation and blebbing in a dose dependent 
manner; such features are indicative of apoptosis (Figure 3.4A & B). This 
morphology was not present in OS cells treated with 5 µM CC alone (Figure 
3.4A & B); however, the frequency of these morphological changes induced by 
JCTH-4 was enhanced when used with 5 µM CC (Figure 3.4A & B).  All of the 
aforementioned treatments did not produce apoptotic morphology in both HOb 
and NFF cells (Figure 3.5A & B). Selective induction of apoptosis by JCTH-4 
alone and in combination with CC in OS cells was confirmed by Annexin V 
binding to externalized phosphatidylserine, a marker for apoptosis, indicated by 
green fluorescence (Figure 3.6 & 3.7) (Zhang et al. 1997).  
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Figure 3.4. JCTH-4 alone and in combination with CC yields apoptotic 
morphology in OS cells. Nuclear and cellular morphology of (A) Saos-2 cells 
after 96 hours of treatment and (B) U-2 OS cells after 72 hours of treatment.  
Cells were treated with JCTH-4, CC, and solvent control (Me2SO).  Post 
treatment, the cells were stained with Hoechst 33342 dye. Corresponding phase 
micrographs are shown below the Hoechst micrographs. Apoptotic morphology is 
evident in cells with bright and condensed nuclei accompanied by apoptotic 
bodies, as well as cell shrinkage and blebbing. Images were taken at 400x 
magnification on a fluorescent microscope. Scale bar = 15 µm. 
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Figure 3.5. JCTH-4 and CC do not yield apoptotic morphology in HOb and 
NFF cells. Nuclear and cellular morphology of (A) HOb and (B) NFF cells after 
72 hours of treatment.  Cells were treated with JCTH-4, CC, and solvent control 
(Me2SO). Post treatment, the cells were stained with Hoechst 33342 dye. 
Corresponding phase micrographs are shown below the Hoechst micrographs. 
Apoptotic morphology is evident in cells with bright and condensed nuclei 
accompanied by apoptotic bodies, as well as cell shrinkage and blebbing. 
Images were taken at 400x magnification on a fluorescent microscope. Scale bar 
= 15 µm. 
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Figure 3.6. JCTH-4 alone and in combination with CC induces 
phosphatidylserine externalization in OS cells. Annexin V binding to 
externalized phosphatidylserine was monitored to confirm induction of apoptosis 
in (A) Saos-2 cells after 96 hours of treatment and (B) U-2 OS cells after 72 
hours of treatment with the indicated concentrations of JCTH-4, CC, and solvent 
control (Me2SO). Cells were also stained with Hoechst dye. Images were taken at 
400x magnification on a fluorescent microscope. Green fluorescence is indicative 
of Annexin V binding to externalized phosphatidylserine of the plasma 
membrane.  Scale bar = 15 µm. 
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Figure 3.7. JCTH-4 alone and with CC does not induce phosphatidylserine 
externalization in HOb and NFF cells.  Annexin V binding to externalized 
phosphatidylserine was monitored to confirm that apoptosis was not induced in 
(A) HOb and (B) NFF cells after 72 hours of treatment. Cells were treated with 
the indicated concentrations of JCTH-4, CC and solvent control (Me2SO). Cells 
were also stained with Hoechst dye. Images were taken at 400x magnification on 
a fluorescent microscope. Green fluorescence is indicative of Annexin V binding 
to externalized phosphatidylserine of the plasma membrane.  Scale bar = 15 µm.  
 
 
 
 
 
 116 
 
JCTH-4 alone and in combination with CC targets OS cell mitochondria 
In preceding studies, PST has been found to exert its effects by way of 
mitochondrial targeting; thus, mechanistic studies were performed to verify such 
targeting by JCTH-4 in OS cells (McLachlan et al. 2005; Siedlakowski et al. 2008; 
Chatterjee et al. 2010; Griffin, Karnik, et al. 2011). Saos-2 and U-2 cells were 
treated for 96 and 72 hours respectively with JCTH-4 and CC at the indicated 
concentrations and stained with Hoechst dye and TMRM, an indicator of intact 
MMP and impermeabilized mitochondrial membrane, depicted by red 
fluorescence. Greatest dissipation of MMP was seen in OS cells treated with 1 
µM JCTH-4 (Figure 3.8A & B). Dissipation of MMP was also seen with lower 
doses of JCTH-4; this dissipation by JCTH-4 was enhanced with the addition of 5 
µM CC, which had no observable effect on MMP its own (Figure 3.8A & B). 
Additionally, none of these treatments yielded MMP dissipation in HOb and NFF 
cells (Figure 3.9A & B). 
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Figure 3.8. JCTH-4 dissipates MMP alone and in combination with CC in OS 
cells. Effect of JCTH-4 and CC on MMP in (A) Saos-2 cells after 96 hours of 
treatment and (B) U-2 OS cells after 72 hours of treatment was examined by 
TMRM staining. Cells were grown on coverslips, treated with the indicated 
concentrations of JCTH-4, CC, and solvent control (Me2SO) and stained with 
TMRM and Hoechst dye. Images were taken at 400x magnification on a 
fluorescent microscope. Red fluorescent punctuate marks are indicative of 
mitochondria with intact MMP. Scale bar = 15 µm. 
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Figure 3.9. JCTH-4 and CC do not dissipate MMP in HOb and NFF cells. 
Effect of JCTH-4 and CC on MMP in (A) HOb and (B) NFF cells after 72 hours of 
treatment was examined by TMRM staining.  Cells were grown on coverslips, 
treated with the indicated concentrations of JCTH-4, CC, and solvent control 
(Me2SO), and stained with TMRM and Hoechst dye. Images were taken at 400x 
magnification on a fluorescent microscope. Red fluorescent punctuate marks are 
indicative of mitochondria with intact MMP. Scale bar = 15 µm. 
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Oxidative stress produced in the mitochondria has been associated with 
the dysfunction of this organelle; in particular, mitochondrial permeabilization and 
apoptogenic factor release have both been linked to increases in ROS production 
(Madesh & Hajnóczky 2001; Simon et al. 2000; Batandier et al. 2004; Cochemé 
& Murphy 2008). After apoptogenic factors are released into the cytosol from the 
mitochondria, some can execute apoptosis by translocating to the nucleus or 
participating in cytosolic downstream pathways (Earnshaw 1999). To evaluate 
the ability of JCTH-4 to induce the generation of ROS directly in mitochondria of 
OS cells, mitochondria were isolated from Saos-2 and U-2 OS cells, treated 
directly with various doses of JCTH-4 and CC for 2 hours, and analyzed for ROS 
production with Amplex Red. JCTH-4 alone at several concentrations caused an 
increase in ROS production in OS cells which was further enhanced by the 
addition of 5 µM CC (Figure 3.10A & B). 5 µM CC alone also increased ROS 
generation in isolated OS cell mitochondria (Figure 10A,B) PQ, known to cause 
ROS production in mitochondria, was used as a positive control (Cochemé & 
Murphy 2008). Furthermore, isolated mitochondria of OS cells treated with JCTH-
4 alone or with CC for 2 hours were monitored for the release of apoptogenic 
factors. Post treatment, mitochondrial samples were resuspended and 
centrifuged; resultant post mitochondrial supernatants and mitochondrial pellets 
were monitored by western blot analyses for the release and retention of 
apoptogenic factors respectively. By analyzing the resultant mitochondrial pellet 
samples of U-2 OS cells, isolated U-2 OS cell mitochondria treated with JCTH-4 
retained less of the apoptogenic factor AIF (Figure 3.10C). JCTH-4 also caused 
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the release of the apoptogenic factor EndoG in a dose dependent manner from 
these U-2 OS mitochondria, deduced by the analysis of the post mitochondrial 
supernatants (Figure 3.10C). Similarly, JCTH-4 and 5 µM CC alone caused the 
release of AIF from isolated mitochondria of Saos-2 cells; however, combinatorial 
treatment yielded the greatest release of AIF (Figure 3.10D). 
The execution of apoptosis by released apoptogenic factors from the 
mitochondria can be achieved with the activation of proteins known as caspases, 
a family of cysteine proteases, or directly by the apoptogenic factor (Earnshaw 
1999; Kroemer et al. 2010). To determine the dependence of caspases in JCTH-
4-induced apoptosis, the broad spectrum caspase inhibitor Z-VAD-FMK was 
used at various doses in combination with JCTH-4. However, as determined 
through the WST-1 based colorimetric assay for cell viability, this inhibitor was 
not able to protect Saos-2 cells from JCTH-4 insult (Figure 3.10E). Thus, JCTH-
4 exerts its cytotoxicity against OS cells in a manner independent of caspase 
activation. 
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Figure 3.10. JCTH-4 directly causes mitochondrial ROS production and 
release of apoptogenic factors independent of caspases. (A) Saos-2 and (B) 
U-2 OS isolated mitochondria were treated directly with JCTH-4, CC, PQ, and 
solvent control (Me2SO), and incubated with Amplex Red and horseradish 
peroxidase for 2 hours. Subsequently, fluorescence readings were taken at Ex. 
560 nm and Em. 590 nm and expressed as relative fluorescence units (RFU). 
Statistics were performed using GraphPad Prism version 5.0. Image is 
representative of 3 independent experiments demonstrating similar trends. 
Values are expressed as mean ± SD of quadruplicates of 1 independent 
experiment. *p<0.05, **p<0.01, ***p<0.001 versus solvent control (Me2SO); 
†p<0.01 versus 0.25 μM JCTH-4; @p<0.01 versus 0.5 μM JCTH-4; #p<0.01 
versus 5 μM CC. Isolated mitochondria samples treated directly with JCTH-4, 
CC, and solvent control (Me2SO) for 2 hours were also centrifuged, producing 
mitochondrial pellets and post mitochondrial supernatants which were examined 
for retention and release of apoptogenic factors respectively via western blot 
analyses; (C) Retention of AIF and release of EndoG by U-2 OS cell 
mitochondria and (D) release of AIF by Saos-2 cell mitochondria was monitored. 
Mitochondrial pellets were probed for SDHA to serve as loading controls. 
Densitometric analyses were performed using ImageJ software and statistics 
were calculated using GraphPad Prism version 5.0. Image is representative of 3 
independent experiments demonstrating similar trends. Values are expressed as 
mean ± SD of triplicates of one independent experiment. *p<0.01, **p<0.001 
versus solvent control (Me2SO); †p<0.01 versus 0.25 μM JCTH-4; #p<0.01 
versus 5 μM CC. (E) Saos-2 cells were treated with broad spectrum caspase 
inhibitor Z-VAD-FMK with and without JCTH-4 for 72 hours. WST-1 reagent was 
used to quantify cell viability. Absorbance was read at 450 nm and expressed as 
a percent of solvent control (Me2SO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments. *p<0.001 versus solvent control 
(Me2SO); ns = not significant.  
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JCTH-4 selectively induces autophagy alone and with CC in OS cells 
Various studies have reported chemotherapeutics to trigger both pro-
death and pro-survival autophagy (Dalby et al. 2010). Moreover, because JCTH-
4 produced oxidative stress, a known autophagy inducer, we monitored OS cells 
for autophagic induction following treatment with JCTH-4 and CC. As illustrated 
MDC staining, OS cells treated with various doses of JCTH-4 produced blue 
punctate staining, indicative of autophagic vacuoles (Figure 3.11A & B). Such 
staining was also seen with the combinatorial treatment of 0.25 µM JCTH-4 and 
5 µM CC, but not with 5 µM CC treatment alone (Figure 3.11A & B). 
Corresponding phase and PI images show cell shrinkage and blebbing with 
JCTH-4 treatment alone and in combination, but not with CC alone, while only 
combination treatment gave some positive PI staining (Figure 3.11A & B). 
During autophagy, LC3 situated in the cytosol, referred to as LC3-I, is 
converted to LC3-II, a lipidated form of LC3 that is recruited to autophagosomal 
membranes (Kabeya et al. 2000). To confirm the induction of autophagy in OS 
cells, western blot analyses were carried out on cell lysates of Saos-2 cells 
treated with the indicated concentrations of JCTH-4 and CC for 72 hours to 
monitor the conversion of LC3-I to LC3-II. TAM, a known inducer of autophagy, 
was used as a positive control. This conversion was enhanced with JCTH-4 at 
various concentrations (Figure 3.11C). With the treatment of 5 µM CC alone, 
LC3-II conversion decreased, and when used with 0.25 µM JCTH-4, the effect 
was not significantly different from 0.25 µM JCTH-4 alone (Figure 3.11C).  In 
HOb and NFF cells, autophagic induction was only seen in the TAM positive 
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control groups but not in cells treated with JCTH-4 and CC alone and in 
combination (Figure 3.12A & B). Therefore, JCTH-4 selectively induces 
autophagy in OS cells.  
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Figure 3.11. JCTH-4 induces autophagy in OS cells alone and with CC. The 
presence of autophagic vacuoles in (A) Saos-2 after 96 hours of treatment and 
(B) U-2 OS cells after 72 hours of treatment with JCTH-4, CC, and solvent 
control (Me2SO) was determined by MDC staining. Bright blue punctate marks 
are indicative of autophagic vacuoles. Corresponding phase and PI micrographs 
are shown below the MDC images. Scale bar = 15 µm. (C) Cell lysates of Saos-2 
cells treated with JCTH-4, CC, TAM as positive control, and solvent control 
(Me2SO) for 72 hours were examined for the conversion of LC3-I to LC3-II by 
western blot analyses. β-actin was probed to serve as a loading control. 
Densitometric analyses were done using ImageJ software and statistics were 
calculated using GraphPad Prism version 5.0. Image is representative of 3 
independent experiments demonstrating similar trends. Values are expressed as 
mean ± SD of triplicates of one independent experiment. *p<0.05, **p<0.01 
versus solvent control (Me2SO); #p<0.01 versus 5 μM CC.  
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Figure 3.12. JCTH-4 and CC do not induce autophagy in Hob and NFF cells. 
MDC staining was used to detect the presence of autophagic vacuoles in (A) 
HOb and (B) NFF cells after 72 hours of treatment with JCTH-4, CC, and solvent 
control (Me2SO) at the indicated concentrations. Bright blue punctate marks are 
indicative of autophagic vacuoles. Corresponding phase and PI micrographs are 
shown below the MDC images. Scale bar = 15 µm.  
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Discussion 
 In this study, we demonstrate JCTH-4 to be a highly potent agent against 
OS cells. More specifically, JCTH-4 exerts its cytotoxicity against OS by way of 
apoptotic induction; OS cells treated with JCTH-4 exhibited cell shrinkage, 
blebbing, nuclear condensation, apoptotic body formation, phosphatidylserine 
externalization, and MMP dissipation (Figure 3.4, 3.6, 3.8). OS cells treated with 
JCTH-4 alone were negative for PI staining, a plasma membrane impermeable 
DNA stain, suggesting these cells were not dying by necrosis, a form of cell 
death characterized by lysis of the plasma membrane (Figure 3.11A & B) 
(Pollack & Leeuwenburgh 2001). However, some PI positive staining was 
present in the combination treatment with CC, which could be a result of the 
permeabilization of cell membranes of late apoptotic cells (Figure 3.11A & B) 
(Gregory & Devitt 2004). Considerable toxicity to non-malignant tissue has been 
associated with a majority of the chemotherapeutics used for OS (Singal & 
Iliskovic 1998; Ta et al. 2006; Flombaum & Meyers 1999; Gurjal et al. 1999; 
Loebstein & Koren 1998). However, HOb cells, a normal non-cancerous 
equivalent to the OS cells used in this study, as wells as NFF cells exhibited 
markedly decreased sensitivity and did not show evident signs of apoptotic 
induction with JCTH-4 treatment (Figure 3.2C, 3.5, 3.7, 3.9); therefore, JCTH-4 
is selective towards OS cells and may prove to be a safer alternative for OS 
treatment to the current chemotherapeutics in use. Such selectivity suggests a 
specific target in cancer cells. 
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Previously, we have provided supporting evidence suggesting that PST 
targets cancer cell mitochondria (McLachlan et al. 2005; Griffin, Karnik, et al. 
2011). Complementing this data, we report similar results with JCTH-4. In 
addition to the JCTH-4-induced collapse of MMP in OS cells, observations made 
after direct JCTH-4-insult to isolated OS mitochondria strongly suggest this 
specific apoptotic activity to be attributed to mitochondrial targeting; with regards 
to isolated mitochondria from OS cells, JCTH-4 caused an increase in ROS 
generation and the release of apoptogenic factors (Figure 3.10).  Likewise, PST 
selectively dissipated MMP with whole cell treatment and caused ROS 
production in isolated cancer cell mitochondria and not in non-cancerous cell 
mitochondria (McLachlan et al. 2005; Siedlakowski et al. 2008). Additionally, the 
tumor suppressor p53, which causes the expression of proapoptotic proteins that 
permeabilize the mitochondria in response to different forms of intracellular 
stress, proved to be of little importance in JCTH-4-induced apoptosis (Zilfou & 
Lowe 2009); Saos-2 cells, which do not express p53, and U-2 OS cells, with 
wildtype p53, were equally very sensitive to JCTH-4 insult (Figure 3.2A & B, 3.4) 
(Masuda et al. 1987; Navaraj et al. 2005).  This circumvention in p53 activity 
strengthens the argument for a mitochondrial target as all p53 cellular events 
upstream of mitochondrial permeabilization have been proven to be insignificant 
in JCTH-4-induced cytotoxicity. As well as taking part in apoptosis pathways 
involved with the mitochondria, caspases are also utilized in apoptosis pathways 
independent of the mitochondria (Degterev et al. 2003). Akin to PST, we have 
found caspases to be nonessential in JCTH-4-induced apoptosis (Figure 3.10E), 
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and that AIF and EndoG, two apoptogenic factors involved in caspase-
independent pathways of apoptosis, are released from the mitochondria by direct 
JCTH-4 insult (Figure 3.10C & D); thus, caspase signalling upstream of 
mitochondrial membrane permeabilization and independent of mitochondria are 
not vital for the induction of apoptosis by JCTH-4, thereby further supporting the 
notion of a mitochondrial target by JCTH-4 (Griffin, Karnik, et al. 2011; Earnshaw 
1999; Degterev et al. 2003; Susin et al. 1999; Li et al. 2001). It is this targeting of 
the mitochondria that may provide the means to cancer selectivity by JCTH-4.  
Cancer cells possess many distinct characteristics, such as marked 
differences in their mitochondria and energy metabolism, which may be exploited 
for cancer selective therapy (Gogvadze et al. 2008; Chen et al. 2010). Cancer 
cells possess a distinct metabolic phenotype, a phenomenon referred to as the 
Warburg effect, in which levels of aerobic glycolysis are elevated; thus, these 
cells have high glucose uptake and through the production of lactate, produce an 
acidic microenvironment (Warburg 1956; Gambhir 2002; Gatenby & Gillies 
2004). Consequently, this glycolytic shift confers a proliferative advantage and an 
acquired resistance to apoptosis in cancer cells; intermediates of glycolysis 
provide a vast source of resources needed for nucleotide and lipid synthesis and 
alterations of the outer mitochondrial membrane have rendered it less 
susceptible to permeabilization (DeBerardinis et al. 2008; Gogvadze et al. 2010; 
Plas & Thompson 2002). Therefore, a promising strategy in cancer therapy 
would be to divert cancer cell metabolism away from glycolysis, which was 
demonstrated by other efforts via the promotion of oxidative phosphorylation 
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(Bonnet et al. 2007). Such a strategy may be employed by JCTH-4. A major 
factor promoting the resistance to apoptosis as a result of this metabolic shift is 
the glycolytic enzyme hexokinase; its association to the outer mitochondrial 
membrane has been shown to discourage mitochondrial membrane 
permeabilization (Vander Heiden et al. 2009; Pastorino et al. 2002). Cancer cells 
have also been reported to highly express antiapoptotic members of the Bcl-2 
family of proteins, all of which inhibit mitochondrial outer membrane 
permeabilization (Green & Kroemer 2004; Casellas et al. 2002). Thus, JCTH-4 
may act by targeting these proteins.  
Traditional medicines have long used natural products in treating various 
disorders. Modern science is now rediscovering many of these products and their 
potential in rectifying numerous pathological conditions (Griffin, Karnik, et al. 
2011; Chatterjee et al. 2011). The natural compound CC, used to treat an array 
of ailments, has been recognized to possess potent activity against numerous 
cancers, including OS (Walters et al. 2008; Ravindran et al. 2009). As 
determined by the WST-1 colorimetric assay, other reports have established IC50 
values of 17.2 µM and 21.6 µM in Saos-2 and U-2 OS cells respectively after 72 
hours (Walters et al. 2008). By similar means, we found 5 µM CC to have very 
little to no effect on these cell lines (Figure 3.3A & B). However, when used with 
JCTH-4, CC was found to potentiate the cytotoxic effects of JCTH-4 in both 
Saos-2 and U-2 OS cells with HOb and NFF cells being markedly less sensitive 
to this combinatorial treatment (Figure 3.3A-D). Like JCTH-4 treatment alone, 
this combinatorial treatment exerts its cytotoxicity against OS cells selectively 
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through induction of apoptosis (Figure 3.4-3.7). Although whole cell treatment of 
OS cells with 5 µM CC did not appear to effect viability of mitochondria (Figure 
3.8), direct insult to isolated OS mitochondria induced ROS production and 
release of AIF (Figure 3.10A, B, D); such discrepancies between whole cell and 
direct mitochondrial treatment may be attributed to low solubility or uptake of CC 
(Kurien et al. 2007). In accordance with our findings, although at higher doses, 
other studies report whole cell treatment with CC to induce ROS production and 
AIF release from mitochondria (Thayyullathil et al. 2008; Rashmi et al. 2005). 
Interestingly, direct treatment of CC on OS mitochondria enhanced ROS 
production and AIF release (Figure 3.10A, B, D). CC is known to bind and target 
numerous proteins; however, these findings suggest CC binds either one of 
these known targets and/or an unknown protein, both associated to the 
mitochondria (Ravindran et al. 2009; Aggarwal et al. 2007). As JCTH-4 is shown 
to elicit its cancer selective effects via mitochondrial targeting, such targeting by 
CC may be responsible for sensitizing OS cells to JCTH-4-induced apoptosis. 
Dual roles, both pro-death and pro-survival, have been implicated in 
autophagic induction elicited by chemotherapeutic insult (Dalby et al. 2010). 
JCTH-4 was found to induce autophagy at doses between 0.25 µM and 1 µM 
while 5 µM CC yielded no observable autophagic response in OS cells (Figure 
3.11). The autophagic response produced by the combination treatment of 5 µM 
CC and 0.25 µM JCTH-4 was not significantly different from the response elicited 
by the 0.25 µM JCTH-4 treatment alone; this may indicate the enhancement in 
activity of JCTH-4 by CC to be a result of targeting the apoptosis pathway rather 
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than that of autophagy by CC.  Previous work has shown CC alone to induce 
autophagy, although at much higher doses used in this study; inconsistencies 
between these findings and that of this report again may be attributed to the low 
solubility and uptake of CC (Kurien et al. 2007; Aoki et al. 2007). JCTH-4 
treatment yielded autophagic induction which was accompanied by significant 
cytotoxicity and cell death, as depicted in the corresponding phase images and 
previous figures (Figure 3.2A & B, 3.3A & B, 3.4, 3.6, 3.11A & B); this may 
indicate JCTH-induced autophagy to be a detrimental response in OS cells. Such 
induction was not evident in HOb and NFF cells (Figure 3.13); therefore, 
autophagic induction by JCTH-4 is selective towards OS cells. As established in 
this report, JCTH-4 causes mitochondrial ROS production and mitochondrial 
dysfunction. Oxidative stress is a known inducer of autophagy and thus, JCTH-4 
may trigger autophagy as a default mechanism (Kroemer et al. 2010). 
Regardless, because JCTH-4 permeabilizes OS cell mitochondria, these cells 
ultimately die from apoptosis. 
Recapitulating the findings of this report, JCTH-4, was found to effectively 
induce apoptosis and autophagy in OS cells with evidence suggesting this to be 
a result of mitochondria targeting. Additionally, the natural compound CC was 
able to potentiate these cytotoxic effects induced by JCTH-4 against OS cells. 
Importantly, JCTH-4 treatment alone and in combination proved to be selective 
towards OS cells as non-cancerous cells were markedly less sensitive and did 
not show evident signs of apoptotic and autophagic induction. Thus, we present 
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a promising novel strategy, combining the novel synthetic compound JCTH-4 and 
the natural compound CC for the treatment of OS. 
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7-deoxyPST 7-deoxypancratistatin  
AMA  Antimycin A  
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Casp-3 Caspase-3  
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Cyto c cytochrome c  
DCF  2’, 7’-dicholorofluorescein  
DIC  differential interference contrast  
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ETC  electron transport chain  
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Summary 
 Enhanced mitochondrial stability and a decreased dependence on 
mitochondrial oxidative phosphorylation for energy production confer both an 
acquired resistance to apoptosis and a proliferative advantage in cancer cells. 
Thus, exploiting these dissimilarities could strategically be employed for therapy. 
The natural compound pancratistatin (PST), has been shown to selectively 
induce apoptosis in a variety of cancer cell types by mitochondrial targeting. 
However, its low availability in nature and complexities in its chemical synthesis 
have hindered its clinical advancement. To overcome these limiting factors, we 
synthesized a number of PST analogues with the complete anti-cancer 
pharmacophore of PST and related alkaloids. A medium throughput screen was 
completed on 18 cancer cell lines and non-cancerous cells. PST analogues 
SVTH-7, -6, and -5 demonstrated potent anti-cancer activity with greater efficacy 
than natural PST, 7-deoxyPST analogues, and several standard 
chemotherapeutics. They were efficient in disrupting mitochondrial function, 
activating the intrinsic pathway of apoptosis in both monolayer and spheroid 
culture, and reducing growth of tumor xenografts in vivo. Interestingly, the pro-
apoptotic effects of SVTH-7 on cancer cells and mitochondria were abrogated 
with the inhibition of mitochondrial complex II, and to a slightly lesser extent 
complex III, signifying mitochondrial or metabolic vulnerabilities may exploited by 
this PST analogue. Therefore, this work provides a scaffold for characterizing 
distinct mitochondrial and metabolic features of cancer cells and reveals several 
lead compounds with high therapeutic potential. 
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Introduction 
 Mitochondria serve many cellular functions including energy production via 
oxidative phosphorylation. Additionally, this organelle plays a pivotal role in 
apoptosis, a cellular suicide program, by housing apoptogenic factors that act to 
the detriment of the cell once released into the cytoplasm (Tait & Green 2010). 
Unlike the extrinsic pathway of apoptosis which requires an external stimulus, the 
intrinsic pathway is elicited by internal stress, such as DNA damage and 
oxidative stress (Fulda & Debatin 2006). Following intracellular stress, 
mitochondrial permeabilization is induced, causing apoptogenic factor release, 
and subsequent execution of apoptosis. This process can occur physiologically, 
during embryogenesis or as a safeguard against DNA damage, or can be 
pathologically altered in various disease states (Brown & Attardi 2005). Cancer 
cells divert most of their means of energy production to glycolysis and away from 
mitochondrial oxidative phosphorylation (Vander Heiden et al. 2009). This 
reallocation in cellular energetics, in additional to the upregulation of anti-
apoptotic proteins, provides additional stability to mitochondria and, 
consequently, an acquired resistance to apoptosis (DeBerardinis et al. 2008; 
Gogvadze et al. 2010; Plas & Thompson 2002). Thus, targeting the differences in 
energy metabolism and cancer cell mitochondria could serve as potential 
strategies for cancer therapy.  
 Mitocans are a class of compounds that have recently emerged and are 
defined as drugs that specifically target cancer cell mitochondria to induce 
mitochondrial dysfunction and activation of mitochondrial mediated apoptosis 
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pathways (Chen et al. 2010; Ralph et al. 2006). These include, but are not limited 
to, electron transport chain (ETC) blockers, activators of the permeability 
transition pore of the mitochondria, pro-apoptotic Bcl-2 protein mimetics, and 
anti-apoptotic Bcl-2 protein inhibitors (Rohlena et al. 2013; Yip & Reed 2008; 
Adams & Cory 2007). Mitocans have been shown to be generally well tolerated 
by non-cancerous cells and effective anti-cancer agents, alone or in combination 
to enhance the activity of other cancer therapies (Neuzil et al. 2013).  
 We have previously discovered one such compound, pancratistatin (PST), 
an Amaryllidaceae alkaloid isolated from the Hymenocallis littoralis plant, that 
selectively induces apoptosis in numerous cancer cell types by mitochondrial 
targeting (Kekre et al. 2005; McLachlan et al. 2005; Siedlakowski et al. 2008; 
Chatterjee et al. 2010; Griffin et al. 2010; Griffin, McNulty, et al. 2011; Griffin, 
Karnik, et al. 2011). However, further development of PST has been hindered by 
its low availability in the Hymenocallis littoralis species and complications in its 
chemical synthesis. Circumventing these bottlenecks, we have synthesized a 
number of PST analogues that possess the proposed anti-cancer 
pharmacophore of PST and related alkaloids (Vshyvenko et al. 2011).  
 In this study, anti-cancer activity of these compounds, 7-
deoxypancratistatin (7-deoxyPST) analogues, natural PST and common 
chemotherapeutics was evaluated via a medium throughput screen in 18 cancer 
cell lines and non-cancerous cells. Several PST analogues, including SVTH-7, -
6, and -5 demonstrated selective, potent anti-cancer activity, having greater 
efficacy than natural PST, their C-7 deoxy counterparts, and most importantly 
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several standard chemotherapeutics. These analogues were effective in 
disrupting mitochondrial function and activating the intrinsic pathway of 
apoptosis. Furthermore, these analogues were able to induce apoptosis of 
cancer cells grown in three-dimensional spheroid culture selectively and reduce 
growth of colorectal cancer and glioblastoma tumor xenografts in vivo. 
Interestingly, inhibition of mitochondrial complex II, and to a slightly lesser extent 
complex III, abolished the mitochondrial pro-apoptotic effects of SVTH-7, 
confirming that a mitochondrial vulnerability may be exploited by this PST 
analogue. These findings form a basis for discerning important mitochondrial and 
metabolic features in cancer cells and present several compounds with high 
therapeutic potential. 
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Materials and Methods 
Cell Culture 
 The E6-1 acute T-cell leukemia cell line (American Type Culture 
Collection, Cat. No. TIB-152, Manassas, VA, USA), was cultured with RPMI-1640 
medium (Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 
10% (v/v) fetal bovine serum (FBS) standard (Thermo Scientific, Waltham, MA, 
USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). 
 The MV-4-11 Chronic myelomonocitic leukemia cell line (ATCC, Cat. No. 
CRL-9591, Manassas, VA, USA). was cultured with Iscove's Modified Dulbecco's 
Medium (ATCC, Cat. No. 30-2005, Manassas, VA, USA) supplemented with 10% 
(v/v) FBS standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL 
gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). 
 The U-937 histiocytic lymphoma cell line (ATCC, Cat. No. CRL-1593.2, 
Manassas, VA, USA). was cultured with Iscove's Modified Dulbecco's Medium 
(ATCC, Cat. No. 30-2005, Manassas, VA, USA) supplemented with 10% (v/v) 
FBS standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada). 
 The MDA-MB-231 and MDA-MB-468 triple negative breast 
adenocarcinoma cell lines (ATCC, Cat. No. HTB-26 & HTB-132, Manassas, VA, 
USA) were cultured with Dulbecco’s Modified Eagles Medium HAM F12 (Sigma-
Aldrich, Mississauga, ON, Canada) supplemented with 10% (v/v) FBS standard 
(Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada). 
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 The SUM149 inflammatory breast cancer cell line (a generous gift from Dr. 
Stephen Ethier, Wayne State University, Detroit, MI, USA) was cultured in 
Dulbecco’s Modified Eagles Medium HAM F12 (Sigma-Aldrich, Mississauga, ON, 
Canada) supplemented with 5% (v/v) FBS standard (Thermo Scientific, Waltham, 
MA, USA), 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada), 
5 μg/ml insulin (Sigma-Aldrich, Mississauga, ON, Canada), and  1 μg/ml 
hydrocortisone (Sigma-Aldrich, Mississauga, ON, Canada). 
The human colorectal cancer cell lines HT-29 and HCT 116 (ATCC, Cat. 
No. CCL-218 & CCL-247, Manassas, VA, USA) were cultured with McCoy’s 
Medium 5a (Gibco BRL, VWR, Mississauga, ON, Canada) supplemented with 2 
mM L-glutamine, 10% (v/v), FBS (Thermo Scientific, Waltham, MA, USA) and 10 
mg/ml gentamicin (Gibco, BRL, VWR, Mississauga, ON, Canada).   
The BxPC-3 (ATCC, Cat. No. CRL-1687, Manassas, VA, USA) pancreatic 
adenocarcinoma cell line was grown in RPMI-1640 medium (Sigma-Aldrich 
Canada, Mississauga, ON, Canada) supplemented with 10% (v/v) FBS standard 
(Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada).  
The PANC-1 (ATCC, Cat. No. CRL-1469, Manassas, VA, USA), 
epithelioid carcinoma cell line of the pancreas was grown in Dulbecco's Modified 
Eagle's Medium (Sigma-Aldrich Canada, Mississauga, ON, Canada) 
supplemented with 10% (v/v) FBS standard (Thermo Scientific, Waltham, MA, 
USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). 
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The osteosarcoma cell lines, U-2 OS and Saos-2 (ATCC, Cat. No. HTB-96 
& HTB-85, Manassas, VA, USA), were grown in McCoy’s 5A Medium Modified 
(Sigma-Aldrich Canada, Mississauga, ON, Canada). The U-2 OS medium was 
supplemented with 10% (v/v) FBS standard (Thermo Scientific, Waltham, MA, 
USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). 
The Saos-2 medium was supplemented with 15% (v/v) FBS standard (Thermo 
Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, 
Mississauga, ON, Canada).  
The U-87 MG glioblastoma cell line (ATCC, Cat. No. HTB-14, Manassas, 
VA, USA) was grown with Eagle’s Minimum Essential Medium (Sigma-Aldrich 
Canada, Mississauga, ON, Canada) supplemented with 10% FBS standard 
(Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada).  
The NCI-H23 non-small cell lung cancer cell line (ATCC, Cat. No. CRL-
5800, Manassas, VA, USA) was grown and cultured in RPMI-1640 medium 
(Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 10% (v/v) 
FBS standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada).    
The A549 non-small cell lung cancer cell line (ATCC, Cat. No. CRM-CCL-
185, Manassas, VA, USA) was grown and cultured in F-12K medium (ATCC, 
Cat. No. 30-2004, Manassas, VA, USA) supplemented with 10% (v/v) FBS 
standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada).    
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The OVCAR-3 ovarian adenocarcinoma cell line (ATCC, Cat. No. HTB-
161, Manassas, VA, USA) was grown and cultured in RPMI-1640 medium 
(Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 0.01 
mg/mL bovine insulin, 20% (v/v) FBS standard (Thermo Scientific, Waltham, MA, 
USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada).    
The MCF7 human breast adenocarcinoma cell line (ATCC, Cat. No. HTB-
22, Manassas, VA, USA) was grown in RPMI-1640 medium (Sigma-Aldrich 
Canada, Mississauga, ON, Canada) supplemented with 10% FBS standard 
(Thermo Scientific, Waltham, MA) and 10 mg/mL gentamicin (Gibco BRL, VWR, 
Mississauga, ON, Canada). 
The G-361 malignant melanoma cell line (ATCC, Cat. No. CRL-1424, 
Manassas, VA, USA), was grown in McCoy’s 5A Medium Modified (Sigma-
Aldrich Canada, Mississauga, ON, Canada) supplemented with 10% (v/v) FBS 
standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada).  
The DU 145 prostate carcinoma cell line (ATCC, Cat. No. HTB-81, 
Manassas, VA, USA) was grown with Eagle’s Minimum Essential Medium 
(Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 10% FBS 
standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada).  
The AG09309 normal human skin fibroblasts (Coriell Institute for Medical 
Research, Cat. No. AG09309, Camden, NJ, USA) was grown in Dulbecco’s 
Modified Eagle’s Medium, High Glucose (Thermo Scientific, Waltham, MA, USA) 
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supplemented with 15 % (v/v) FBS and 10 mg/mL gentamicin (Gibco BRL, VWR, 
Mississauga, ON, Canada). 
The CCD-18Co normal colon fibroblasts (ATCC, Cat. No. CRL-1459, 
Manassas, VA, USA) was grown with Eagle’s Minimum Essential Medium 
(Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 10% FBS 
standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada).  
The normal-derived colon mucosa (NCM460) cell line (INCELL 
Corporation, LLC., San Antonio, TX, USA) was grown in INCELL’s M3BaseTM 
medium (INCELL Corporation, LLC., Cat. No. M300A500) supplemented with 10 
% (v/v) FBS and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, 
Canada).  
All cells were grown in optimal growth conditions of 37˚C and 5 % CO2. 
Furthermore, all cells were cultured and passaged for less than 6 months and no 
authentication of cell lines was performed by the author. 
 
Isolation and Culture of Peripheral Blood Mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were collected and isolated 
from healthy volunteers. In brief, whole blood was collected in BD 
Vacutainer®CPTTM Tubes with Sodium HeparinN (Becton, Dickinson and 
Company, Cat. No. 362753, Franklin Lakes, NJ, USA) at room temperature. 
Tubes were immediately inverted 5 times and centrifuged for 30 minutes at room 
temperature at 1500-1800 x g. The layer of PBMCs under the plasma layer in 
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each tube was collected, pooled together, resuspended in 50 mL of PBS,  and 
centrifuged at room temperature at 300 x g for 15 minutes.  The supernatant was 
methodically aspirated without disturbing the pellet and PBMCs were 
resuspended and cultured in RPMI-1640 medium (Sigma-Aldrich Canada, 
Mississauga, ON, Canada), supplemented with 10%  (v/v) FBS standard 
(Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada) at 37 oC and at 5% CO2. PBMCs from healthy 
volunteers 1, 2, 3, and 4 (PBMCs V1, PBMCs V2, PBMCs V3, PBMCs V4) were 
taken from a healthy 28 year old female, a healthy 18 year old male, a healthy 48 
year old male, and a healthy 31 year old female respectively. 
 
Chemicals and Cell Treatment 
 Cells were treated with PST, PST Analogues, Taxol (Sigma-Aldrich 
Canada, Cat. No. T7402, Mississauga, ON, Canada), Staurosporine (STS) 
(Sigma-Aldrich Canada, Cat. No. S4400, Mississauga, ON, Canada), 
Doxorubicin (DOX) (Sigma-Aldrich Canada, Cat. No. D1515, Mississauga, ON, 
Canada), Gemcitabine (GEM) (Sigma-Aldrich Canada, Cat. No. G6423, 
Mississauga, ON, Canada), piperlongumine (PL) (INDOFINE Chemical 
Company, Inc., Cat. No. P-004, Hillsborough, NJ, USA), the broad spectrum 
caspase inhibitor, Z-VAD-FMK (EMD Chemicals, Gibbstown, NJ, USA), 
Antimycin A (AMA) (Sigma-Aldrich Canada, Cat. No. A8674, Mississauga, ON, 
Canada), Thenoyltrifluoroacetone (TTFA) (Sigma-Aldrich Canada, Cat. No. 
T27006, Mississauga, ON, Canada), and rotenone (ROT) (Sigma-Aldrich 
 156 
 
Canada, Cat. No. R8875, Mississauga, ON, Canada)  dissolved in DMSO stock 
solutions. PST analogues were produced by synthesis from bromobenzene 
(Collins et al. 2010; Vshyvenko et al. 2011).  
 
WST-1 Assay for Cell Viability 
The WST-1 based colorimetric assay (Roche Applied Science, 
Indianapolis, IN, USA) was performed to quantify cell viability via as a function of 
cellular metabolism. Cells were seeded in 96-well clear bottom tissue culture 
plates and grown for 24 hours. Subsequently, cells were treated with the 
indicated concentrations of chemicals for the indicated time durations. WST-1 
reagent was incubated for 4 hours at 37˚ C with 5 % CO2. In actively 
metabolizing cells, the WST-1 reagent is cleaved by cellular enzymes to produce 
formazan. The presence of formazan was quantified via absorbance readings at 
450 nm on a Wallac Victor3 TM 1420 Multilabel Counter (PerkinElmer, 
Woodbridge, ON, Canada). Absorbance readings were expressed as 
percentages of the solvent  treated control group.  Inhibitory dose-response 
curves (log(inhibitor) vs. response -- Variable slope (four parameters)) were 
calculated using GraphPad Prism 6. 
 
Cell Death Analysis: Annexin V Binding Assay & Propidium Iodide (PI) Staining  
The Annexin V binding assay and propidium iodide staining was done in 
parallel to monitor the externalization of phosphatidylserine on the outer cellular 
surface, a marker of early apoptosis, and cell permeabilization, a marker of 
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necrotic or late apoptotic cell death, respectively. Cells were washed with 
phosphate buffer saline (PBS) and suspended in Annexin V binding buffer (10 
mM HEPES, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4) with green fluorescent 
Annexin V AlexaFluor-488 (1:20) (Life Technologies Inc, Cat. No. A13201, 
Burlington, ON, Canada) and 0.01mg/mL of red fluorescent PI (Life Technologies 
Inc, Cat. No. P3566, Burlington, ON, Canada) for 15 minutes at 37 oC protected 
from light. The percentage of early (green), late apoptotic cells (green and red), 
and necrotic cells (red) were quantified using image-based cytometry with a 
Tali® Image-Based Cytometer (Life Technologies Inc, Cat. No. T10796, 
Burlington, ON, Canada). Cells from at least 18 random fields were analyzed 
using both the green (ex. 458 nm; em. 525/20 nm) and red (ex. 530 nm; em. 585 
nm) channels. Fluorescent micrographs were taken at 400x magnification using 
LAS AF6000 software with a Leica DMI6000 fluorescent microscope (Wetzlar, 
Germany). Cells monitored with microscopy were counterstained with Hoechst 
33342 (Molecular Probes, Eugene, OR, USA) to visualize nuclei using a final 
concentration of 10 μM during the 15 minute incubation. 
 
Quantitation of Reactive Oxygen Species (ROS) 
 The small molecule 2’, 7’-dicholorofluorescin diacetate (H2DCFDA) was 
used to montitor whole cell ROS generation. H2DCFDA enters the cell and is 
deacetylated by esterases and oxidized by ROS to the highly fluorescent 2’, 7’-
dicholorofluorescein (DCF) (excitation 495 nm; emission 529 nm). Cells were 
pretreated with 20 μM H2DCFDA (Sigma-Aldrich Canada, Cat. No. D6883, 
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Mississauga, ON, Canada) for 30 minutes at 37°C protected from light at 5% 
CO2. Cells were treated for the indicated durations, centrifuged at 600 x g for 5 
minutes and suspended in PBS. Percentage of DCF positive cells was quantified 
using the Tali® Image-Based Cytometer (Life Technologies Inc, Cat. No. 
T10796, Burlington, ON, Canada) using 12 random fields per group with the 
green channel (excitation 458 nm; emission 525/20 nm). 
Tetramethylrhodamine Methyl Ester (TMRM) Detection of Mitochondrial 
Membrane Potential 
Tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, VWR, 
Mississauga, ON, Canada) was used for detecting mitochondrial membrane 
potential (MMP), an indicator of healthy intact mitochondria. Treated cells were 
incubated with 100 nM TMRM in growth medium for 45 minutes at 37˚ C and 5% 
CO2 protected from light. The percentage of TMRM cells was quantified using 
image-based cytometry with a Tali® Image-Based Cytometer (Life Technologies 
Inc, Cat. No. T10796, Burlington, ON, Canada). Cells from at least 18 random 
fields were analyzed using the red channel (ex. 530 nm; em. 585 nm). 
Fluorescent micrographs were taken at 400x magnification using LAS AF6000 
software with a Leica DMI6000 fluorescent microscope (Wetzlar, Germany). 
Cells monitored with microscopy were counterstained with Hoechst 33342 
(Molecular Probes, Eugene, OR, USA) to visualize nuclei using a final 
concentration of 10 μM during the 45 minute incubation. 
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Mitochondrial Isolation  
To isolate mitochondria, cells were washed once in cold PBS, re-
suspended in hypotonic buffer (1 mM EDTA, 5 mM Tris–HCl, 210 mM mannitol, 
70 mM sucrose, 10 μM Leu-pep and Pep-A, 100 μM PMSF) and subjected to 
manual homogenization with a glass tissue grinder. Homogenized cells were 
centrifuged at 600 x g for 5 minutes at 4˚ C. The supernatant was centrifuged at 
15000 x g for 15 minutes at 4˚ C and the mitochondrial pellet was suspended in 
cold reaction buffer (2.5 mM malate, 10 mM succinate, 10 μM Leu-pep and Pep-
A, 100 μM PMSF in PBS). 
 
Treatment of Isolated Mitochondria & Evaluation of Apoptogenic Factor Release 
Isolated mitochondria were treated with drugs at the indicated 
concentrations and incubated for 2 hours in cold reaction buffer (2.5 mM malate, 
10 mM succinate, 10 μM Leu-pep, 10 μM Pep-A, and 100 μM PMSF in PBS). 
Following treatment,  mitochondria samples were vortexed and centrifuged at 
15,000 x g for 15 minutes at 4˚C. Western Blot analysis was performed on the 
resulting supernatants and mitochondrial pellets suspended in cold reaction 
buffer to screen for release or retention of apoptogenic factors. 
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Western Blot Analyses 
Protein samples were subjected to SDS-PAGE, transferred onto a PVDF 
membrane, and blocked with 5% w/v milk or BSA in TBST (Tris-Buffered Saline 
Tween-20) solution for 1 hour. Membranes were incubated with primary 
antibodies overnight at 4 °C: anti-caspase-9 antibody (1:1000) raised in rabbit 
(Cell Signalling, Cat. No. 9502, Danvers, MA, USA), anti-caspase-3 antibody 
(1:2000) (Novus Biologicals, Cat. No. NB100-56709V2, Littleton, CO, USA), anti-
β-actin antibody (1:1000) (Santa Cruz Biotechnology, Inc., Cat. No. sc-81178, 
Paso Robles, CA, USA), anti-cytochrome c (Cyto c) antibody (1:1000) raised in 
mice (Abcam, Cat. No. ab13575, Cambridge, MA, USA),  anti-succinate 
dehydrogenase subunit A antibody (1:1000) raised in mice (Santa Cruz 
Biotechnology, Inc., sc-59687, Paso Robles, CA, USA).  Membranes were 
quickly rinsed twice, washed once for 15 minutes, and then washed twice for 5 
minutes in TBST. Membranes were incubated with horseradish peroxidase-
conjugated secondary antibodies for 1 hour: goat anti-mouse antibody (1:2000) 
(Novus Biologicals, Cat. No. NBP2- 30347H, Littleton, CO, USA), goat anti-rabbit 
antibody (1:2000) (Novus Biologicals, Cat. No. NBP2-30348H, Littleton, CO, 
USA). Membranes were quickly rinsed twice and washed for three 5 minute 
washes with TBST. Chemiluminescence reagent (Thermo Fisher Scientific, Cat. 
No. 34095, Rockford, IL, USA) was used for band visualization. Densitometry 
analyses were performed using ImageJ software. 
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Oxygen Consumption Quantitation 
 The MitoXpress® Xtra - Oxygen Consumption Assay [HS Method] (Luxcel 
Biosciences Ltd., Cat. No. MX-200, Cork, Ireland) was used to meausure 
mitochondrial function. 1 000 000 cells/well were seeded in a 96-well black clear 
bottom tissue culture plate and incubated for an hour at 37˚ C and 5% CO2. On a 
heat pack, 10 μL of MitoXpress® reagent was added to each well excluding the 
blanks, cells were treated with test compounds, the plate was shaken with a plate 
shaker, and 2 drops of pre-warmed high sensitivity mineral oil was added to each 
well to seal off the air supply. Bottom read fluorescence measurements were 
taken at Ex. 380 nm and Em. 650, every 2 minutes for 2 hours at 37 °C using a 
SpectraMax Gemini XS multi-well plate reader (Molecular Devices, Sunnyvale, 
CA, USA). Increases in fluorescence are indicative of oxygen consumption. 
Oxygen consumption rates were determined by calculating the slope of the linear 
regions of the oxygen consumption curves using GraphPad Prism 6 software. 
 
Three-Dimensional Spheroid Culture and Assays  
 To establish three dimensional spheroid cultures, tissue culture plates 
were coated with basement membrane extract (BMX). Prior to coating, 3-D 
Culture Matrix™ Basement Membrane Extract Reduced Growth Factor (phenol 
red free) (Trevigen, Inc., Cat No. 3445-005-01, Gaithersburg, MD, USA) was 
thawed at 4°C overnight. As BMX forms a solid gel at room temperature, clear 
96-well tissue culture plates, 35 mm glass bottom tissue culture dishes (MatTek 
Corporation, Cat No. P35G-0-14-C, Ashland, MA, USA) and pipette tips were 
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chilled at -20°C overnight prior to use. On ice and in sterile conditions, clear 96-
well tissue culture plate wells or the 14 mm diameter microwells of chilled 35 mm 
glass bottom tissue culture dishes, were coated with 35 µL and 50 μL BMX 
respectively, with chilled pipette tips and incubated for 10 minutes at 37°C. 
Approximately 2000 - 4000 and 5000 cells were seeded in clear 96-well plate 
wells and microwells of glass bottom dishes respectively and grown in medium 
with 2% (v/v) BMX 48 hours with 5 % CO2 at 37°C. Following 48 hours of 
incubation, medium was replaced with fresh medium supplemented with 2% (v/v) 
BMX and spheroids were treated with test compounds for 72 hours. Spheroids 
grown in 96-well plates and glass bottom dishes were subjected to the WST-1 
Assay and confocal fluorescence microscopy, respectively. Confocal 
micrographs were taken with an Olympus Fluoview FV1000 confocal microscope 
(Olympus Corporation, Shinjuku, Tokyo, Japan) using a UPLSAPO 20X, 0.75 
numerical aperture dry objective (Olympus Corporation, Shinjuku, Tokyo, Japan). 
Cells were counterstained with NucRed Live 647 ReadyProbes® Reagent (Life 
Technologies Inc, Cat. No. R37106, Burlington, ON, Canada) to visualize nuclei.  
 
 
 
 
 
 163 
 
In Vivo Xenograft Models 
 Immunocompromised CD-1 nu/nu male mice (Charles River Laboratories, 
Cat. No. 086, Sherbrooke, QC, Canada) were housed in conditions of a 12-hour 
light/dark cycle, in accordance with the animal care protocols outlined by the 
University of Windsor Animal Care Committee (AUPP # 14-15). Mice were 
injected with  2 x 106 HT-29, HCT 116, or U-87 MG cells suspended in 200 µL of 
PBS using a 23-gauge needle in the hind flanks of mice. After establishment of 
palpable tumors (~ 1 week), mice were treated by intratumoral injection (4-6 
mice/group) three times a week for five weeks of 3 mg/kg of PST analogues or 
DMSO in 200 μL of PBS. Tumors were measured with calipers and volumes 
were calculated using the ellipsoid formula п/6 x length x width x height. Changes 
in body mass were measured with a scale. 
  
Statistical Analysis 
Statistics were performed by GraphPad Prism 6 software. A p-value below 
0.05 was considered significant. For experiments with single variable 
measurements, which include quantification of MMP, and whole cell ROS, a 
One-Way ANOVA (nonparametric) was conducted and each sample’s mean was 
compared to the mean of the DMSO control unless otherwise specified. For 
experiments that contained multi-variables (e.g. multiple group comparisions), 
such as the quantification of live and dead cells, Two-Way ANOVA 
(nonparametric) was used and each sample’s mean was compared to the mean 
of the control (DMSO vehcile) unless otherwise specified. 
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Results 
PST Analogues have Selective and Potent Anti-Cancer Activity with Efficacy 
Surpassing Standard Chemotherapeutics and Natural PST 
 The preclinical advancement of PST has been hindered by its low yield 
from its natural source and complexities in its chemical synthesis. Previously, we 
have shown modest to comparable anti-cancer activity of a 7-deoxyPST 
analogue in comparison to natural PST (Ma et al. 2011; Ma, Tremblay, et al. 
2012; Ma, Collins, et al. 2012). Recently, we have synthesized several PST 
analogues with a C-7 hydroxyl group (Figure 4.1), and resultantly, possess the 
complete proposed pharmacophore attributed to the anticancer activity of PST 
and related alkaloids (Vshyvenko et al. 2011). A comprehensive screen of anti-
cancer activity of these analogues, in parallel with 7-deoxyPST analogues, PST, 
and common chemotherapeutics, was completed on 18 cancer cell lines as well 
as non-cancerous cells using the WST-1 colorimetric assay (Figure 4.2). Taken 
as a whole, SVTH-7, followed by SVTH-6 and SVTH-5, had the most potent 
activity, with SVTH-7 having much greater activity than natural PST while SVTH-
6 and -5 possessed comparable or greater efficacy than natural PST with 
regards to their half-maximal inhibitory concentration (IC50) values. As predicted, 
SVTH-6 and SVTH-5, which are C-7 hydoxylated forms of JCTH-4 and JCTH-3, 
respectively, were markedly more effective than their 7-deoxyPST counterparts. 
Triple negative breast cancer (TNBC) lacks the estrogen, progesterone, and 
HER2 receptor, and thus, traditional breast cancer therapies including hormone 
therapy and Herceptin are not effective (Lips et al. 2015). Standard 
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chemotherpeutics for TNBC include Taxol and Doxorubicin (DOX). Interestingly, 
SVTH-7, -6, and -5 had lower IC50 values than Taxol and DOX in the TNBC cell 
lines MDA-MB-231 and MDA-MB-468. SVTH-7 and  SVTH-6 were also more 
effective than Gemcitabine (GEM), the standard chemotherapeutic for notoriously 
chemoresistant pancreatic cancer (Berlin & Benson 2010), in the BxPC-3 and 
PANC-1 pancreatic cancer cell lines. Furthermore, JCTH-3 and -4, and SVTH-5, 
-6, and -7 were more potent than Cisplatin and GEM, having lower IC50 values in 
the NCI-H23 non-small cell lung cancer cell line, a commonly chemoresistant 
cancer. Moreover, SVTH-7 and -6 had lower IC50 values than Taxol in MV-4-11 
leukemia, U-87 MG glioblastoma, and MCF7 breast adeonocarcinoma cells. 
Notably, the IC50 values of PST and its analogues in the AG09309 and CCD-
18Co non-cancerous cells were well above those observed in the cancer cells 
lines tested, demonstrating a selective therapeutic window. Additional time 
points, doses and statistical analyses of compounds tested are shown in 
Supplemental Figures S4.1A-V. 
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Figure 4.1. Structure of PST and PST Analogues 
 
 
 
 
 
 
 
 
 
 167 
 
 
 168 
 
Figure 4.2. PST Analogues have Selective and Potent Anti-Cancer Activity 
with Efficacy Surpassing Standard Chemotherapeutics and Natural PST. 
The WST-1 colorimetric assay was used to screen the anti-cancer activity of PST 
analogues, PST, Taxol, Doxorubicin (DOX), and Gemcitabine (GEM) in 18 
cancer cell lines and non-cancerous cells. After 48 hours of treatment, the 
absorbance of the processed WST-1 reagent formazan, used to quantify cell 
viability,  was read at 450 nm and expressed as a percent of solvent control 
(DMSO).  Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments.  *p<0.01 vs. solvent control (DMSO). X-axis: 
Concentration (µM) (using a Log 10 Scale). Y-axis: Absorbance at 450 nm (% of 
Control). 
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PST Analogues Induce Apoptosis Selectively in Cancer Cells 
 To evaluate cell death caused by PST analogues, the Annexin V binding 
assay and propidium iodide staining was done in parallel to monitor early 
apoptosis (Fadok et al. 1998), and necrotic or late apoptotic cell death 
respectively (Poon et al. 2010). PST analogues were effective in inducing 
apoptosis in the U-937, E6-1, and MV-4-11 blood cancer cell lines (Figure 4.3A). 
SVTH-7, followed by SVTH-6 and SVTH-5 was the most effective in inducing 
apoptosis compared to natural PST and the 7-deoxyPST analogues. 
Staurosporine (STS) was used as a positive control for apoptotic induction 
(Belmokhtar et al. 2001). Non-cancerous cells, including peripheral blood 
mononuclear cells from healthy volunteers 1 (PBMCs V1) and 2 (PBMCs V2) and 
AG09309 normal human fibroblasts, were much less sensitive to apoptotic 
induction. Only SVTH-7 and SVTH-6, at much higher doses required to induce 
apoptosis in cancer cells, demonstrated mild toxicity (Figure 4.3B). Cell death 
analyses of additional non-cancerous peripheral blood mononuclear cells from 
other healthy volunteers with similar resilience against PST analogue treatment 
are depicted in Supplemental Figure S4.2. Representative micrographs of E6-1 
leukemia cells undergoing apoptosis after 48 hours of PST analogue treatment 
are shown in Figure 4.3C. SVTH-7, -6, and -5 were the most effective at yielding 
condensed cell morphology, nuclear condensation, and Annexin V (green) and PI 
(red) fluorescence, which are indicative of apoptotic induction. 
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Figure 4.3. PST Analogues Induce Apoptosis Selectively in Cancer Cells. 
Annexin V binding and PI staining of cells treated for 48 hours was monitored 
with image-based cytometry. (A) U-937, E6-1, and MV-4-11 cancer cell lines. (B) 
Non-cancerous cells: peripheral blood mononuclear cells from volunteer 1 
(PBMCs V1) and 2 (PBMCs V2), and AG0309 normal fibroblasts. Values are 
expressed as mean ± SD from at least 3 independent experiments. *p<0.01 vs. 
DMSO control. (C) Annexin V binding (green) and PI staining (red) monitored 
with fluorescent microscopy in E6-1 leukemia cells treated for 48 hours 
counterstained with Hoechst (cyan). Cell morphology is shown using differential 
interference contrast (DIC) microscopy. Scale bar = 25 µm. Micrographs are 
representative of 3 independent experiments. 
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PST Analogues Cause Mitochondrial Dysfunction and Activate the Intrinsic 
Pathway of Apoptosis in Cancer Cells 
 Mitochondria play a pivotal role in the induction of intrinsic apoptosis. 
When dysfunctional, these organelles can permeabilize and release apoptogenic 
factors, leading to the execution of apoptosis (Shi 2001). One of the first events 
of mitochondrial dysfunction is the generation of reactive oxygen species (ROS) 
(Lin & Beal 2006). Using H2DCFDA, an indicator of ROS, PST analogues and 
PST were shown to increase the production of ROS in MV-4-11 leukemia cells 
after 3 hours of treatment (Figure 4.4A). Piperlongumine (PL) was used as a 
positive control for ROS generation (Raj et al. 2011).  This was followed by 
dissipation of mitochondrial membrane potential (MMP) at 3 and 6 hours 
(Supplemental Figure S4.3A), with a more pronounced effect at 12 hours 
(Figure 4.4B & C), as shown by a decrease of TMRM red fluorescence. Thus, 
PST analogues and PST were effective in permeabilizing the mitochondrial 
membrane, which was not observed in the non-cancerous PBMCs V1 (Figure 
4.4B). Full time kinetics of TMRM analyses of MV-4-11 and E6-1 leukemia cells 
treated with PST analogues are depicted in Supplemental Figures S4.3A & B. 
 Following MMP collapse and mitochondrial permeabilization, apoptogenic 
factors are released and cause subsequent activation of apoptosis. One such 
factor is cytochrome c (Cyto c), which upon its release from the mitochondria, 
leads to the conversion of Pro-Caspase-9 (Pro-Casp-9) to Caspase-9 (Casp-9), 
which in turn cleaves Pro-Caspase-3 (Pro-Casp-3) to Caspase-3 (Casp-3) (Ow et 
al. 2008). The executioner caspase, Casp-3, exerts its lethal effects by cleaving a 
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multitude of cellular proteins needed for cellular function, structural stability, and 
survival (Fischer et al. 2003). After 12 hours, JCTH-4, SVTH-5, -6, and -7 
treatment yielded cleavage of Pro-Casp-9 and Pro-Casp-3 in MV-4-11 cells, 
demonstrating their ability to induce the aforementioned caspase-dependent 
pathway of apoptosis (Figure 4.4D). To confirm the dependence of caspases in 
PST analogue-induced apoptosis, the Z-VAD-FMK broad-spectrum caspase 
inhibitor was used (Figure 4.4E). Interestingly, this inhibitor was only able to 
partially rescue E6-1 leukemia cells from PST and PST analogue-induced 
apoptosis, suggesting caspases and other apoptosis inducers are involved in 
such cell death. DOX was used as a positive control for Z-VAD-FMK-mediated 
rescue (Gamen et al. 2000). Similar results were seen with the MV-4-11 
leukemia cell line (Supplemental Figure S4.4). To determine if PST analogues 
are able to directly act on cancer cell mitochondria to release Cyto c, 
mitochondria isolated from MV-4-11 cells were directly treated with PST 
analogues for 2 hours and the release of Cyto c was monitored (Figure 4.4F). 
Interestingly, such treatment caused release of this apoptogenic factor with the 
most pronounced effect observed with SVTH-6 and -7. Collectively, these 
findings suggest that PST analogues are able to act on the mitochondria to 
induce the intrinsic pathway of apoptosis. 
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Figure 4.4. PST Analogues Cause Mitochondrial Dysfunction and Activate 
the Intrinsic Pathway of Apoptosis in Cancer Cells. (A) H2DCFDA was used 
to measure whole cell ROS in MV-4-11 cells treated for 3 hours with image-
based cytometry. *p<0.01 vs. DMSO control. (B) TMRM was used to monitor 
MMP in MV-4-11 leukemia cells and non-cancerous peripheral blood 
mononuclear cells from volunteer 1 (PBMCs V1) with image-based cytometry. 
*p<0.01 vs. DMSO control. (C) TMRM fluorescence microscopy counterstained 
with Hoechst (cyan). Scale bar = 25 μm. (D) Western Blot analyses of caspase 
cleavage of MV-4-11 cells treated for 12 hours. (E) E6-1 leukemia cells were pre-
treated with 30 μM Z-VAD-FMK broad spectrum caspase inhibitor for 1 hour and 
then treated with PST analogues to determine the dependence of caspases in 
PST analogue-induced apoptosis. Doxorubicin (DOX) was used as a positive 
control for Z-VAD-FMK mediated rescue. Values are expressed as mean ± SD 
from at least 3 independent experiments. *p<0.01 vs. DMSO control (comparison 
of viable cells only); #p<0.001 vs. respective groups untreated with Z-VAD-FMK 
(comparison of viable cells only). (F) Western Blot analysis of Cyto C release (of 
post mitochondrial supernatant) from directly treated mitochondria isolated from 
MV-4-11 cells for 2 hours. SDHA was probed in the mitochondrial pellet samples 
as a loading control. All quantitative values are expressed as mean ± SD from at 
least 3 independent experiments. Micrographs and Western Blots are 
representative of at least 3 independent experiments demonstrating similar 
trends. 
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PST Analogues Decrease Oxygen Consumption Capabilities of Cancer Cells 
 Oxygen consumption of cells is a direct indicator on mitochondrial function 
(Brand & Nicholls 2011). To assess the effect of PST analogues on oxygen 
consumption, the MitoXpress® Xtra - Oxygen Consumption Assay was used 
(Figure 4.5). SVTH-6, -7, and PST were able to effectively decrease the rate of 
oxygen consumption in E6-1 leukemia cells. In U-937 lymphoma cells, SVTH-5, -
6, and -7 were effective in decreasing oxygen consumption rates. Antimycin A 
(AMA), a complex III inhibitor of the electron transport chain (ETC), was used as 
a positive control for oxygen consumption cessation. These results indicate that 
PST analogues are effective in reducing oxygen consumption and thus, 
mitochondrial function.  
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Figure 4.5. PST Analogues Decrease Oxygen Consumption Capabilities of 
Cancer Cells. The MitoXpress® Xtra - Oxygen Consumption Assay was used to 
monitor oxygen consmption via fluorescence generation. Cells were treated, and 
the fluorescent MitoXpress® reagent monitored at Ex. 380 nm and Em. 650, 
every 2 minutes for 2 hours at 37 °C. Oxygen consumption rates were calculated 
by measuring the slopes of the linear regions of the oxygen consumption curves. 
Values are expressed as mean ± SD from at least 3 independent experiments. 
*p<0.001 vs. DMSO control.   
 
 
 
 178 
 
PST Analogue-Induced Apoptosis is Dependent on Functional Complex II and III 
of the Mitochondrial Electron Transport Chain 
 As we have shown PST analogues to act on cancer cell mitochondria, we 
investigated the role of mitochondrial ETC complexes in PST analogue-induced 
apoptosis using the complex II inhibitor Thenoyltrifluoroacetone (TTFA) and the 
complex III inhibitor AMA (Chen et al. 2007; Spinazzi et al. 2012). Interestingly, 
TTFA was able to rescue these cells from SVTH-7 insult as seen at 48 hours, 
bringing the percentage of dead cells statistically similar to those of the DMSO 
control treated group (Figure 4.6A). Cell salvation by TTFA was specific to 
SVTH-7 as this inhibitor had no significant effect on Taxol, DOX and STS 
treatment. A slightly less dramatic rescue was observed with AMA.  
 Likewise, TTFA was able to protect cancer cell mitochondria from SVTH-
7-induced dissipation of MMP at 12 hours and bring the percentage of TMRM 
positive cells to levels statistically similar to values observed in the DMSO control 
treated group (Figure 4.6B). A similar but less dramatic rescue of MMP was 
observed with AMA. Prevention of mitochondrial membrane permeabilization by 
TTFA was specific to SVTH-7 treatment as no significant changes in the 
percentage of TMRM positive cells was observed with Taxol, DOX, and STS 
treatment in conjunction with this inhibitor. Interestingly, inhibition of complex I 
with the inhibitor Rotenone (ROT) (Spinazzi et al. 2012) had no significant effect 
of SVTH-7 activity (Supplemental Figure S4.5). Therefore, these observations 
imply that functional complex II, and to a lesser extent, complex III are required 
for SVTH-7 to exert its pro-apoptotic effects in cancer cells. 
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Figure 4.6. PST Analogue-Induced Apoptosis is Dependent on Functional 
Complex II and III of the Mitochondrial Electron Transport Chain. (A) MV-4-
11, and U-937 cancer cells were pre-treated with TTFA complex II inhibitor or 
antimycin A (AMA) complex III inhibitor for 1 hour and then treated with PST 
analogues, staurosporine (STS), Doxorubicin (DOX), and Taxol for 48 hours. 
Annexin V binding (green) and PI staining (PI) (red) was quantified with image 
based cytometry *p<0.01 vs. DMSO control (comparison of viable cells only); 
#p<0.001 vs. respective groups without TTFA or AMA (comparison of viable cells 
only). (B) TMRM quantitation of MMP of cells treated as described for 12 hours 
was performed using image based cytometry. *p<0.01 vs. DMSO control 
(comparison of viable cells only); #p<0.001 vs. respective groups without TTFA 
or AMA (comparison of viable cells only). All values are expressed as mean ± SD 
from at least 3 independent experiments. 
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PST Analogues Selectively Induce Apoptosis in 3D Spheroid Models of Cancer 
 The three-dimensional architecture of tumors has been shown to dictate 
the responsiveness of cancer cells to chemotherapeutics (Imamura et al. 2015). 
To evaluate the efficacy of PST analogues in a more architecturally accurate 
context, cells were grown in three-dimensional spheroid culture on basement 
membrane extract (BMX) coated surfaces for 48 hours, which provides a scaffold 
for cells to form three-dimensional structures (Lee et al. 2007), and treated with 
PST analogues for 72 hours. SVTH-7, -6, -5 and natural PST were the most 
effective on the HCT 116 colorectal cancer and BxPC-3 pancreatic cancer 
spheroids as determined by the WST-1 viability assay (Figure 4.7A). 
Interestingly, SVTH-6 and natural PST had comparable anti-cancer activity 
compared to GEM, the current standard chemotherapeutic for pancreatic cancer 
(Berlin & Benson 2010), in BxPC-3 spheroids while SVTH-7 had significantly 
superior activity compared to GEM. 
 Annexin V binding was monitored in HCT 116 colorectal cancer spheroids 
(Figure 4.7B). Similarly to the STS positive control for apoptosis, HCT 116 cells 
treated with SVTH-6 and -7 were positive for Annexin V binding, indicated by the 
green fluorescence. This was accompanied by nuclear condensation and cell 
shrinkage, as depicted in fluorescence and corresponding differential 
interference contrast (DIC) micrographs respectively, which are all indicative of 
apoptosis. Minimal Annexin V binding was present in the solvent DMSO control. 
In the DIC micrograph of the solvent control, spheroids were dramatically larger 
and cells exhibited large, round, healthy cellular morphology. NCM460 normal 
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colon mucosa spheroid cells were dramatically less sensitive to SVTH-6 and -7. 
Unlike the STS positive control, minimal Annexin V binding was observed in both 
the solvent control and SVTH-6 and -7 treated cells which exhibited healthy 
nuclear and cell morphology.  
 MMP collapse was monitored as another marker of apoptosis (Figure 
4.7C) (Kroemer et al. 2007). SVTH-6 and -7 were able to dissipate MMP in HCT 
116 and BxPC-3 cancer cells in spheroid culture as indicated by the dissipation 
of red TMRM fluorescence. However, no such dissipation was evident in the 
NCM460 normal colon mucosa spheroid cells. Together, these results indicate 
that PST analogues SVTH-6 and -7 are both effective and selective against 
cancer cells in three-dimensional spheroid culture. 
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Figure 4.7. PST Analogues Selectively Induce Apoptosis in 3D Spheroid 
Models of Cancer. Cells were cultured in on basement membrane exttract 
(BMX) to form 3D spheroids, grown for 48 hours, and treated for 72 hours. (A) 
The WST-1 reagent was used to quantify viability. Absorbance was read at 450 
nm and expressed as a % of control. Values are expressed as mean ± SD from 
triplicates of at least three independent experiments. * p < 0.05; ** p < 0.005; *** 
p < 0.0005 vs. DMSO control. #p<0.001 vs. 0.5 µM GEM. (B) Confocal 
microscopy was used to monitor Annexin V binding (green) and (C) TMRM 
fluorescence (red). Cells were counterstained with NucRed Live 647 
ReadyProbes® Reagent to visualize nuclei (blue in B, cyan in C). Scale bar = 20 
μm. Micrographs are representative of 3 independent experiments with similar 
trends. 
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PST Analogues Decrease Growth of Tumors in Xenograft Mouse Models 
 To evaluate the anti-cancer activity of PST analogues in vivo, cancer cells 
were subcutaneously injected into the flanks of immunocompromised mice. After 
palpable tumors were established approximately 1 week after injections, mice 
were treated with 3 mg/kg of PST analogues intratumorally 3 times a week for 
approximately 5 weeks. JCTH-4 and SVTH-5 were able to reduce the growth of 
both HCT 116 and HT-29 colorectal tumor xenografts with SVTH-5 showing 
greater efficacy (Figure 4.8A &B). SVTH-6 was also effective in reducing growth 
of HT-29 tumors (Figure 4.8C). Furthermore, SVTH-6 and -7 were very effective 
in reducing the growth of HCT 116 colorectal cancer and U-87 MG glioblastoma 
tumor xenongrafts as tumor volumes were drastically smaller than the DMSO 
solvent control treated tumors (Figure 4.8C). Mice treated with JCTH-4, SVTH-5, 
-6, and -7 all increased in mass throughout the studies and did not significantly 
differ from the masses of mice treated with DMSO solvent control (Figure 4.8A-
C). These findings demonstrate that PST analogues are able to decrease the 
growth of tumors in vivo and are well tolerated by mice at their effective doses. 
 
 
 
 
 
 186 
 
 
 
 
 
 
 
 187 
 
Figure 4.8. PST Analogues Decrease Growth of Tumors in Xenograft Mouse 
Models. Cancer cells were injected subcutaneously into the flanks of nude mice 
to establish (day 0). After palpable tumors were detected (approximately 1 week), 
mice were treated via intratumoral injection with DMSO vehicle control or 3 
mg/kg of (A) JCTH-4, (B) SVTH-5, (C) SVTH-6, and SVTH-7 3x/week for 
approximately 5 weeks. Scale bar for representative tumor sizes at time of 
sacrifice = 1 cm. Values for tumor volumes and body weights are expressed as 
mean ± SD (n=4-6). *p < 0.05 vs. control. No significant difference in body 
masses between control and PST analogue treated mice was observed. 
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Discussion 
 In this structure activity relationship analysis, we have discovered that the 
anti-cancer activity of these alkaloids to be highly dependent on the C-7 hydroxyl 
group and the functional substitutions on C-1. Several synthetic analogues with 
the full anti-cancer pharmacophore of PST, including the C-7 hydroxyl group 
(refer to Figure 4.1), were evaluated. Accordingly, SVTH-6 and -5 were more 
potent against cancer cells compared to their related compounds JCTH-4 and -3, 
respectively, which lack this functional group. Furthermore, the functional group 
at C-1 dramatically dictates analogue potency. For example, JCTH-1 and JCTH-
2 only different from JCTH-4 in their C-1 functional groups and are nearly devoid 
of any anti-cancer activity (Figure 4.2 & 4.3A). Likewise, SVTH-7 differs only in 
the group at C-1, when compared to SVTH-6 and -5, and has much greater 
efficacy against most cancer cell lines tested (Figure 4.2 & 4.3A). These findings 
suggest the C-7 hydroxyl and, more heavily, the C-1 functional groups play a 
particular role in interaction with the cellular target(s) of interest at specific 
binding pocket(s). The high anti-cancer activity of SVTH-7 may imply an 
interaction between the C-1 functional group and a specific hydrophobic pocket, 
as this analogue possesses a bulky benzene ring at this position. 
 Very importantly, PST analogues demonstrated potent anti-cancer activity 
with low therapeutic doses, with minimal effect in normal cells (Figure 4.2 & 4.3). 
In particular, SVTH-7, -6, and -5 demonstrated greater efficacy than the common 
chemotherapeutics, Taxol, DOX, GEM, and Cisplatin in a multitude of cancer cell 
types including leukemia, triple negative breast cancer, pancreatic cancer, 
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glioblastoma, and non-small cell lung cancer (Figure 4.2). Additionally, these 
analogues were both effective and selective in inducing apoptosis in cancer cells 
grown in three-dimensional culture (Figure 4.7), demonstrating their ability to 
penetrate tumor architecture and induce cell death in cells supported by 
extracellular matrix. More importantly, these analogues were able to reduce 
growth of tumors in vivo without any apparent toxicity to mice as there was no 
reduction in body mass or decrease in normal activity (Figure 4.8). Thus, these 
compounds appear to show anti-cancer efficacy indicating that they are stable in 
physiological systems and could have great potential for anti-cancer therapy in 
patients.  
 These analogues do not appear to affect tubulin dynamics (Supplemental 
Figure S4.6), as with the chemotherapeutics Taxol and Colchicine, which would 
otherwise produce detrimental effects in normal fast dividing cells in the body 
(Jordan & Wilson 2004). Our findings indicate that this cancer selectivity may be 
attributed to the ability of these compounds to specifically target cancer cell 
mitochondria (Figure 4.4 & 4.5). Cancer cells have been shown to protect their 
mitochondria with an abundance of anti-apoptotic proteins, including anti-
apoptotic members of the Bcl-2 family of proteins, while downregulating pro-
apoptotic proteins (Yip & Reed 2008). Moreover, heavy reliance on glycolysis 
and having relatively inactive mitochondria limits the generation of ROS by the 
ETC, further decreasing the likelihood of oxidative stress-induced apoptosis. 
Inhibiting these anti-apoptotic proteins, mimicking pro-apoptotic proteins, or 
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targeting ETC complexes could potentially mechanism employed by PST 
analogues.  
 Mounting evidence suggests targeting complexes of the ETC to be an 
effective strategy for targeting cancer cells (Ralph et al. 2006). ETC complex 
manipulation has been shown to increase ROS, which can promote apoptosis 
selectively as cancer cells have demonstrated to be more sensitive to oxidative 
stress (Trachootham et al. 2006; Trachootham et al. 2009). Interestingly, 
inhibiting ETC complexes II and III abolishes the pro-apoptotic effects of the PST 
analogue SVTH-7 on cancer cells and their mitochondria, with a slightly more 
pronounced effect with complex II inhibition (Figure 4.6). It may be possible for 
this PST analogue to directly target these complexes, an interacting partner of 
these complexes, exploit an unidentified feature of the metabolic state created by 
these functional complexes, or affect something downstream of these 
complexes. One such interacting partner of Complex II is TRAP1. This protein 
has been shown to have an inhibitory effect on complex II, acting as an anti-
oxidant and producing anti-apoptotic effects on tumor cells (Guzzo et al. 2014). 
Furthermore, succinate dehydrogenase (SDH) or complex II was found to be a 
mediator of apoptosis, producing ROS for cell death upon intracellular 
acidification (Lemarie et al. 2011). However, further investigation is required to 
clarify the role of complex II and III in SVTH-7-mediated apoptosis. 
 This study comprehensively compares the activity of a number of PST 
analogues and has shown SVTH-7, followed by SVTH-6 and SVTH-5, to be the 
most effective against a battery of cancer cell lines, surpassing the anti-cancer 
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activity of natural PST, 7-deoxyPST analogues, and several chemotherapeutics 
in vitro. These analogues were shown to target cancer cell mitochondria and be 
selective towards cancer cells in cell and animal models. The requirement of 
functional complex II and III for SVTH-7 to exert its pro-apoptotic effects in 
cancer cells points to a potential vulnerability in cancer cells that can be further 
characterized and exploited to strategically devise new treatment regimes.  
Therefore, this work provides a scaffold for characterizing distinct mitochondrial 
and metabolic characteristics in cancer cells that may be used to devise novel 
therapeutic strategies and highlights several PST analogues with high 
therapeutic potential. 
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Supplemental Figure S4.1A. PST Analogues & PST Decrease Viability of 
MV-4-11 Leukemia Cells in a Time and Dose Dependent Manner. The WST-1 
colorimetric assay was performed on MV-4-11 cells treated with the indicated 
concentrations of compounds for the indicated durations. The WST-1 reagent 
was added and the absorbance of the processed WST-1 reagent formazan, used 
to quantify cell viability, was read at 450 nm and expressed as a percent of 
solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO).  
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Supplemental Figure S4.1B. Taxol Decreases Viability of MV-4-11 Leukemia 
Cells. The WST-1 colorimetric assay was performed on MV-4-11 cells treated 
with the indicated concentrations of Taxol for the indicated durations. The WST-1 
reagent was added and the absorbance of the processed WST-1 reagent 
formazan, used to quantify cell viability, was read at 450 nm and expressed as a 
percent of solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO).  
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Supplemental Figure S4.1C. PST Analogues & PST Decrease Viability of E6-
1 Leukemia Cells in a Time and Dose Dependent Manner. The WST-1 
colorimetric assay was performed on E6-1 leukemai cells treated with the 
indicated concentrations of compounds for the indicated durations. The WST-1 
reagent was added and the absorbance of the processed WST-1 reagent 
formazan, used to quantify cell viability, was read at 450 nm and expressed as a 
percent of solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO). 
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Supplemental Figure S4.1D. PST Analogues & PST Decrease Viability of U-
937 Leukemia Cells in a Dose Dependent Manner. The WST-1 colorimetric 
assay was performed on U-937 lymphoma cells treated with the indicated 
concentrations of compounds for 48 hours. The WST-1 reagent was added and 
the absorbance of the processed WST-1 reagent formazan, used to quantify cell 
viability, was read at 450 nm and expressed as a percent of solvent control 
(DMSO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments.  *p<0.05 vs. solvent control (DMSO). 
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Supplemental Figure S4.1E. PST Analogues Decrease Viability of MDA-MB-
231 Triple Negative Breast Cancer Cells in a Dose Dependent Manner with 
Greater Efficacy than Taxol and Doxorubicin. The WST-1 colorimetric assay 
was performed on MDA-MB-231 triple negative breast cancer cells treated with 
the indicated concentrations of compounds for 48 hours. The WST-1 reagent 
was added and the absorbance of the processed WST-1 reagent formazan, used 
to quantify cell viability, was read at 450 nm and expressed as a percent of 
solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.   
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Supplemental Figure S4.1F. PST Analogues & PST Decrease Viability of 
MDA-MB-468 Triple Negative Breast Cancer Cells in a Time and Dose 
Dependent Manner. The WST-1 colorimetric assay was performed on MDA-MB-
468 triple negative breast cancer cells treated with the indicated concentrations 
of compounds for the indicated durations. The WST-1 reagent was added and 
the absorbance of the processed WST-1 reagent formazan, used to quantify cell 
viability, was read at 450 nm and expressed as a percent of solvent control 
(DMSO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments.   
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Supplemental Figure S4.1G. Taxol and Doxorubicin Decrease Viability of 
MDA-MB-468 Triple Negative Breast Cancer Cells with Less Efficacy than 
PST Analogues. The WST-1 colorimetric assay was performed on MDA-MB-468 
triple negative breast cancer cells treated with the indicated concentrations of 
compounds for 48 hours. The WST-1 reagent was added and the absorbance of 
the processed WST-1 reagent formazan, used to quantify cell viability, was read 
at 450 nm and expressed as a percent of solvent control (DMSO). Values are 
expressed as mean ± SD from quadruplicates of 3 independent experiments.   
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Supplemental Figure S4.1H. PST Analogues & PST Decrease Viability of 
SUM 149 Breast Cancer Cells in a Time and Dose Dependent Manner. The 
WST-1 colorimetric assay was performed on SUM 149 breast cancer cells 
treated with the indicated concentrations of compounds for the indicated 
durations. The WST-1 reagent was added and the absorbance of the processed 
WST-1 reagent formazan, used to quantify cell viability, was read at 450 nm and 
expressed as a percent of solvent control (DMSO). Values are expressed as 
mean ± SD from quadruplicates of 3 independent experiments.  *p<0.05 vs. 
solvent control (DMSO). 
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Supplemental Figure S4.1I. PST Analogues & PST Decrease Viability of 
HCT 116 Colorectal Carcinoma Cells in a Time and Dose Dependent 
Manner. The WST-1 colorimetric assay was performed on HCT 116 colorectal 
cells treated with the indicated concentrations of compounds for the indicated 
durations. The WST-1 reagent was added and the absorbance of the processed 
WST-1 reagent formazan, used to quantify cell viability, was read at 450 nm and 
expressed as a percent of solvent control (DMSO). Values are expressed as 
mean ± SD from quadruplicates of 3 independent experiments.  *p<0.05 vs. 
solvent control (DMSO). 
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Supplemental Figure S4.1J. PST Analogues Decrease Viability of BxPC-3 
Pancreatic Adenocarcinoma Cells in a Time and Dose Dependent Manner 
with Greater Efficacy than Gemcitabine (GEM) and Taxol. The WST-1 
colorimetric assay was performed on BxPC-3 pancreatic adenocarcinoma cells 
treated with the indicated concentrations of compounds for the indicated 
durations. The WST-1 reagent was added and the absorbance of the processed 
WST-1 reagent formazan, used to quantify cell viability, was read at 450 nm and 
expressed as a percent of solvent control (DMSO). Values are expressed as 
mean ± SD from quadruplicates of 3 independent experiments.  *p<0.05 vs. 
solvent control (DMSO). 
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Supplemental Figure S4.1K. PST Analogues Decrease Viability of PANC-1 
Pancreatic Cancer Cells in a Time and Dose Dependent Manner with 
Greater Efficacy than Gemcitabine (GEM). The WST-1 colorimetric assay was 
performed on PANC-1 pancreatic cancer cells treated with the indicated 
concentrations of compounds for the indicated durations. The WST-1 reagent 
was added and the absorbance of the processed WST-1 reagent formazan, used 
to quantify cell viability, was read at 450 nm and expressed as a percent of 
solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO). 
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Supplemental Figure S4.1L. PST Analogues Decrease Viability of Saos-2 
Osteosarcoma Cells in a Time and Dose Dependent Manner. The WST-1 
colorimetric assay was performed on Saos-2 osteosarcoma cells treated with the 
indicated concentrations of compounds for the indicated durations. The WST-1 
reagent was added and the absorbance of the processed WST-1 reagent 
formazan, used to quantify cell viability, was read at 450 nm and expressed as a 
percent of solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO). 
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Supplemental Figure S4.1M. PST Analogues Decrease Viability of U-2 OS 
Osteosarcoma Cells in a Time and Dose Dependent Manner. The WST-1 
colorimetric assay was performed on U-2 OS osteosarcoma cells treated with the 
indicated concentrations of compounds for the indicated durations. The WST-1 
reagent was added and the absorbance of the processed WST-1 reagent 
formazan, used to quantify cell viability, was read at 450 nm and expressed as a 
percent of solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO). 
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Supplemental Figure S4.1N. PST Analogues & PST Decrease Viability of U-
87 MG Glioblastoma Cells in a Time and Dose Dependent Manner with 
Greater Efficacy than Taxol. The WST-1 colorimetric assay was performed on 
U-87 MG glioblastoma cells treated with the indicated concentrations of 
compounds for the indicated durations. The WST-1 reagent was added and the 
absorbance of the processed WST-1 reagent formazan, used to quantify cell 
viability, was read at 450 nm and expressed as a percent of solvent control 
(DMSO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments.  *p<0.05 vs. solvent control (DMSO). 
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Supplemental Figure S4.1O. PST Analogues Decrease Viability of G-361 
Malignant Melanoma Cells in a Time and Dose Dependent Manner. The 
WST-1 colorimetric assay was performed on G-361 malignant melanoma cells 
treated with the indicated concentrations of compounds for the indicated 
durations. The WST-1 reagent was added and the absorbance of the processed 
WST-1 reagent formazan, used to quantify cell viability, was read at 450 nm and 
expressed as a percent of solvent control (DMSO). Values are expressed as 
mean ± SD from quadruplicates of 3 independent experiments.  *p<0.05 vs. 
solvent control (DMSO). 
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Supplemental Figure S4.1P. PST Analogues Decrease Viability of OVCAR-3 
Ovarian Adenocarcinoma Cells in a Time and Dose Dependent Manner. The 
WST-1 colorimetric assay was performed on OVCAR-3 ovarian adenocarcinoma 
cells treated with the indicated concentrations of compounds for the indicated 
durations. The WST-1 reagent was added and the absorbance of the processed 
WST-1 reagent formazan, used to quantify cell viability, was read at 450 nm and 
expressed as a percent of solvent control (DMSO). Values are expressed as 
mean ± SD from quadruplicates of 3 independent experiments.  *p<0.05 vs. 
solvent control (DMSO). 
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Supplemental Figure S4.1Q. PST Analogues Decrease Viability of NCI-H23 
Non-Small Cell Lung Cancer Cells in a Time and Dose Dependent Manner 
with Greater Efficacy than Cisplatin and Gemcitabine. The WST-1 
colorimetric assay was performed on NCI-H23 non-small cell lung cancer cells 
treated with the indicated concentrations of compounds for the indicated 
durations. The WST-1 reagent was added and the absorbance of the processed 
WST-1 reagent formazan, used to quantify cell viability, was read at 450 nm and 
expressed as a percent of solvent control (DMSO). Values are expressed as 
mean ± SD from quadruplicates of 3 independent experiments.  *p<0.05 vs. 
solvent control (DMSO). 
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Supplemental Figure S4.1R. PST Analogues Decrease Viability of A549 
Non-Small Cell Lung Cancer Cells in a Dose Dependent Manner. The WST-1 
colorimetric assay was performed on A549 non-small cell lung cancer cells 
treated with the indicated concentrations of compounds for 48 hours. The WST-1 
reagent was added and the absorbance of the processed WST-1 reagent 
formazan, used to quantify cell viability, was read at 450 nm and expressed as a 
percent of solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO). 
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Supplemental Figure S4.1S. PST Analogues & PST Decrease Viability of 
MCF7 Breast Cancer Cells in a Time and Dose Dependent Manner. The 
WST-1 colorimetric assay was performed on MCF7 breast cancer cells treated 
with the indicated concentrations of compounds for the indicated durations. The 
WST-1 reagent was added and the absorbance of the processed WST-1 reagent 
formazan, used to quantify cell viability, was read at 450 nm and expressed as a 
percent of solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO). 
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Supplemental Figure S4.1T. PST Analogues Decrease Viability of DU-145 
Prostate Carcinoma Cells in a Dose Dependent Manner. The WST-1 
colorimetric assay was performed on DU-145 prostate cancer cells treated with 
the indicated concentrations of compounds for 48 hours. The WST-1 reagent 
was added and the absorbance of the processed WST-1 reagent formazan, used 
to quantify cell viability, was read at 450 nm and expressed as a percent of 
solvent control (DMSO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments.  *p<0.05 vs. solvent control 
(DMSO). 
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Supplemental Figure S4.1U. PST Analogues & PST have Minimal Toxicity 
on AG09309 Normal Human Fibroblasts. The WST-1 colorimetric assay was 
performed on AG09309 normal human fibroblasts treated with the indicated 
concentrations of compounds for 48 and 72 hours. The WST-1 reagent was 
added and the absorbance of the processed WST-1 reagent formazan, used to 
quantify cell viability, was read at 450 nm and expressed as a percent of solvent 
control (DMSO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments.  *p<0.05 vs. solvent control (DMSO). 
 
 
 
 
 
 
 221 
 
 
Supplemental Figure S4.1V. PST Analogues & PST have Minimal Toxicity 
on CCD-18Co Normal Colon Fibroblasts. The WST-1 colorimetric assay was 
performed on CCD-18Co normal human colon fibroblasts treated with the 
indicated concentrations of compounds for 48 hours. The WST-1 reagent was 
added and the absorbance of the processed WST-1 reagent formazan, used to 
quantify cell viability, was read at 450 nm and expressed as a percent of solvent 
control (DMSO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments.  *p<0.05 vs. solvent control (DMSO). 
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Supplemental Figure S4.2. PST Analogues & PST Induce Apoptosis 
Selectively in Cancer Cells: Minimal Induction of Apoptosis was Induced in 
Non-Cancerous Peripheral Blood Mononuclear Cells. Annexin V binding and 
PI staining of peripheral blood mononuclear cells from healthy volunteer 3 
(PBMCs V3) and 4 (PBMCs V4) treated for 48 hours was monitored with image-
based cytometry. Values are expressed as mean ± SD from at least 3 
independent experiments. *p<0.01 vs. DMSO control. 
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Supplemental Figure S4.3A. PST Analogues & PST Cause Mitochondrial 
Membrane Potential (MMP) Collapse in a Time Dependent Manner in MV-4-
11 Leukemia Cells. TMRM was used to monitor MMP in MV-4-11 leukemia cells 
with image-based cytometry at the indicated times. *p<0.01 vs. DMSO control. All 
quantitative values are expressed as mean ± SD from at least 3 independent 
experiments. MMP collapse is first observed at 1 and 3 hours with SVTH-7, and 
at 6 hours with JCTH-4 and SVTH-6. Complete or more pronounced MMP 
collapse was observed at 12 and 24 hours with JCTH-4 and with SVTH-5, -6, 
and -7. Taxol was used as a positive control. 
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Supplemental Figure S4.3B. PST Analogues & PST Cause Mitochondrial 
Membrane Potential (MMP) Collapse in a Time Dependent Manner in E6-1 
Leukemia Cells. TMRM was used to monitor MMP in E6-1 leukemia cells with 
image-based cytometry at the indicated times. *p<0.01 vs. DMSO control. All 
quantitative values are expressed as mean ± SD from at least 3 independent 
experiments. MMP collapse is first observed at 3 hours with a more pronounced 
effect at 6, 12 and 24 hours with JCTH-4 and with SVTH-5, -6, and -7. Taxol and 
piperlongumine (PL) was used as positive controls. 
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Supplemental Figure S4.4. PST Analogues Induce Apoptosis in MV-4-11 
Leukemia Cells in a Partial Caspase-Dependent Manner. MV-4-11 leukemia 
cells were pre-treated with 30 μM Z-VAD-FMK broad spectrum caspase inhibitor 
for 1 hour and then treated with PST analogues to determine the dependence of 
caspases in PST analogue-induced apoptosis. Values are expressed as mean ± 
SD from at least 3 independent experiments. *p<0.01 vs. DMSO control 
(comparison of viable cells only); #p<0.001 vs. respective groups untreated with 
Z-VAD-FMK (comparison of viable cells only). Z-VAD-FMK was able to partially 
rescue cells from SVTH-6 and -7, indicating that apoptosis induced by these 
compounds is partially dependent on caspases. 
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Supplemental Figure S4.5. PST Analogue-Induced Apoptosis is not 
Dependent on Functional Complex I of the Mitochondrial Electron 
Transport Chain. (A) Different doses of the complex I inhibitor rotenone were 
tested in MV-4-11 leukemia cells to find a concentration that was well tolerated. 
(B) MV-4-11 leukemia cells were pre-treated with the complex I inhibitor rotenone 
(ROT) at a well tolerated dose for 1 hour and then treated with PST analogue for 
48 hours. Annexin V binding (green) and PI staining (PI) (red) was quantified with 
image based cytometry. *p<0.01 vs. DMSO control (comparison of viable cells 
only). All values are expressed as mean ± SD from at least 3 independent 
experiments. ROT did not appear to affect the apoptosis inducing activity of 
SVTH-7. 
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Supplemental Figure S4.6. PST Analogues Do not Evidently Affect Tubulin 
Polymerization. A tubulin polymerization assay kit (Cytoskeleton Inc., Cat. No. 
BK011P, Denver, CO, USA) was used to evaluate PST analogues in their ability 
to alter tubulin polymerization dynamics. A 96-well plate was pre-warmed at 37°C 
for half an hour prior to the assay. Wells were treated with DMSO solvent control 
and PST analogues dissolved in PBS. All wells were incubated with 2 mg/mL 
tubulin in tubulin polymerization buffer (80 mM PIPES pH 6.9, 2 mM MgCl2, 0.5 
mM EGTA, 1 mM GTP and 15% glycerol). Fluorescence was measured (Ex. 360 
nm; Em. 450 nm) every 1 minute for 1 hour using a SpectraMax Gemini XS multi-
well plate reader (Molecular Devices, Sunnyvale, CA, USA) at 37°C. 
Fluorescence emission at 450 nm increases as tubulin polymerizes due to the 
incorporation of a fluorescent reporter. Statistical significance was determined by 
comparing the relative fluorescence units (RFU) at the 60 minute endpoint 
between the DMSO solvent control and the compound of interest. All values are 
expressed as mean ± SD from at least 3 independent experiments. *p<0.001 vs. 
DMSO control. Colchicine and Taxol were used as controls for tubulin 
destabilization and tubulin polymerization respectively. 
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List of Abbreviations 
AIF  apoptosis inducing factor 
AMA  Antimycin A 
CBR1  carbonyl reductase1 
Cyto c  cytochrome c 
DCF  2’, 7’-dicholorofluorescein 
ETC  electron transport chain 
GSTP1 glutathione S-transferase pi 1 
H2DCFDA 2’, 7’-dicholorofluorescin diacetate 
MMP  mitochondrial membrane potential 
NAC  N-Acetyl-L-cysteine 
PBMCs peripheral blood mononuclear cells 
PI  propidium iodide 
PL  piperlongumine 
PST  pancratistatin 
ROS  reactive oxygen species 
SDHA  succinate dehydrogenase subunit A 
TMRM tetramethylrhodamine methyl ester 
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Summary 
 Chemoresistance and harsh side effects as result of non-specific targeting 
of cancer chemotherapeutics currently pose as large obstacles in cancer therapy; 
thus, it would be invaluable to devise novel approaches to specifically target 
cancer cells. The natural compound pancratistatin (PST) has been shown to 
preferentially induce apoptosis in a variety of cancer cell types. Various 
analogues of PST were synthesized by de novo synthesis and  an efficacious 
analogue, SVTH-6, was found to inflict its cytotoxic effects selectively in a variety 
of aggressive cancers by way of apoptotic induction via cancer cell mitochondrial 
targeting; it caused dissipation of mitochondrial membrane potential, decreased 
oxygen consumption, and with isolated mitochondria, induced the release of 
apoptogenic factors. The natural compound piperlongumine (PL) has been 
shown to target the stress response to reactive oxygen species (ROS). 
Interestingly, when combined with SVTH-6, an increase in mitochondrial 
dysfunction was observed, leading to an enhanced cytotoxic effect against 
cancer cells. This enhanced effect was found to dependent on ROS generation 
as an anti-oxidant was able to rescue cancer cells from this combination 
treatment. Most importantly, noncancerous cells were markedly less sensitive to 
this combination of compounds. Hence, we present a combinatorial approach 
targeting mitochondrial and oxidative vulnerabilities in cancer cells with a novel 
PST analogue and PL as a potentially safe and effective alternative to current 
chemotherapeutics. 
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Introduction 
Striking dissimilarities exist between cancer and noncancerous cells which 
have long been ignored. Cancer cells possess a distinct metabolic phenotype, in 
which cancer cells depend less on the mitochondria and more on glycolysis for 
energy (Warburg, 1956); consequently, this glycolytic shift and mitochondrial 
remodelling confers a proliferative advantage and an acquired resistance to 
apoptosis, by discouraging mitochondrial membrane permeabilization required 
for apoptosis execution, in cancer cells (DeBerardinis et al. 2008; Gogvadze, 
Orrenius, and Zhivotovsky 2008; Gogvadze, Zhivotovsky, and Orrenius 2010; 
Plas and Thompson 2002; Vander Heiden, Cantley, and Thompson 2009; 
Pastorino, Shulga, and Hoek 2002; Chen et al. 2010; Green and Kroemer 2004; 
Casellas, Galiegue, and Basile 2002). Additionally, cancer cells have been 
observed to possess high basal levels of reactive oxygen species (ROS) (Diehn 
et al. 2009) while noncancerous cells do not (Schumacker 2006; Fruehauf and 
Meyskens 2007; Trachootham, Alexandre, and Huang 2009); thus, cancer cells 
are predicted to be highly dependent on cellular stress response mechanisms to 
ROS (Gogvadze, Orrenius, and Zhivotovsky 2008; Trachootham, Alexandre, and 
Huang 2009; Szatrowski and Nathan 1991). Consequently, exploitation of these 
distinct characteristics may offer selective strategies in targeting cancer cells.  
We have found that the natural compound pancratistatin (PST) (Figure 
5.1A), isolated from the Hymenocallis littoralis plant, specifically induces 
apoptosis in numerous cancer cell types with minimal effect on noncancerous 
cells by mitochondrial targeting (Kekre et al. 2005; McLachlan et al. 2005; 
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Siedlakowski et al. 2008; Griffin et al. 2011; Griffin, McNulty, and Pandey 2011). 
We have previously synthesized and found that JCTH-4 (Figure 5.1B), a C-1 
acetoxymethyl analogue of 7-deoxypancratistatin, to possess comparable anti-
cancer activity to that of PST, inducing apoptosis in numerous cancer cell types 
by way of mitochondrial targeting (Collins et al. 2010; Ma, Tremblay, et al. 2012; 
Ma, Collins, et al. 2012). Recently, we have created a C-7 hydroxylated version 
of JCTH-4, SVTH-6 (Figure 5.1C), a C-1 acetoxymethyl analogue of PST, by de 
novo synthesis; this is the first time chemical synthesis of a PST analogue with 
the full pharmacophore for anti-cancer activity has been achieved. In this study, 
we report this novel PST analogue to be extremely potent against an array of 
aggressive cancers, surpassing JCTH-4 in efficacy, while noncancerous cells 
showed a markedly decrease in sensitivity to this compound. SVTH-6 effectively 
induced apoptosis in these cancer cells with evidence pointing to a mitochondrial 
target. Other work has shown preferential targeting of cellular defence 
mechanisms against ROS by the natural compound piperlongumine (PL) to 
selectively harm cancer cells (Raj et al. 2011). As we have shown PST and its 
synthetic analogues to preferentially induce mitochondrial ROS production and 
dysfunction in cancer cells, we subjected cancer cells to both SVTH-6 and PL in 
combination and found this treatment to produce an enhanced cytotoxic effect 
selectively in cancer cells. N-acetyl cysteine (NAC) was able to rescue cancer 
cells from SVTH-6 alone and in combination with PL. Thus, we demonstrate 
targeting of both mitochondria and cellular defense mechanisms against 
oxidative stress as a promising approach for cancer treatment. 
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Materials and Methods  
Cell Culture 
The BxPC-3 (ATCC, Cat. No. CRL-1687, Manassas, VA, USA) pancreatic 
adenocarcinoma cell line was grown in RPMI-1640 media (Sigma-Aldrich 
Canada, Mississauga, ON, Canada) supplemented with 10% (v/v) FBS standard 
(Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada). The PANC-1 (ATCC, Cat. No. CRL-1469, 
Manassas, VA, USA), epithelioid carcinoma cell line of the pancreas was grown 
in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich Canada, Mississauga, 
ON, Canada) supplemented with 10% (v/v) FBS standard (Thermo Scientific, 
Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, 
ON, Canada). 
The human colorectal cancer cell lines HT-29 and HCT 116 (ATCC, CCL-
218 & CCL-247, Manassas, VA, USA) were cultured with McCoy’s Medium 5a 
(Gibco BRL, VWR, Mississauga, ON, Canada) supplemented with 2 mM L-
glutamine, 10% (v/v) FBS (Thermo Scientific, Waltham, MA, USA) and 10 mg/ml 
gentamicin (Gibco, BRL, VWR, Mississauga, ON, Canada).   
The OVCAR-3 (American Type Culture Collection, Cat. No. HTB-161, 
Manassas, VA, USA) ovarian adenocarcinoma cell line was grown and cultured 
in RPMI-1640 media (Sigma-Aldrich Canada, Mississauga, ON, Canada) 
supplemented with 0.01 mg/mL bovine insulin, 20% (v/v) fetal bovine serum 
(FBS) standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL 
gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada).    
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 The MV-4-11 Chronic myelomonocitic leukemia cell line (ATCC, Cat. No. 
CRL-9591, Manassas, VA, USA). was cultured with Iscove's Modified Dulbecco's 
Medium (ATCC, Cat. No. 30-2005, Manassas, VA, USA) supplemented with 10% 
(v/v) FBS standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL 
gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). 
 The U-937 histiocytic lymphoma cell line (ATCC, Cat. No. CRL-1593.2, 
Manassas, VA, USA). was cultured with Iscove's Modified Dulbecco's Medium 
(ATCC, Cat. No. 30-2005, Manassas, VA, USA) supplemented with 10% (v/v) 
FBS standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada). 
 The NCI-H23 non-small cell lung cancer cell line (ATCC, Cat. No. CRL-
5800, Manassas, VA, USA) was grown and cultured in RPMI-1640 medium 
(Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 10% (v/v) 
FBS standard (Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada).    
The normal-derived colon mucosa NCM460 cell line (INCELL Corporation, 
LLC., San Antonio, TX, USA) was grown in INCELL’s M3BaseTM medium 
(INCELL Corporation, LLC., Cat. No. M300A500) supplemented with 10 % (v/v) 
FBS and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada).  
The normal colon fibroblast CCD-18Co cell line (ATCC, Cat. No. CRL-
1459, Manassas, VA, USA) was cultured with Eagle’s Minimal Essential Medium 
supplemented with 10 % (v/v) FBS and 10 mg/mL gentamycin (Gibco BRL, 
VWR, Mississauga, ON, Canada).  
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All cells were grown in optimal growth conditions of 37˚C and 5 % CO2. 
Furthermore, all cells were passaged for less than 6 months and no 
authentication of cell lines was performed by the authors. 
 
Isolation and Culture of Peripheral Blood Mononuclear cells (PBMCs) 
Peripheral blood mononuclear cells (PBMCs) were collected and isolated 
from healthy volunteers. In brief, whole blood was collected in BD 
Vacutainer®CPTTM Tubes with Sodium HeparinN (Becton, Dickinson and 
Company, Cat. No. 362753, Franklin Lakes, NJ, USA) at room temperature. 
Tubes were immediately inverted 5 times and centrifuged for 30 minutes at room 
temperature at 1500-1800 x g. The layer of PBMCs under the plasma layer in 
each tube was collected, pooled together, resuspended in 50 mL of PBS,  and 
centrifuged at room temperature at 300 x g for 15 minutes.  The supernatant was 
methodically aspirated without disturbing the pellet and PBMCs were 
resuspended and cultured in RPMI-1640 medium (Sigma-Aldrich Canada, 
Mississauga, ON, Canada), supplemented with 10%  (v/v) FBS standard 
(Thermo Scientific, Waltham, MA, USA) and 10 mg/mL gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada) at 37 oC and at 5% CO2. PBMCs from healthy 
volunteers 1 and 2 (PBMCs V1, PBMCs V2) were taken from a healthy 28 year 
old female, a healthy 18 year old male respectively. 
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Cell Treatment 
 Cells were grown to 60-70% confluence, before being treated with SVTH-
6, piperlongumine (PL) (INDOFINE Chemical Company, Inc., Cat. No. P-004, 
Hillsborough, NJ, USA), and N-Acetyl-L-cysteine (NAC) (Sigma-Aldrich Canada, 
Cat. No. A7250) at the indicated concentrations and time points. SVTH-6, a C-1 
acetoxymethyl analogue of PST, was produced by synthesis from bromobenzene 
(Vshyvenko et al. 2011). NAC was dissolved in sterile water. All other 
compounds were dissolved in dimethylsulfoxide (DMSO).  
 
WST-1 Assay for Cell Viability 
The WST-1 based colorimetric assay was performed as per the 
manufacturer’s protocol (Roche Applied Science, Indianapolis, IN, USA) to 
quantify cell viability via correlation with active cellular metabolism. 96-well clear 
bottom tissue culture plates were seeded with cells. Subsequently, the cells were 
treated with compounds at the indicated concentrations and time points. The 
treated cells were incubated with WST-1 reagent for 4 hours at 37˚ C with 5 % 
CO2. In actively metabolizing cells, the WST-1 reagent is cleaved to formazan by 
cellular enzymes. The presence of formazan was quantified via absorbance 
readings at 450 nm on a Wallac Victor3 TM 1420 Multilabel Counter (PerkinElmer, 
Woodbridge, ON, Canada). Cellular viability through measured absorbance 
readings expressed as percentages of the solvent control group.  
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Cell Death Analysis: Annexin V Binding Assay & Propidium Iodide (PI) Staining  
The Annexin V binding assay and propidium iodide staining was done in 
parallel to respectively monitor early apoptosis and cell permeabilization, a 
marker of necrotic or late apoptotic cell death. Cells were washed with phosphate 
buffer saline (PBS) and suspended in Annexin V binding buffer (10 mM HEPES, 
140 mM NaCl, 2.5 mM CaCl2, pH 7.4) with green fluorescent Annexin V 
AlexaFluor-488 (1:20) (Life Technologies Inc, Cat. No. A13201, Burlington, ON, 
Canada) and 0.01mg/mL of red fluorescent PI (Life Technologies Inc, Cat. No. 
P3566, Burlington, ON, Canada) for 15 minutes at 37 oC protected from light. 
The percentage of early (green), late apoptotic cells (green and red), and 
necrotic cells (red) were quantified using image-based cytometry with a Tali® 
Image-Based Cytometer (Life Technologies Inc, Cat. No. T10796, Burlington, 
ON, Canada). Cells from at least 18 random fields were analyzed using both the 
green (ex. 458 nm; em. 525/20 nm) and red (ex. 530 nm; em. 585 nm) channels. 
Fluorescent micrographs were taken at 400x magnification using LAS AF6000 
software with a Leica DMI6000 fluorescent microscope (Wetzlar, Germany). 
Cells monitored with microscopy were counterstained with Hoechst 33342 
(Molecular Probes, Eugene, OR, USA) to visualize nuclei using a final 
concentration of 10 μM during the 15 minute incubation. 
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Tetramethylrhodamine Methyl Ester (TMRM) Staining 
Tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, VWR, 
Mississauga, ON, Canada) was used for the purpose of detecting mitochondrial 
membrane potential (MMP). Cells were grown on coverslips and treated with 
various concentrations of drugs for the indicated time points and incubated with 
with 100 nM TMRM for 45 minutes at 37˚ C. Fluorescent micrographs were taken 
at 400x magnification on a Leica DM IRB inverted fluorescence microscope 
(Wetzlar, Germany). The percentage of TMRM cells was quantified using image-
based cytometry with a Tali® Image-Based Cytometer (Life Technologies Inc, 
Cat. No. T10796, Burlington, ON, Canada). Cells from at least 18 random fields 
were analyzed using the red channel (ex. 530 nm; em. 585 nm). Fluorescent 
micrographs were taken at 400x magnification using LAS AF6000 software with a 
Leica DMI6000 fluorescent microscope (Wetzlar, Germany). Cells monitored with 
microscopy were counterstained with Hoechst 33342 (Molecular Probes, 
Eugene, OR, USA) to visualize nuclei using a final concentration of 10 μM during 
the 45 minute incubation. 
 
Oxygen Consumption Quantitation 
 The MitoXpress® Xtra - Oxygen Consumption Assay [HS Method] (Luxcel 
Biosciences Ltd., Cat. No. MX-200, Cork, Ireland). 1 000 000 cells/well were 
seeded in a 96-well black clear bottom tissue culture plate and incubated for an 
hour at 37˚ C and 5% CO2. On a heat pack, 10 μL of MitoXpress® reagent was 
added to each well excluding the blanks, cells were treated with test compounds, 
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the plate was shaken with a plate shaker, and 2 drops of pre-warmed high 
sensitivity mineral oil was added to each well to seal off the air supply. Bottom 
read fluorescence measurements were taken at Ex. 380 nm and Em. 650, every 
2 minutes for 2 hours at 37 °C using a SpectraMax Gemini XS multi-well plate 
reader (Molecular Devices, Sunnyvale, CA, USA). Increases in fluorescence are 
indicative of oxygen consumption. Oxygen consumption rates were  determined 
by calculating the slope of the linear regions of the oxygen consumption curves 
using GraphPad Prism 6 software. 
 
Mitochondrial Isolation  
To isolate mitochondria from untreated cancer cells, the cells were 
washed once in cold PBS. Subsequently, they were resuspended in hypotonic 
buffer (1 mM EDTA, 5 mM Tris–HCl, 210 mM mannitol, 70 mM sucrose, 10 μM 
Leu-pep and Pep-A, 100 μM PMSF) and subjected to manual homogenization. 
The homogenized cells were centrifuged at 600 x g for 5 minutes at 4˚ C. The 
supernatant was retrieved and centrifuged at 15000 x g for 15 minutes at 4˚ C 
and the mitochondrial pellet was resuspended in cold reaction buffer (2.5 mM 
malate, 10 mM succinate, 10 μM Leu-pep and Pep-A, 100 μM PMSF in PBS). 
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Treatment of Isolated Mitochondria & Evaluation of Apoptogenic Factor Release 
The isolated mitochondria were treated with SVTH-6, PL or a combination 
of the two drugs at the indicated concentrations and incubated for 2 hours in cold 
reaction buffer (2.5 mM malate, 10 mM succinate, 10 μM Leu-pep, 10 μM Pep-A, 
and 100 μM PMSF in PBS). The control group was treated with solvent (DMSO). 
Following treatment, the mitochondrial samples were vortexed and centrifuged at 
15,000 x g for 15 minutes at 4˚C. Western Blot analysis was done on the 
resulting supernatant and mitochondrial pellet (resuspended in cold reaction 
buffer) to screen for mitochondrial release or retention of apoptogenic factors. 
 
Western Blot Analyses 
Protein samples including mitochondrial pellets and post mitochondrial 
supernatants were subjected to SDS-PAGE. The samples were transferred onto 
a nitrocellulose membrane and blocked with 5% w/v milk TBST (Tris-Buffered 
Saline Tween-20) solution for 1 hour. Membranes were then incubated with an 
anti-cytochrome c (Cyto c) antibody (1:1000) raised in mice (Abcam, ab13575, 
Cambridge, MA, USA), an anti-succinate dehydrogenase subunit A antibody 
(1:1000) raised in mice (Santa Cruz Biotechnology, Inc., sc-59687, Paso Robles, 
CA, USA), or an anti-apoptosis inducing factor (AIF) antibody raised in rabbits 
(1:1000) (Abcam, Cat. No. ab1998, Cambridge, MA, USA) overnight at 4˚ C. 
Following incubation with primary antibody, the membrane was washed once for 
15 minutes and then twice for 5 minutes in TBST. The membranes were then 
incubated with an anti-mouse (1:2000) or an anti-rabbit (1:2000) horseradish 
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peroxidase-conjugated secondary antibody (1:2000) (Abcam, ab6728, ab6802, 
Cambridge, MA, USA) for 1 hour at 25˚ C. Probing with secondary antibody was 
followed by three 5 minute washes in TBST. Lastly, chemiluminescence reagent 
(Sigma-Aldrich, CPS160, Mississauga, ON, Canada) was used to allow for band 
visualization (Sigma-Aldrich, CPS160, Mississauga, ON, Canada). Densitometry 
analyses were performed using ImageJ software. 
 
Quantitation of Reactive Oxygen Species (ROS) 
 The small molecule 2’, 7’-dicholorofluorescin diacetate (H2DCFDA) was 
used to montitor whole cell ROS generation. H2DCFDA enters the cell and is 
deacetylated by esterases and oxidized by ROS to the highly fluorescent 2’, 7’-
dicholorofluorescein (DCF) (excitation 495 nm; emission 529 nm). Cells were 
pretreated with 20 μM H2DCFDA (Sigma-Aldrich Canada, Cat. No. D6883, 
Mississauga, ON, Canada) for 30 minutes at 37°C protected from light at 5% 
CO2. Cells were treated for the indicated durations, centrifuged at 600 x g for 5 
minutes and suspended in PBS. Percentage of DCF positive cells was quantified 
using the Tali® Image-Based Cytometer (Life Technologies Inc, Cat. No. 
T10796, Burlington, ON, Canada) using 12 random fields per group with the 
green channel (excitation 458 nm; emission 525/20 nm). 
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Statistical Analysis 
All statistics were performed by GraphPad Prism 6 statistical software. A 
p-value below 0.05 was considered significant. For the experiments with single 
variable measurements, which include quantification of MMP, and whole cell 
ROS, a One-Way ANOVA (nonparametric) was conducted and each sample's 
mean was compared to the mean of the negative control (DMSO vehcile) unless 
otherwise specified. For experiments that contained multi-variables (e.g. multiple 
group comparisions), such as the quantification of live and dead cells, Two-Way 
ANOVA (nonparametric) was used and each sample's mean was compared to 
the mean of the negative control (DMSO vehcile) unless otherwise specified. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 243 
 
Results 
SVTH-6 Selectively Induces Cytotoxicity in Cancer Cells with Greater Efficacy 
than JCTH-4  
The anti-cancer activity of SVTH-6 was evaluated in various cancer cell 
types using the WST-1 based colorimetric assay measuring cell viability as a 
function of cell metabolism. SVTH-6 was shown to be more effective than JCTH-
4 as seen in OVCAR-3 ovarian cancer cells and induce apoptotic morphology 
including cell shrinkage and nuclear condensation (Figure 5.1D & E). Importantly 
after 72 hours, noncancerous NCM460 colon mucosa cells were markedly less 
sensitive to SVTH-6 compared to the HCT 116 and HT-29 colorectal cancer and 
the notoriously chemoresistant BxPC-3 pancreatic cancer cells, all of which were 
very sensitive to SVTH-6 insult; the dose of 0.25 µM SVTH-6 presented the best 
therapeutic window (Figure 5.1F). Thus, SVTH-6 acts in a selective manner, 
specifically inducing cytotoxicity in cancer cells with greater anti-cancer activity 
than JCTH-4. 
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Figure 5.1. SVTH-6 Selectively Induces Cytotoxicity in Cancer Cells with 
Greater Efficacy than JCTH-4.  Structures of (A) PST, (B) JCTH-4, and (C) 
SVTH-6. (D) WST-1 viability was performed on OVCAR-3 ovarian cancer cells 
treated for 48 hours. *p<0.001 vs. respective JCTH-4 treated groups. (E) 
OVCAR-3 ovarian cancer cells treated with SVTH-6 for 72 hours and stained with 
Hoechst dye. Scale bar = 15 µm. (F) Effect of SVTH-6 on cellular viability of cells 
was determined by the WST-1 colorimetric assay.  HCT-116, HT-29, BxPC-3 and 
NCM460 cells were treated with SVTH-6 for 72 hours at the indicated 
concentrations.  The WST-1 reagent was used to quantify cell viability.  
Absorbance was read at 450 nm and expressed as a percent of the solvent 
control (DMSO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments. *p<0.01 vs. HCT 116, #p<0.01 vs. HT-29, †p<0.05 vs. 
BxPC-3. 
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PL Enhances Cytotoxicity in Selectively in Cancer Cells  
The natural compound PL has previously been demonstrated to 
preferentially cause cytotoxicity in cancer cells by selectively targeting their 
stress response mechanisms against ROS (Raj et al. 2011). We have formerly 
shown PST and JCTH-4 to induce ROS production in cancer cells (McLachlan et 
al. 2005; Siedlakowski et al. 2008; Collins et al. 2010; Griffin et al. 2011; Griffin, 
McNulty, and Pandey 2011; Ma et al. 2011; Ma, Tremblay, et al. 2012; Ma, 
Collins, et al. 2012). Thus, we evaluated the combinatorial effect of both SVTH-6 
and PL on cancer cells. Interestingly, an enhanced cytotoxic effect with produced 
with this combination treatment selectively in cancer cells including BxPC-3 
pancreatic cancer, OVCAR-3 ovarian cancer, NCI H23 non-small cell lung 
cancer, and MV-4-11 leukemia cells (Figure 5.2A-D); this combination treatment 
had minimal effect on noncancerous NCM460 cells (Figure 5.2E). Thus, PL is 
able to enhance the anti-cancer activity of SVTH-6 selectively in cancer cells. 
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Figure 5.2. PL Enhances Cytotoxicity in Selectively in Cancer Cells. Effect of 
SVTH-6 and PL on cellular viability was determined by the WST-1 colorimetric 
assay.  (A) BxPC-3 pancreatic cancer cells, (B) OVCAR-3 ovarian cancer cells, 
(C) NCI H23 non-small cell lung cancer cells and (D) MV-4-11 leukemia cells 
were treated with SVTH-6 and PL for 48 hours at the indicated concentrations. 
Values are expressed as mean ± SD from quadruplicates of 3 independent 
experiments. BxPC-3 & OVCAR-3: *p<0.001 vs. control; #p<0.05 vs. 0.05 µM 
SVTH-6; †p<0.005 vs. 0.1 µM SVTH-6; &p<0.05 vs. 2.5 µM PL; @p<0.01 vs. 
0.25 µM SVTH-6; $p<0.005 vs. 5 µM PL. NCI H23: *p < 0.005 vs. Control; 
$p<0.005 vs. 0.05 SVTH-6; @p<0.005 vs. 0.005 SVTH-6; #p<0.005 vs. 2 PL; 
^p<0.005 vs. 1.5 PL. MV-4-11: *p<0.001 vs. solvent control (DMSO); @p<0.01 
vs. 0.5 µM PL; &p<0.01 vs. 1.0 PL µM; $p<0.005 vs. 1.5 µM PL; #p<0.01 vs. 0.01 
μM SVTH-6; %p<0.001 vs. 0.015 μM SVTH-6. (E) Noncancerous NCM460 
epithelial cells were also treated for 48 hours with the indicated concentrations of 
SVTH-6 and PL. Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments; *p<0.01 vs. 0.1 µM SVTH-6 + 5 µM PL with BxPC-3 
cells (Fig. 2A); #p<0.01 vs. 0.1 µM SVTH-6 + 5 µM PL with OVCAR-3 cells (Fig. 
2B); †p<0.05 vs. 0.25 µM SVTH-6 + 5 µM PL with BxPC-3 cells (Fig. 2A); 
@p<0.05 vs. 0.25 µM SVTH-6 + 5 µM PL with OVCAR-3 cells (Fig. 2B).  
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Selective Induction of Cell Death in Cancer Cells by SVTH-6 is Enhanced with 
PL  
To evaluate the ability of SVTH-6 and PL combination to induce apoptosis, 
cancer cells were treated for 48 hours with SVTH-6 and PL alone and in 
combination. Subsequently, these cells were monitored for Annexin V binding to 
externalized phosphatidylserine, a biochemical marker of apoptosis and 
propidium iodide staining, an indicator of cell membrane permeabilization, and by 
extension, necrosis and late apoptosis. As determined by image-based 
cytometry, PL was able to enhance cell death induction in U-937 lymphoma cells 
after 48 hours of treatment (Figure 5.3A). Notably, this combination treatment 
was well tolerated by peripheral blood mononuclear cells collected from healthy 
volunteers 1 (PBMCs V1) and 2 (PBMCs V2) at 48 hours (Figure 5.3B). 
Fluorescence micrographs revealed nuclei of BxPC-3 pancreatic cancer 
cells treated with SVTH-6 and PL alone and in combination for 48 hours to be 
brightly stained and condensed, indicative of apoptosis (Figure 5.3C). 
Furthermore, these cells were positive for Annexin V binding, as depicted by the 
green fluorescence. Such features of apoptosis were not evident in 
noncancerous NCM460 epithelial cells treated for 48 hours (Figure 5.3D). These 
findings collectively demonstrate this combination treatment to be selective in 
cancer cells. 
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Figure 5.3. Selective Induction of Cell Death in Cancer Cells by SVTH-6 is 
Enhanced with PL. Annexin V binding and PI staining of cells treated for 48 
hours was monitored with image-based cytometry. (A) U-937 lymphoma cells. 
(B) Non-cancerous cells: peripheral blood mononuclear cells from volunteer 1 
(PBMCs V1) and 2 (PBMCs V2). Values are expressed as mean ± SD from at 
least 3 independent experiments. *p<0.01 vs. DMSO control (comparison of 
viable cells only). (C) Annexin V binding (green) monitored with fluorescent 
microscopy in BxPC-3 pancreatic cancer  cells and (D) NCM460 normal epithelial 
cells treated for 48 hours counterstained with Hoechst. Scale bar = 15 µm. 
Micrographs are representative of 3 independent experiments. 
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PL Selectively Enhances Mitochondrial Membrane Potential (MMP) Dissipation 
by SVTH-6 in Cancer Cells 
We have previously established PST and JCTH-4 to target cancer cell 
mitochondria (Siedlakowski et al. 2008; McLachlan et al. 2005; Griffin et al. 2011; 
Griffin, McNulty, and Pandey 2011; Collins et al. 2010; Ma et al. 2011; Ma, 
Tremblay, et al. 2012). To validate such targeting by SVTH-6, various 
mitochondrial assays were executed. Cancer cells were treated and stained with 
TMRM, an indicator of intact MMP and an intact mitochondrial membrane. As 
depicted with image-based cytometry, SVTH-6 caused dissipation of MMP alone 
and in combination with PL, as depicted by the loss of red TMRM fluorescence. 
PL was able to enhance SVTH-6-induced MMP collapse in BxPC-3 pancreatic 
cancer cells in a time dependent manner (Figure 5.4A). This enhancement was 
also observed in U-937 lymphoma cells at 24 hours (Figure 5.4B). 
OVCAR-3 ovarian cancer cells treated for 48 hours with SVTH-6 caused 
dissipation of MMP alone and in combination with PL, indicated by the loss of red 
TMRM fluorescence, and nuclear condensation as seen with fluorescence 
microscopy (Figure 5.4C). PL insult alone also caused MMP dissipation. MMP 
dissipation and nuclear apoptotic morphology were not observed in CCD-18Co 
normal colon fibroblasts after 72 hours (Figure 5.4D). 
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Figure 5.4. PL Selectively Enhances Mitochondrial Membrane Potential 
(MMP) Dissipation by SVTH-6 in Cancer Cells. TMRM was used to monitor 
MMP in (A) BxPC-3 and (B) U-937 cancer cells with image-based cytometry. 
*p<0.001 vs. DMSO control; #p<0.01 SVTH-6 treatment alone; &p<0.001 vs. PL 
treatment alone. (C) Micrographs of depicting the effect of SVTH-6 and PL on 
MMP in (C) OVCAR-3 ovarian cancer cells and (D) CCD-18Co normal human 
fibroblasts after 48 hours with TMRM staining.  Red fluorescent punctuate marks 
are indicative of mitochondria with intact MMP. Scale bar = 15 µm.  Micrographs 
are representative of 3 independent experiments. 
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PL Enhances Mitochondrial Dysfunction by SVTH-6 
 A direct indicator on mitochondrial function is oxygen consumption (Brand 
and Nicholls 2011). To assess the effect of SVTH-6 alone and in combination 
with PL on oxygen consumption, the MitoXpress® Xtra - Oxygen Consumption 
Assay was used. SVTH-6 was able to effectively decrease the rate of oxygen 
consumption in U-937 lymphoma cells (Figure 5.5A). PL alone did not have a 
drastic effect on oxygen consumption, however, it was able to enhance the ability 
of SVTH-6 to decrease oxygen consumption in U-937 cells. Antimycin A (AMA), 
a complex III inhibitor of the electron transport chain (ETC), was used as a 
positive control for hindering oxygen consumption. These results indicate that PL 
is effective at enhancing  the ability of SVTH-6 in reducing oxygen consumption 
in lymphoma cells, and thus, mitochondrial function. 
Subsequent to the collapse of MMP and permeabilization of the 
mitochondrial membrane, various apoptogenic factors, such as AIF and Cyto c, 
are released from the mitochondria into the cytosol where they can directly or 
indirectly execute apoptosis (Earnshaw 1999; Degterev, Boyce, and Yuan 2003). 
To evaluate the ability of SVTH-6 and PL alone and in combination to act directly 
on cancer cell mitochondria to cause release of apoptogenic factors, 
mitochondria from OVCAR-3 cells were isolated and were directly subjected 
SVTH-6 and PL insult. After 2 hours, samples were vortexed, centrifuged and 
post mitochondrial supernatants were analyzed by western blot analysis for the 
release of apoptogenic factors from the mitochondria; mitochondrial pellet 
samples were probed with succinate dehydrogenase subunit A (SDHA) to serve 
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as loading controls.  Interestingly, SVTH-6 and PL alone and in combination were 
able to cause release of both Cyto c and AIF from these isolated cancer cell 
mitochondria, indicative of direct mitochondrial targets by these compounds 
(Figure 5.5B).  
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Figure 5.5. PL Enhances Mitochondrial Dysfunction by SVTH-6. (A) The 
MitoXpress® Xtra - Oxygen Consumption Assay was used to monitor oxygen 
consmption via fluorescence generation. U-937 Cells were treated, and the 
fluorescent MitoXpress® reagent monitored at Ex. 380 nm and Em. 650, every 2 
minutes for 2 hours at 37 °C. Oxygen consumption rates were calculated by 
measuring the slopes of the linear regions of the oxygen consumption curves. 
Values are expressed as mean ± SD from at least 3 independent experiments. 
*p<0.01 vs. DMSO control; $p<0.01 vs. SVTH-6 treatment alone; #p<0.01 vs. PL 
treatment alone.  (B) Isolated mitochondria of OVCAR-3 cells were treated 
directly with SVTH-6, PL, and solvent control (Me2SO) for 2 hours. Following 
treatment, samples were centrifuged, producing post mitochondrial supernatants, 
which were examined for the release of apoptogenic factors AIF and Cyto c 
respectively via western blot analyses, and mitochondrial pellets which were 
probed for SDHA to serve as loading controls. Image is representative of 3 
independent experiments demonstrating similar trends. Values are expressed as 
mean ± SD of quadruplicates of 1 independent experiment; *p<0.01 versus 
solvent control (DMSO). 
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Enhancement of SVTH-6 Anti-Cancer Activity by PL is Dependent on Oxidative 
Stress 
To determine the involvement of ROS in SVTH-6 induced cytotoxicity 
alone and in combination with PL, the antioxidant NAC was utilized. Combination 
treatment of SVTH-6 and PL yielded an enhancement in ROS production as 
seen with the H2DCFDA ROS indicator (Figure 5.6A), which was completely 
diminished with NAC treatment. Interestingly, NAC was able rescue cancer cells 
from this combination treatment in BxPC-3 and U-937 cancer cells (Figure 5.6B 
& C), and rescued U-937 cells from MMP collapse in U-937 cells (Figure 5.6D). 
Therefore, the enhanced cytotoxic effect produced by this combination treatment 
selectively in cancer cells is dependent on oxidative stress. 
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Figure 5.6. Enhancement of SVTH-6 Anti-Cancer Activity by PL is 
Dependent on Oxidative Stress. (A) ROS production monitored with H2DCFDA 
with imaged-based cytometry. *p<0.001 vs. DMSO control; #p<0.001 vs. 
respective group without NAC; $p<0.001 vs. PL treatment alone; %p<0.001 vs. 
SVTH-6 treatment alone. (B) BxPC-3 cells were treated with SVTH-6 and PL at 
the indicated concentrations for 48 hours with or without NAC to determine the 
dependency of ROS. The WST-1 reagent was used to quantify cell viability.  
Absorbance was read at 450 nm and expressed as a percent of the solvent 
control (Me2SO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments; *p<0.001 vs. 0.1 µM SVTH-6; #p<0.01 vs. 0.25 µM 
SVTH-6; †p<0.005 vs. 0.5 µM SVTH-6; @p<0.01 vs. 5 µM PL; &p<0.01 vs. 0.1 
µM SVTH-6 + 5 µM PL; $p<0.005 vs. 0.25 µM SVTH-6 + 5 µM PL.  (C) U-937 
cells monitored for Annexin V binding and PI staining with image-based 
cytometry. *p<0.01 vs. DMSO control; $p<0.001 vs. respective group without 
NAC; #p<0.001 vs. SVTH-6 treatment alone; @p<0.001 vs. PL treatment alone; 
all comparisons for p values are with viable cells only. (D) MMP dissipation of U-
937 cells was monitored with TMRM. *p<0.01 vs. DMSO control; &p<0.001 vs. 
respective group without NAC; #p<0.001 vs. SVTH-6 treatment alone; @p<0.001 
vs. PL treatment alone. 
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Discussion 
We present a synthetic analogue of PST, SVTH-6, which has potent anti-
cancer activity by targeting cancer cell mitochondria that was enhanced by 
exploiting oxidative vulnerabilities in cancer cells with PL. This PST analogue, 
SVTH-6, effectively caused cytotoxicity in an array of aggressive cancer cell 
types by way of apoptotic induction as shown by nuclear condensation and 
Annexin V binding to phosphatidylserine (Figure 5.3). This anti-cancer effect was 
enhanced when combined with the natural compound PL. However, a crucial 
finding of this study was the selective nature of SVTH-6 alone and in combination 
with PL; noncancerous PBMCs V1, PBMCs V2, NCM460 and CCD-18Co cells 
were significantly less sensitive to these treatments (Figure 5.1F, 5.2E, 5.3B, 
5.3D). This is in contrast to most chemotherapeutics currently available, such as 
Taxol, which we have previously shown to be very toxic to noncancerous cells 
(McLachlan et al. 2005).  
A new class of compounds collectively known as mitocans, includes anti-
cancer agents that directly or indirectly target cancer cell mitochondria to induce 
apoptosis selectively (Chen et al. 2010); through the findings of this report, 
SVTH-6 can put into this classification of compounds. We have formerly shown 
PST and JCTH-4 to selectively target cancer cell mitochondria to selectively 
induce apoptosis in cancer cells (McLachlan et al. 2005; Siedlakowski et al. 
2008; Griffin et al. 2011; Collins et al. 2010; Ma et al. 2011; Ma, Tremblay, et al. 
2012). Likewise, this study has shown SVTH-6 to dissipate MMP in cancer cells 
selectively, decrease oxygen consumption and cause release of apoptogenic 
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factors Cyto c and AIF from isolated cancer cell mitochondria alone and in 
combination with PL (Figure 5.4 & 5.5). These findings suggest direct 
mitochondrial targets by SVTH-6.  
The development of aggressive malignancies has been associated with 
elevated levels of oxidative stress (Kumar et al. 2008). Moreover, cancer cells 
have been found to exhibit higher levels of endogenous ROS compared to 
noncancerous cells (Diehn et al. 2009; Schumacker 2006). In turn, it is projected 
that cancer cells are more dependent on cellular defence mechanisms against 
ROS (Gogvadze, Orrenius, and Zhivotovsky 2008; Trachootham, Alexandre, and 
Huang 2009). Thus, targeting these oxidative vulnerabilities in cancer cells 
presents as a promising therapeutic tactic (Fruehauf and Meyskens 2007). 
Indeed, this strategy proved to be advantageous as demonstrated by SVTH-6 
and PL in this study. It has been previously suggested that the anti-cancer effects 
of PL are a result of selective targeting of the stress response to ROS (Raj et al. 
2011). Furthermore, our previous reports have revealed PST and JCTH-4 to 
induce ROS generation in cancer cells (McLachlan et al. 2005; Siedlakowski et 
al. 2008; Griffin et al. 2011; Ma, Tremblay, et al. 2012; Ma et al. 2011). When 
SVTH-6 and PL were used in combination, an enhanced cytotoxic response, 
MMP dissipation, and generation of ROS was produced in cancer cells (Figure 
5.2A-D, 5.3A & C, 5.4, 5.5, 5.6A). The cytotoxic effects produced by SVTH-6 
alone and in combination with PL were confirmed to be dependent on oxidative 
stress as the antioxidant NAC was able to rescue cancer cells from these 
treatments (Figure 5.6). Past studies have suggested proteins such as 
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glutathione S-transferase pi 1 (GSTP1) and carbonyl reductase1 (CBR1) to be 
direct or indirect targets of PL (Raj et al. 2011). However, increased levels of 
ROS induced by PL were not affected with the knockdown of GSTP1 or CBR1; 
thus, it is likely for PL to have multiple targets. Interestingly, we demonstrated PL 
to cause release of both Cyto c and AIF from isolated cancer cell mitochondria 
(Figure 5.5B) which may point towards mitochondrial target(s) by PL.   
There are many distinct differences in cancer cell metabolism and 
mitochondria which may allow for cancer specific targeting by SVTH-6 and 
possibly by PL (Gogvadze, Orrenius, and Zhivotovsky 2008; Chen et al. 2010). 
Cancer cells rely less on the mitochondria and more heavily on glycolytic 
metabolism for energy, a phenomenon known as the Warburg effect (Vander 
Heiden, Cantley, and Thompson 2009). Consequently, this metabolic phenotype 
gives rise to an acidic cytosolic environment, partially contributing to the 
hyperpolarization of cancer cell mitochondria. Hyperpolarized mitochondria in 
cancer cells have been associated with increased invasiveness and a heightened 
ability to evade apoptosis (Heerdt, Houston, and Augenlicht 2006). Nevertheless, 
it is this very feature that may allow selective targeting of cancer cells; once 
taken into the cell, SVTH-6 could be processed into a positively charged 
molecule that can be selectively taken up into hyperpolarized cancer cell 
mitochondria. Furthermore, there is a differential expression of various 
antiapoptotic proteins between cancer and noncancerous cells.  The glycolytic 
enzyme hexokinase II and antiapoptotic proteins of the Bcl-2 family, all of which 
discourage mitochondrial membrane permeabilization, have been shown to be 
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highly expressed in cancer cells (Green and Kroemer 2004; Casellas, Galiegue, 
and Basile 2002; Mathupala, Rempel, and Pedersen 1997).  
Adverse side effects produced by unspecific targeting and 
chemoresistance remain as large obstacles with present chemotherapeutics. We 
have in hand, a novel synthetic analogue of PST, SVTH-6, with highly selective 
and potent anti-cancer activity against many aggressive malignancies acting 
through mitochondrial targeting. Combining SVTH-6, shown to cause 
mitochondrial dysfunction with PL, which cripples cellular defence mechanisms 
against ROS preferentially in cancer cells, presents a promising strategy in 
eradicating cancer. We have demonstrated this approach to produce an 
enhanced response against cancer cells; thus, lower doses of each drug are 
required for the same desired effect, minimizing any minor side effects these 
compounds may have at higher doses. This approach targets two or more 
different vulnerabilities of cancer cells, which may decrease the likelihood of 
chemoresistance. Elucidating the target protein(s) and pathway(s) of SVTH-6, 
may give rise to a novel outlook to cancer etiology and provide a scaffold for the 
design of additional therapeutic approaches. Given the unprecedented selective 
anti-cancer activity uncovered thus far, we present a promising strategy that may 
serve as a safer and more effective alternative to the cancer therapies currently 
available.  
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General Discussion 
 In this dissertation, various synthetic analogues of the natural compound 
pancratistatin (PST) (Figure 6.1), a compound we have found to selectively 
induce apoptosis in cancer cells, were systematically evaluated for anti-cancer 
activity in a battery of cancer cell lines. The synthesis and screening of these 
novel analogues was completed in an effort to overcome the low availability of 
native PST in nature and to produce more efficacious analogues.  
 The initial work on this project involved the screening of four 7-
deoxypancratistatin (7-deoxyPST) analogues: JCTH-1, JCTH-2, JCTH-3, and 
JCTH-4 (Collins et al. 2010). JCTH-4 was found to have comparable anti-cancer 
activity compared to natural PST. JCTH-3 had limited anti-cancer activity while 
the effects of JCTH-1 and JCTH-2 were very minimal in cancer cells. This was 
the first time a synthetic analogue of 7-deoxyPST was shown to have 
comparable anti-cancer activity to PST.  JCTH-4, a C-1 acetoxymethyl analogue 
of 7-deoxyPST, was further evaluated and characterized in various cancer cell 
types alone in combination with other anti-cancer agents (Chapter 2 & 3, 
Appendix A & B).  
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Figure 6.1. Structure of PST and Synthetic PST Analogues 
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 JCTH-4 was found to be effective against colorectal cancer cells (Chapter 
2), osteosarcoma cells (Chapter 3), pancreatic cancer cells (Appendix A), 
neuroblastoma cells (Appendix B), and breast cancer cells (Appendix B). As 
with natural PST, JCTH-4 was able to induce apoptosis in these cancer cells 
selectively by targeting mitochondria. Furthermore, the preferential pro-apoptotic 
effect in cancer cells was potentiated by Tamoxifen (Chapter 2, Appendix B) 
and curcumin (Chapter 3), by enhancing mitochondrial dysfunction in cancer 
cells. This enhancement is proposed to be a result of the ability of Tamoxifen and 
curcumin to target cancer cell mitochondria, sensitizing this organelle to JCTH-4 
insult (Moreira et al. 2006; Ravindran et al. 2009; Aggarwal et al. 2007). 
 Upon finding potent anti-cancer activity comparable to PST in JCTH-4, a 
7-deoxyPST analogue, and drawing from previous structure activity relationship 
analyses (McNulty et al. 2005; Collins et al. 2008; Collins et al. 2010), additional 
PST analogues were designed and synthesized in an effort to find chemical 
modifications to maximize anti-cancer activity.  PST analogues containing the full 
proposed anti-cancer pharmacophore of PST and related alkaloids were 
synthesized, which incorporated the C-7 hydroxyl group (Vshyvenko et al. 2011). 
These included SVTH-5 and -6, the C-7 hydroxylated equivalents of JCTH-3 and 
-4, respectively, and the novel analogue SVTH-7 (Figure 6.1).  
 To evaluate the anti-cancer activity of these compounds, a medium 
throughput screen was completed on 18 cancer cell lines and non-cancerous 
cells (Chapter 4). PST analogues SVTH-7, -6, and -5 demonstrated potent anti-
cancer activity with greater efficacy than natural PST, 7-deoxyPST analogues, 
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and several standard chemotherapeutics, with SVTH-7 having greatest activity, 
followed by SVTH-6 and -5. Likewise, they were efficient in disrupting 
mitochondrial function, activating the intrinsic pathway of apoptosis in both 
monolayer and spheroid culture, and reducing growth of tumor xenografts in vivo. 
These results demonstrate the ability of PST analogues to target a broad range 
of different cell types, which demonstrates a possible targeting of a common 
cancer vulnerability . 
 Collectively, these findings suggest the anti-cancer activity of these 
compounds to be highly dependent on the C-7 hydroxyl group and the functional 
group substitutions on C-1. Notably, the functional group at C-1 dramatically 
alters analogue potency against cancer cells as seen with JCTH-1 and JCTH-2, 
compounds nearly devoid of anti-cancer activity, compared to JCTH-4, which 
only differs in the functional group at the C-1 position (Collins et al. 2010).  
Moreover, SVTH-7 varies only in the C-1 functional group compared to SVTH-6 
and -5, and has much greater efficacy (Chapter 4). The findings of these 
structural activity analyses point to the possible role and importance of the C-7 
hydroxyl group and the C-1 functional groups in the interaction between the 
cellular target(s) of PST and its analogues at very specific binding sites(s). In 
particular, SVTH-7, the most efficacious PST analogue, has a bulky benzene 
group at C-1, suggesting an interaction between the C-1 functional group and a 
specific hydrophobic pocket on the cellular target(s). 
 Although the exact cellular target of PST and its analogues has not yet 
been identified and characterized, evidence from this body of work and previous 
 273 
 
findings suggest cancer cell mitochondria to play a pivotal role in the anti-cancer 
activity of these compounds (Chapter 2-4, Appendix A & B) (McLachlan et al. 
2005; Siedlakowski et al. 2008; Griffin et al. 2011; Ma et al. 2012; Ma et al. 
2011). PST and its synthetic analogues have been shown to dissipate 
mitochondrial membrane potential (MMP) early after treatment, cause an 
increase in reactive oxygen species (ROS), disrupt oxygen consumption, and 
promote release of apoptogenic factors from cancer cell mitochondria. 
Furthermore, isolated cancer cell mitochondria treated with PST and PST 
analogues were shown to have increases in ROS, and release apoptogenic 
factors, indicating that these compounds are able to act directly on this organelle. 
 Like other mitocans, chemical agents that target cancer cell mitochondria 
to induce apoptosis, these compounds could be interacting with anti-apoptotic 
Bcl-2 proteins overexpressed in cancer cells, interacting with proteins of the 
permeability transition pore to induce mitochondrial permeabilization,  functionally 
mimicking the activity of various pro-apoptotic Bcl-2 family proteins, or targeting 
complexes of the electron transport chain (ETC) (Neuzil et al. 2013; Ralph et al. 
2006).  Interestingly, inhibiting ETC complex II was able to abolish the anticancer 
activity of SVTH-7 (Chapter 4). A similar but less pronounced effect was 
observed with complex III inhibition.  
 This surprising observation could be the result targeting of these 
complexes directly or through interacting partners. Alternatively, studies have 
shown complex II to be a mediator of apoptosis (Guzzo et al. 2014; Lemarie et al. 
2011), however, the exact role of complex II and III in PST analogue-induced 
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apoptosis remains unclear. Further experiments involving functional ETC 
complex activity assays, siRNAs or shRNAs for ETC complexes, and 
overexpression of ETC complexes are needed to characterize the role of 
complex II and III. However, to identify direct binding partners of PST analogues, 
affinity chromatography with a PST analogue-linked resin can be employed. 
These additional studies may reveal specific cancer vulnerabilities that can be 
used for the design of novel therapeutic strategies. 
 Targeting ETC complexes has been shown to increase ROS, which can 
selectively induce apoptosis in cancer cells as they have been demonstrated to 
be more vulnerable to oxygen radical insult (Trachootham et al. 2006; 
Trachootham et al. 2009). Therefore, mitocans that target mitochondria in 
combination with agents that can increase oxidative stress could be an effect 
way to eliminate cancer cells. Indeed, the ability of SVTH-6 to induce 
mitochondrial dysfunction and apoptosis selectively in cancer cells was 
enhanced with piperlongumine (PL), a compound found to target cellular defense 
mechanisms against oxidative stress (Chapter 5). Such findings demonstrate the 
potential of exploiting cancer cell mitochondria and oxidative vulnerabilities to 
selectively induce apoptosis in cancer cells.  
Although, the broad spectrum caspase inhibitor Z-VAD-FMK was unable 
to prevent JCTH-4-induced cytotoxicity (Chapter 2), this result was obtained 
using the WST-1 assay which measures active cell metabolism. The dependence 
of caspases in PST analogue-induced apoptosis was more appropriately 
evaluated by monitoring early and late apoptosis induction with Annexin V 
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binding and propidium iodide staining (Chapter 4). These studies revealed Z-
VAD-FMK to only partially rescue cancer cells from PST analogues, indicating 
that caspases are only partially but not completely necessary in the induction of 
apoptosis. This supports the case for PST analogues targeting cancer cell 
mitochondria which are upstream of executioner caspases and can cause 
release of various apoptogenic factors involved in both caspase dependent and 
independent pathways of apoptosis.   
 Marked differences in cancer cell mitochondria provide opportunities for 
selectively promoting cell death. (Gogvadze et al. 2008; Gogvadze et al. 2010). 
In contrast, many chemotherapeutics currently in use targeting DNA or tubulin 
dynamics do not discriminate between normal and cancerous cells, and exert 
their effects on fast dividing cells in the body which can lead to a variety of side 
effects (Jordan & Wilson 2004). At low concentrations, PST analogues 
demonstrated potent anti-cancer activity with minimal effect in normal cells, 
which may be a result of its ability to exploit cancer cell mitochondria. In addition 
to selectively targeting cancer cells, SVTH-7, -6, and -5 were shown to be more 
effective than common chemotherapeutics, Taxol, Doxorubicin (DOX), 
Gemcitabine (GEM), and Cisplatin in a multitude of cancer cell types including 
leukemia, triple negative breast cancer, glioblastoma, and non-small cell lung 
cancer in vitro. Notably, GEM, a nucleoside analogue and the standard 
chemotherapeutic for notoriously chemoresistant pancreatic cancer (Berlin & 
Benson 2010), was surpassed in efficacy by these PST analogues.  
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 As we have shown these compounds to be both selective and more 
effective than multiple standard chemotherapeutics, it presents a strong case for 
their clinical development.  More importantly, these analogues were able to 
reduce growth of tumor spheroids and human tumor xenografts in vivo  in mice. 
No apparent toxicity to mice was observed as there was no reduction in body 
mass and decrease in normal activity. However, further toxicology and 
pathological analyses are required to fully characterize their tolerance in animals. 
Additional in vivo studies using various modes of drug administration including 
oral feeding, intraperitoneal injection and intravenous injection will further validate 
our findings. In summary, these in vivo studies demonstrate the ability of these 
analogues to penetrate tumor architecture and remain stable and effective in 
physiological systems, warranting their investigation for human use. Future work 
involving rigorous pharmacokinetic and pharmacodynamic studies are required to 
characterize how these analogues are absorbed, dsitributed, metabolized, and 
excreted, as well as identifying potentially dangerous interactions these 
compounds may have in the body. These will be crucial prerequisites for the 
approval of these analogues for human clincial trails by Health Canada. 
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Conclusion 
 This dissertation has addressed the initial hurdles in advancing the 
development of PST as a chemotherapeutic including its low availability in 
nature. SVTH-7 had the most anti-cancer activity, followed by -6, and -5. These 
compounds can be made in abundance and their chemical modification of the C-
1 functional group has provided greater anti-cancer activity compared to natural 
PST and multiple chemotherapeutics in various aggressive cancer cell types in 
two- and three-dimensional cell culture. Further validation of the efficacy and 
selectivity of these analogues was found in animal models. Evidence from this 
work suggests a mitochondrial target in cancer cells.  The requirement of 
functional complex II and III for the anti-cancer activity of  SVTH-7 points to a 
potential vulnerability in cancer cells that can be further characterized and 
exploited for the development of novel therapeutic regimes. In addition, this work 
has demonstrated the potential benefit of using novel non-genotoxic anti-cancer 
agents targeting mitochondrial and oxidative susceptibilities in combination. 
Consequently, using these analouges as sensitizing agents in adjuvant therapy 
with standard chemotherapeutics could potentially bring down the effective 
concentrations of these drugs needed for therapeutic benefit while minimizing 
any known toxic effects observed at higher doses.   Therefore, this work provides 
a basis for characterizing and exploiting distinct mitochondrial and metabolic 
vulnerabilities in cancer cells with synthetic analogues of PST with high 
therapeutic potential.  
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Summary 
 Pancreatic cancer is amongst the deadliest cancers in the world. It is 
associated with poor prognosis, is notorious for developing chemoresistance, 
and very few approved chemotherapeutics are available to treat this disease. 
The natural compound pancratistatin (PST) has shown to effectively induce 
cytotoxicity selectively in numerous cancer cell types. However, it is present in 
only minute quantities in its natural source and many complications have 
burdened its chemical synthesis. We have overcome these bottlenecks by 
synthesizing a C-1 acetoxymethyl analogue of 7-deoxypancratistatin, JC-TH-
acetate-4 (JCTH-4), which we have shown to have similar selective anti-cancer 
activity to that of PST. In this report, we show JCTH-4 to be a potent 
chemotherapeutic against pancreatic cancer cells (BxPC-3, PANC-1). It induced 
apoptosis selectively in BxPC-3 and PANC-1 cells by targeting the mitochondria; 
it dissipated mitochondrial membrane potential, caused release of apoptogenic 
factors, and in isolated mitochondria, increased the generation of reactive oxygen 
species. Furthermore, JCTH-4 selectively induced autophagy in pancreatic 
cancer cells while normal human fetal fibroblasts were markedly less sensitive to 
JCTH-4 insult. Altogether, this study outlines JCTH-4 as a potentially safe and 
effective chemotherapeutic agent in treating notoriously chemoresistant 
pancreatic cancer. 
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Introduction 
Type I programmed cell death or apoptosis induction can arise 
extrinsically, as a result of death receptor ligation at the plasma membrane or 
intrinsically, as a response to internal cellular stress [1]. Such internal stress, 
including DNA damage, triggers upregulation of proapoptotic proteins which 
cause permeabilization of the mitochondrial membrane, dissipation of 
mitochondrial membrane potential (MMP), and release of apoptogenic factors 
[2,3]. Once released from the mitochondria, these factors can execute apoptosis 
directly or indirectly via activation of caspases, a family of cysteine proteases 
[2,3]. 
Alternatively, type II programmed cell death, or autophagic cell death, 
results from the extensive activation of autophagy, a process which normally 
functions as a pro-survival stress response that allows cells to persist under 
unfavourable conditions [4]. Autophagy can be triggered by various forms of 
cellular stress such as oxidative stress, dysfunctional organelles, deficiencies in 
growth factors and nutrients, hypoxia, and pathogens [5]. Upon autophagic 
induction a membrane sac, a phagophore, engulfs portions of cytoplasm 
containing proteins and organelles to be degraded [6]. This gives rise to double-
membrane vesicles termed autophagosomes which subsequently fuse with 
lysosomes to yield autolysosomes; previously engulfed contents are then 
degraded via lysosomal hydrolases [6]. Avoidance of programmed cell death has 
been implicated in cancer etiology and restoration or selective induction of these 
pathways may prove to be advantageous strategies in cancer therapy [7,8]. 
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Pancreatic cancer is notoriously one of the most deadly cancers 
worldwide [9,10]. Most patients are diagnosed at advanced stages of this disease 
and consequently few live longer than 6 months post diagnosis [11,12]. The 
standard therapy for pancreatic cancer has been gemcitabine, increasing quality 
of life and survival time [13]. However, the largest obstacles in combating this 
malignancy are inherent and developed resistance against chemotherapy 
[14,15]. Currently, there are only a few other approved chemotherapeutic agents 
available for treating pancreatic cancer, and thus, it would be invaluable to find 
and develop novel compounds with greater efficacy and specificity towards these 
malignancies. 
In preceding studies, we have reported the Amaryllidaceae alkaloid 
pancratistatin (PST) to induce apoptosis selectively in a variety of cancer cell 
types at low doses and decrease the volume of human tumors in vivo; PST is 
well tolerated in mice and non-cancerous cells are drastically less sensitive to 
this compound [16-22]. Nevertheless, the availability of this compound has 
impeded its preclinical and clinical work; PST is present in only minuscule 
quantities in the Hymenocallis littoralis plant and many difficulties have been 
encountered with its chemical synthesis. To overcome these issues, we have 
produced 7-deoxypancratistatin derivatives via chemoenzymatic synthesis from 
bromobenzene and have screened them for similar anti-cancer activity; one C-1 
acetoxymethyl analogue, JC-TH-acetate-4 (JCTH-4), was identified to have 
comparable efficacy and specificity to PST in several cancer cell types [23]. 
Herein, we report JCTH-4 to be an effective inducer of apoptosis and autophagy 
 285 
 
selectively in pancreatic cancer cells. Such activity in pancreatic cancer may be 
attributed to mitochondrial targeting by JCTH-4; this compound caused the 
release of apoptogenic factors from the mitochondria, dissipated mitochondrial 
membrane potential, and in isolated mitochondria, increased the production of 
reactive oxygen species (ROS). Such cytotoxicity was not observed in normal 
human fetal fibroblasts (NFF). Thus, these results present JCTH-4 as a potential 
selective and potent chemotherapeutic against pancreatic cancer. 
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Materials and Methods 
Cell Culture 
A pancreatic adenocarcinoma cell line, BxPC-3 (American Type Culture 
Collection, Cat. No. CRL-1687, Manassas, VA, USA), was cultured in RPMI-1640 
medium (Sigma-Aldrich Canada, Mississauga, ON, Canada) supplemented with 
10% (v/v) fetal bovine serum (FBS) standard (Thermo Scientific, Waltham, MA, 
USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). 
A pancreatic epithelioid carcinoma cell line, PANC-1 (American Type Culture 
Collection, Cat. No. CRL-1469, Manassas, VA, USA), was cultured in Dulbecco's 
Modified Eagle's Medium (Sigma-Aldrich Canada, Mississauga, ON, Canada) 
supplemented with 10% (v/v) FBS standard (Thermo Scientific, Waltham, MA, 
USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). 
Apparently normal human fetal fibroblast (NFF) cells (Coriell Institute for Medical 
Research, Cat. No. AG04431B, Camden, NJ, USA) were grown in Dulbecco’s 
Modified Eagle’s Medium, High Glucose (Thermo Scientific, Waltham, MA, USA) 
supplemented with 15% (v/v) FBS standard (Thermo Scientific, Waltham, MA, 
USA) and 10 mg/mL gentamicin (Gibco BRL, VWR, Mississauga, ON, Canada). 
All cells were maintained at 37˚ C and 5 % CO2. 
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Cell Treatment 
In this study, cells were cultured to 60–70 % confluence and subsequently 
treated with tamoxifen (TAM) citrate salt (Sigma-Aldrich Canada, Cat. No. T9262, 
Mississauga, ON, Canada), the broad spectrum caspase inhibitor Z-VAD-FMK 
(EMD Chemicals, Gibbstown, NJ, USA), and JC-TH-acetate-4 (JCTH-4) at the 
indicated concentrations and durations. As previously described, JCTH-4 was 
created by chemoenzymatic synthesis from bromobenzene [23]. Compounds 
were dissolved in dimethylsulfoxide (Me2SO).  
 
Nuclear Staining 
Following treatment and incubation with the aforementioned drugs, cells 
were incubated with 10 µM Hoechst 33342 dye (Molecular Probes, Eugene, OR, 
USA) for 5 minutes to visualize the nuclei. Images were aquired at 400x 
magnification on a Leica DM IRB inverted fluorescence microscope (Wetzlar, 
Germany).  
 
Annexin V Binding Assay 
The Annexin V binding assay was carried out to validate apoptosis. After 
drug treatment, cells were washed with phosphate buffer saline (PBS) twice, 
resuspended in Annexin V binding buffer (10 mM HEPES, 10 mM NaOH, 140 
mM NaCl, 1 mM CaCl2, pH 7.6), and incubated with Annexin V AlexaFluor-488 
(1:50) (Sigma-Aldrich Canada, Mississauga, ON, Canada) for 15 minutes. 
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Fluorescent micrographs were acquired at 400x magnification on a Leica DM IRB 
inverted fluorescence microscope (Wetzlar, Germany).  
WST-1 Assay for Cell Viability 
The WST-1 based colorimetric assay was carried out as per the 
manufacturer’s protocol (Roche Applied Science, Indianapolis, IN, USA) to 
quantify cell viability as a function of active cell metabolism. Clear bottom 96-well 
tissue culture plates were seeded with approximately 4.0 x 103 BxPC-3 cells/well, 
6.0 x 103 PANC-1 cells/well, or 5.0 x 103 NFF cells/well and subsequently, cells 
were treated with JCTH-4 and Z-VAD-FMK at the indicated doses and durations. 
After treatment, the WST-1 reagent, which is converted to formazan by cellular 
enzymes, was administered into each well and incubated for 4 hours at 37˚ C. 
Absorbance readings were taken at 450 nm on a Wallac Victor3 TM 1420 
Multilabel Counter (PerkinElmer, Woodbridge, ON, Canada) to quantify the 
formazan product. Absorbance readings were expressed as percentages of the 
solvent control groups. 
 
Tetramethylrhodamine Methyl Ester (TMRM) Staining 
To detect MMP, tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, 
VWR, Mississauga, ON, Canada) was used. Cells were grown on coverslips and 
treated with JCTH-4 at the indicated concentrations and for the indicated 
durations.  After treatment, cells were incubated with 200 nM TMRM for 45 
minutes at 37˚ C. Fluorescent micrographs were taken at 400x magnification on 
a Leica DM IRB inverted fluorescence microscope (Wetzlar, Germany). 
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Mitochondrial Isolation  
Mitochondria were isolated from untreated BxPC-3 cells. BxPC-3 cells 
were washed two times in cold PBS, resuspended in hypotonic buffer (1 mM 
EDTA, 5 mM Tris–HCl, 210 mM mannitol, 70 mM sucrose, 10 μM Leu-pep, 10 
μM Pep-A, and 100 μM PMSF), homogenized, and centrifuged at 600 x g for 5 
minutes at 4˚ C. The supernatant was centrifuged at 15,000 x g for 15 minutes at 
4˚ C. The resulting cytosolic supernatant was discarded and the mitochondrial 
pellet was resuspended in cold reaction buffer (2.5 mM malate, 10 mM succinate, 
10 μM Leu-pep, 10 μM Pep-A, and 100 μM PMSF in PBS). 
 
Amplex Red Assay 
ROS production was measured with Amplex Red (Molecular Probes, 
Eugene, OR, USA). Isolated mitochondria suspended in cold reaction buffer were 
loaded into wells of an opaque 96-well plate (20 µg of protein/well) with the 
indicated concentrations of drugs. Paraquat (PQ) (Sigma-Aldrich Canada, 
Mississauga, ON, Canada) was used as a positive control at 250 µM. Amplex 
Red reagent was added to each well at a final concentration of 50 µM and 
horseradish peroxidase (HRP) (Sigma-Aldrich Canada, Mississauga, ON, 
Canada) was added in the ratio of 6 U/200 µL.  Fluorescence readings were 
taken after 2 hours of incubation at Ex. 560 nm and Em. 590 nm on a 
spectrofluorometer (SpectraMax Gemini XS, Molecular Devices, Sunnyvale, CA, 
USA). Fluorescence readings were expressed as relative fluorescence units 
(RFU).  
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Cellular Lysate Preparation 
After 72 hours of treatment with the indicated concentrations of JCTH-4 
and TAM, cells were manually  homogenized in cold hypotonic buffer (10 mM 
Tris HCl at pH 7.2, 5 mM KCl, 1 mM MgCl2, 1 mM EGTA, 1% Triton-X-100; 10 
μM Leu-pep, 10 μM Pep-A, and 100 μM PMSF). Cell lysates were stored at -20˚ 
C until use. 
 
Western Blot Analyses 
Protein samples were subjected to SDS-PAGE and transferred to a 
nitrocellulose membrane. Membranes were blocked with a 5% w/v milk TBST 
(Tris-Buffered Saline with Tween-20) solution for 1 hour and probed overnight at 
4˚ C with either: an anti-LC3 antibody raised in rabbits (1:500) (Novus 
Biologicals, Cat. No. NB100-2220, Littleton, CO, USA), an anti-β-Actin antibody 
raised in mice (1:1000) (Santa Cruz Biotechnology, Inc., Cat. No. sc-81178, Paso 
Robles, CA, USA), an anti-cytochrome C (Cyto C) antibody raised in mice 
(1:1000) (Abcam, Cat. No. ab13575, Cambridge, MA, USA), an anti-apoptosis 
inducing factor (AIF) antibody raised in rabbits (1:1000) (Abcam, Cat. No. 
ab1998, Cambridge, MA, USA), an anti-endonuclease G (EndoG) antibody 
raised in rabbits (1:1000) (Abcam, Cat. No. ab9647, Cambridge, MA, USA), or an 
anti-succinate dehydrogenase subunit A (SDHA) antibody raised in mice 
(1:1000) (Santa Cruz Biotechnology, Cat. No. sc-59687, Paso Robles, CA, USA). 
Membranes were subjected to one 15 minute and two 5 minute washes in TBST 
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and were incubated with an anti-mouse (1:2000) (Abcam, Cat. No. ab6278, 
Cambridge, MA, USA) or an anti-rabbit (1:2000) (Abcam, Cat. No. ab6802, 
Cambridge, MA, USA) horseradish peroxidase-conjugated secondary antibody 
for 1 hour at 25˚ C. Membranes were washed three times for 5 minutes in TBST. 
Enhanced chemiluminescence reagent (Sigma-Aldrich Canada, CPS160, 
Mississauga, ON, Canada) was used to visualize the bands. ImageJ software 
was used to perform densitometry analyses. 
 
Monodansylcadaverine (MDC) Staining 
Monodansylcadaverine (MDC) (Sigma-Aldrich Canada, Mississauga, ON, 
Canada) was used to visualize autophagic vacuoles. Cells were grown on 
coverslips and treated with the indicated concentrations of drugs and durations.  
Subsequent to drug treatment, cells were incubated with 0.1 mM MDC for 15 
minutes. Micrographs were acquired at 400x magnification on a Leica DM IRB 
inverted fluorescence microscope (Wetzlar, Germany).  
 
Propidium Iodide (PI) Staining 
 Cell lysis was observed using Propidium iodide (PI) dye (Sigma-Aldrich 
Canada, Mississauga, ON, Canada).  For 10 minutes, cells were incubated with 
PI at a concentration of 1 μg/mL.  Subsequently, micrographs were acquired with 
a Leica DM IRB inverted fluorescence microscope (Wetzlar, Germany) at 400x 
magnification. 
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Results 
JCTH-4 Selectively Induces Cytotoxicity in Pancreatic Carcinoma Cells in a Time 
& Dose-Dependent Manner   
To circumvent the issues surrounding the low availability of PST (Figure 
1A), a potent and selective inducer of cytotoxicity in numerous cancer cell types, 
synthetic analogues of PST were synthesized and evaluated for similar activity in 
BxPC-3 and PANC-1 pancreatic cancer cell lines. Using the WST-1 colorimetric 
assay for cell viability, it was found that JCTH-4 (Figure 1B), a C-1 
acetoxymethyl analogue of 7-deoxypancratistatin, was able to effectively induce 
cytotoxicity in BxPC-3 and PANC-1 cells in a time and dose dependent manner 
(Figure 2A & B). After 96 hours, JCTH-4 had an approximate half-maximal 
inhibitory concentration (IC50) value of 0.25 µM in BxPC-3 cells and 0.5 µM in 
PANC-1 cells. Notably, NFF cells were markedly less sensitive to JCTH-4 insult 
(Figure 2C).  
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Figure 1: Comparison of Chemical Structures. The structures of (A) 
Pancratistatin (PST) and (B) JC-TH-acetate-4 (JCTH-4).  
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Figure 2: JCTH-4 Selectively Induces Cytotoxicity in Pancreatic Carcinoma 
Cells in a Time & Dose-Dependent Manner.  Effect of JCTH-4 on cellular 
viability of cells was determined by the WST-1 colorimetric assay. (A) BxPC-3 
and (B) PANC-1 cells were treated with JCTH-4 at the indicated concentrations 
and times. The WST-1 reagent was used to quantify cell viability. Absorbance 
was read at 450 nm and expressed as a percent of the solvent control (Me2SO). 
Values are expressed as mean ± SD from quadruplicates of 3 independent 
experiments. *p<0.05, **p<0.01 versus solvent control (Me2SO). (C) Viability of 
NFF cells treated with JCTH-4 at the indicated concentrations compared to 
BxPC-3 and PANC-1 cells after 72 hours was determined by the WST-1 
colorimetric assay.  The WST-1 reagent was used to quantify viability. 
Absorbance was read at 450 nm and expressed as a percent of the solvent 
control (Me2SO). Values are expressed as mean ± SD from quadruplicates of 3 
independent experiments. *p<0.01 versus BxPC-3 cells, #p<0.05 versus PANC-1 
cells. 
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JCTH-4 Selectively Induces Apoptosis in Pancreatic Carcinoma Cells 
Apoptotic morphology was observed in pancreatic cancer cells treated 
with JCTH-4 as seen with Hoechst nuclear staining and phase microscopy; cell 
shrinkage, blebbing, brightly stained and condensed nuclei, and apoptotic bodies 
were produced by JCTH-4 in BxPC-3 cells at 0.5 µM and 1 µM and in PANC-1 
cells at 1 µM and 2 µM (Figure 3A and B). Such morphology was absent in NFF 
cells treated with JCTH-4 (Figure 3C). Selective induction of apoptosis in 
pancreatic cancer cells was confirmed with the binding of Annexin V to exposed 
phosphatidylserine, a biochemical marker of apoptosis, as indicated by the green 
fluorescence (Figure 3D-F). These results illustrate JCTH-4 to be a potent and 
selective agent against BxPC-3 and PANC-1 cells via induction of apoptotic cell 
death. 
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Figure 3: JCTH-4 Selectively Induces Apoptosis in Pancreatic Carcinoma 
Cells. Nuclear morphology of (A) BxPC-3, (B) PANC-1 and (C) NFF cells after 
72 hours of treatment.  Cells were treated with JCTH-4 at the indicated 
concentrations and solvent control (Me2SO).  Afterwards, the cells were stained 
with Hoechst 33342 dye. Images were taken at 400x magnification on a 
fluorescent microscope. The accompanying phase images are shown below the 
Hoechst images. Apoptosis is evident in cells with bright and condensed nuclei 
accompanied by apoptotic bodies. Annexin V binding to externalized 
phosphatidylserine, a marker for apoptosis, was monitored in (D) BxPC-3, (E) 
PANC-1, and (F) NFF cells. Cells were treated with the indicated concentrations 
of JCTH-4 and solvent control (Me2SO) for 72 hours. Green fluorescence is 
indicative of Annexin V binding to phosphatidylserine. Cells were also stained 
with Hoechst 33342 dye. Images were taken at 400x magnification on a 
fluorescent microscope. Scale bar = 15 µm. 
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JCTH-4 Selectively Induces Apoptosis by Targeting Mitochondria in Pancreatic 
Carcinoma Cells 
In previous reports, we have attributed the apoptosis-inducing capabilities 
of PST to mitochondrial targeting [17-22]. To substantiate such targeting by 
JCTH-4, mitochondria in pancreatic cancer cells were monitored following JCTH-
4 insult. Following 72 hours of treatment with JCTH-4, cells were evaluated for 
MMP dissipation, an indicator of mitochondrial membrane permeabilization, with 
TMRM dye. Loss of MMP, illustrated by the decrease of red TMRM fluorescence, 
was observed in BxPC-3 and PANC-1 cells but not in NFF cells with the 
indicated concentrations of JCTH-4 (Figure 4A-C). 
Subsequent to mitochondrial membrane permeabilization, various 
apoptogenic factors are released from the mitochondria into the cytosol which 
can then directly or indirectly execute apoptosis [2]. To verify whether or not 
JCTH-4 is able to cause release of these factors, pancreatic cancer cells were 
treated with 1 µM JCTH-4 for 72 hours. Following treatment, cells were lysed and 
centrifuged to produce cytosolic and mitochondrial fractions that were analyzed 
for the release or retention of apoptogenic factors respectively with JCTH-4 
insult. Indeed, JCTH-4 caused the release of the apoptogenic factors AIF and 
Cyto c from mitochondria of BxPC-3 cells and a decreased retention of the 
apoptogenic factor EndoG in PANC-1 mitochondria (Figure 4D-F). 
Complementary to these findings, isolated mitochondria from BxPC-3 cells were 
treated directly with 1 µM JCTH-4 for 2 hours, and exhibited an increase in ROS 
production, an indicator of mitochondrial dysfunction (Figure 4G). PQ was used 
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as a positive control as it is known to induce ROS generation in mitochondria 
[24]. Collectively, these findings clearly demonstrate the mitochondria to be the 
target of JCTH-4. 
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Figure 4: JCTH-4 Selectively Induces Apoptosis by Targeting Mitochondria 
in Pancreatic Carcinoma Cells. (A) BxPC-3, (B) PANC-1 and (C) NFF cells 
were treated with the indicated concentrations of JCTH-4 and solvent control 
(Me2SO) for 72 hours and stained with TMRM and Hoechst dye. Red fluorescent 
punctuate marks are indicative of mitochondria with intact MMP. Images were 
taken at 400x magnification on a fluorescent microscope. Scale bar = 15 µm. 
Cytosolic fractions, separated from mitochondria by centrifugation, of BxPC-3 
cells treated with JCTH-4 or solvent control (Me2SO) for 72 hours were monitored 
for (D) AIF and (E) Cyto c release from mitochondria by western blot analysis; β-
Actin was probed as a loading control. Mitochondrial fractions, produced by 
centrifugation, of PANC-1 cells treated with JCTH-4 or solvent control (Me2SO) 
for 72 hours were monitored for the retention of (F) EndoG in the mitochondria by 
western blot analysis; SDHA was probed as a loading control. Densitometric 
analyses were performed using ImageJ software and statistics were calculated 
using GraphPad Prism version 5.0.  Values are expressed as mean ± SD. 
*p<0.05, **p<0.01 versus solvent control (Me2SO). (G) Isolated mitochondria of 
BxPC-3 cells were treated directly with JCTH-4 and solvent control (Me2SO). 
ROS was measured with Amplex Red substrate in the presence of horseradish 
peroxidase (HRP). Paraquat (PQ) was used as positive control.  Fluorescence 
readings were taken after 2 hours of incubation at Ex. 560 nm and Em. 590 nm 
and were expressed as relative fluorescence units (RFU). Statistics were 
performed using GraphPad Prism version 5.0. Image is representative of 3 
independent experiments demonstrating similar trends. Values are expressed as 
mean ± SD of quadruplicates of 1 independent experiment. *p<0.05, **p<0.001 
versus solvent control (Me2SO). 
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Activity of JCTH-4 is Independent of Caspase Activation 
Upon their expulsion from the mitochondria, apoptogenic factors can 
execute apoptosis directly or indirectly; factors such as AIF and EndoG are able 
to translocate to the nucleus to execute apoptosis directly while Cyto c activates 
a caspase signalling cascade to achieve apoptosis [2,25,26,3]. To assess the 
involvement of caspases in JCTH-4-induced apoptosis, the broad spectrum 
caspase inhibitor Z-VAD-FMK was used in conjunction with 1 µM JCTH-4 on 
BxPC-3 cells for 72 hours. As seen using the WST-1 colorimetric assay for cell 
viability, the inhibitor was unable to protect the BxPC-3 cells from JCTH-4, 
demonstrating a caspase-independent mode of action (Figure 5).  
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Figure 5: Activity of JCTH-4 is Independent of Caspase Activation. Effect of 
broad spectrum caspase inhibition on JCTH-4-induced cytotoxicity in pancreatic 
cancer cells. BxPC-3 cells were treated with Z-VAD-FMK, a broad spectrum 
caspase inhibitor, at the indicated concentrations with and without the presence 
of 1μM JCTH-4 treatment for 72 hours and the WST-1 reagent was used to 
quantify cell viability. Absorbance was read at 450 nm and expressed as a 
percent of solvent control (Me2SO). Values are expressed as mean ± SD from 
quadruplicates of 3 independent experiments. *p<0.001 versus solvent control 
(Me2SO); ns = not significant.  
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Selective Autophagic Induction Occurs in Pancreatic Carcinoma Cells Treated 
with JCTH-4 
Both pro-death and pro-survival autophagic responses have been 
implicated following chemotherapeutic insult [4]. As JCTH-4 causes oxidative 
stress in pancreatic cancer cells, a known inducer of autophagy, we monitored 
pancreatic cancer cells for autophagic induction. PANC-1 cells were treated with 
TAM, a known inducer of autophagy as a positive control, and JCTH-4 at 1 and 2 
µM for 72 hours and stained with MDC, an indicator of autophagosomes. Bright 
blue punctate MDC staining was present in cells treated with JCTH-4, 
comparable to the TAM treated cells (Figure 6A). PANC-1 cells were also 
stained with PI, but none of the aforementioned treatments yielded positive PI 
staining (Figure 6A). Interestingly, JCTH-4 did not induce autophagy in NFF cells 
as seen with MDC staining (Figure 6B). 
The conversion of microtubule-associated protein1 light chain 3 (LC3) 
localized in the cytosol as LC3-I, to LC3-II which is recruited to autophagosomal 
membranes occurs with the induction of autophagy [27]. To validate autophagic 
induction by JCTH-4 in PANC-1 cells, western blot analyses were performed on 
cell lysates of PANC-1 cells treated with 1 µM JCTH-4 for 72 hours to analyze 
the conversion of LC3-I to LC3-II; this conversion was observed with JCTH-4 
treatment and produced at greater autophagic response than the TAM treated 
cells used as a positive control (Figure 6C). Thus, JCTH-4 is capable of 
selectively inducing apoptosis in pancreatic cancer cells. 
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Figure 6: Selective Autophagic Induction Occurs in Pancreatic Carcinoma 
Cells Treated with JCTH-4. (A) PANC-1 and (B) NFF cells were stained with 
MDC after treatment with JCTH-4, TAM, or solvent control (Me2SO) at the 
indicated concentrations for 72 hours. Bright blue MDC punctate marks are 
indicative of autophagic vacuoles. Accompanying phase and propidium iodide-
stained images are shown below the MDC images. Scale bar = 15 µm. (C) 
Western Blot analysis were performed on lysates of PANC-1 cells treated with 
JCTH-4, TAM, and solvent control (Me2SO) at the indicated concentrations for 72 
hours to monitor the conversion of LC3-I to LC3-II, a marker of autophagy. β-
actin was probed as a loading control. Densitometric analyses were done using 
ImageJ software and statistics were calculated using GraphPad Prism version 
5.0. Values are expressed as mean ± SD. *p<0.01 versus solvent control 
(Me2SO); #p<0.01 versus 10 μM TAM. 
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Discussion 
Currently, pancreatic cancer stands as one of the most fatal malignancies 
in the world [9,10]. As this disease lacks distinct and evident symptoms, it is 
difficult to diagnose in its early stages. Thus, pancreatic cancer is often found in 
its advanced stages with most patients showing metastases to the liver, lungs, or 
proximal lymph nodes at the time of diagnosis [11,12]. Very few anti-cancer 
drugs are available for the treatment of this disease as most standard 
chemotherapeutics have been shown to be ineffective; doxorubicin, 5-5-
fluorouracil, and cisplatin have been shown to be ineffective both in vitro and in 
vivo [28]. The nucleoside analogue gemcitabine has been shown to be 
moderately effective and currently serves as the standard chemotherapeutic 
treatment for pancreatic cancer [29]. Despite various efforts to enhance the 
effectiveness of this drug with other chemotherapeutics such as erlotinib, 
gemcitabine still remains only moderately potent against pancreatic cancer and is 
often rendered ineffective with the onset of chemoresistance [30,29]. 
Consequently, the necessity for a more potent treatment presently remains 
unfulfilled. 
In this study, we report the activity of a synthetic analogue of PST, JCTH-
4, against human pancreatic cancer cells. JCTH-4 was able to effectively induce 
cytotoxicity in the BxPC-3 and PANC-1 pancreatic cancer cells by way of 
apoptotic induction in a selective manner. Necrotic cell death, characterized by 
lysis of the plasma membrane, by JCTH-4 was ruled out as cells subjected to 
JCTH-4 were negative for PI staining, a DNA stain impermeable to the plasma 
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membrane (Figure 6A) [31]. Most importantly, we report JCTH-4 to be more 
effective against BxPC-3 and PANC-1 cells than gemcitabine by comparison to 
other studies also utilizing colorimetric tetrazolium salt-based assays for cell 
viability [29]. Although gemcitabine has been previously shown to be effective in 
BxPC-3 cells at submicromolar concentrations, other studies have shown the 
effectiveness of this drug to quickly plateau as the dose is increased [29]. 
Consequently, such reports show only a decrease in cell viability to a range 
between 30% and 40% of the control after 72 hours of treatment with 1 µM 
gemcitabine in BxPC-3 cells [29]. However, we show 1 µM JCTH-4 to be more 
potent after 72 hours in BxPC-3 cells, decreasing cell viability to approximately 
13% of the control (Figure 2A). Furthermore, other work has shown minimal 
sensitivity to gemcitabine by PANC-1 cells; gemcitabine was reported to have an 
IC50 value of 25 µM after 72 hours of treatment [29]. In contrast, JCTH-4 was 
more effective in inducing cytotoxicity in PANC-1 cells and had an IC50 value of 
0.5 µM after 72 hours (Figure 2B). Similar to PST, JCTH-4 is selective against 
cancer cells, showing minimal toxicity in normal human fibroblasts, non-
cancerous peripheral blood mononuclear cells, and NFF cells; NFF cells proved 
to be markedly less sensitive to JCTH-4 compared to both BxPC-3 and PANC-1 
cells (Figure 2C), did not exhibit any observable signs of apoptotic induction 
(Figure 3F), and were not affected in terms of their dividing capacity after 
removal of JCTH-4 (Data not shown) [23]. On the contrary, other 
chemotherapeutics currently available such as Taxol and VP-16 have been 
shown to produce cytotoxicity in normal human fibroblasts at their effective doses 
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[17]. Thus, these findings illustrate JCTH-4 to be a potentially more effective 
chemotherapeutic alternative to current cancer therapies. 
 Previously, we have shown the natural compound PST to be a potent and 
selective anti-cancer agent; PST was able to induce apoptosis in numerous 
cancer cell types with minimal cytotoxicity in non-cancerous cells [16-20]. 
Furthermore, PST was able to decrease the volume of human tumor xenografts 
in vivo and was non-toxic to mice [21,22]. PST however, is only present in parts 
per million quantities in the buds of the Hymenocallis littoralis plant and many 
difficulties have burdened its chemical synthesis. In an attempt to circumvent 
these issues, we subsequently synthesized various analogues of PST and found 
similar anti-cancer activity with JCTH-4 in human neuroblastoma and leukemia 
cell lines, with no evident toxicity to various non-cancerous cell types [23]. The 
findings presented in this study demonstrate JCTH-4 to also be a potent agent 
against BxPC-3 and PANC-1 cells, two different cell lines of a very aggressive 
and deadly cancer. Thus, previous limitations hindering the preclinical and 
clinical work with PST have been surpassed.  
 As with PST, our results indicate the mechanistic target of JCTH-4 is likely 
to be the mitochondria; JCTH-4 was shown to dissipate MMP (Figure 4A & B), 
cause the release of apoptogenic factors from the mitochondria (Figure 4D & E), 
and in isolated mitochondria, increase ROS production (Figure 4G). Such 
mitochondrial targeting was not evident in NFF cells (Figure 4C), complementing 
previous work with PST; mitochondrial ROS production selectively increased in 
isolated mitochondria of cancer cells but not in normal human fibroblast 
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mitochondria with PST treatment [17]. In response to various forms of cellular 
stress, the tumor suppressor p53 transcriptionally activates various proapoptotic 
proteins that can give rise to mitochondrial membrane permeabilization [32]. 
Although moderately differing in sensitivities, both BxPC-3 and PANC-1, two 
different p53-mutated pancreatic cancer cell lines, were responsive to JCTH-4 
[33,34]. Thus, signalling of p53 and its transcriptional targets, all of which are 
cellular events upstream of mitochondrial permeabilization, play an insignificant 
role in JCTH-4-induced apoptosis, supporting the notion of a direct mitochondrial 
target by JCTH-4. The caspase-independent nature of JCTH-4-induced 
apoptosis (Figure 5)  further supports mitochondrial targeting by JCTH-4 as 
caspase signalling can occur upstream of the mitochondria to permeabilize it. 
Although caspases are required for the execution apoptosis through Cyto c, 
JCTH-4 may yield apoptosis through the release of other apoptogenic factors 
such as AIF and EndoG which can directly execute apoptosis in a caspase-
independent manner [2,25,26,3]. 
 Various differences exist between normal and cancer cell mitochondria 
which may serve as the basis by which JCTH-4 targets cancer cells specifically. 
The Warburg effect, a phenomenon in which cancer cells rely heavily on 
glycolysis for ATP generation, is postulated to be a result of mitochondrial 
dysfunction [35]. It is therefore possible for JCTH-4 to target these differences in 
metabolism. Moreover, an acidic cytosolic environment is created as result these 
alterations in metabolic activity which in part contributes to elevated MMP in 
cancer cell mitochondria.  Heightened MMP in cancer cell mitochondria has been 
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linked to an increased capacity to evade apoptosis, invade neighbouring tissue, 
and promote angiogenesis [36]. It is this elevation in MMP however, that may be 
exploited by JCTH-4 for cancer selectivity. Upon entering the cell, JCTH-4 may 
acquire as positive charge through enzymatic processing which may then be 
preferentially taken up selectively by cancer cell mitochondria as a result of their 
increased MMP.  Additionally, cancer cells have been reported to overexpress 
various proteins which act to inhibit mitochondrial outer membrane 
permeabilization such as antiapoptotic proteins of the Bcl-2 family and 
hexokinase II [37-39]. All of these proteins could serve as potential targets of 
JCTH-4.  
 Cellular stress, such as oxidative stress, can trigger the induction of 
autophagy. As JCTH-4 was found to increase the production of ROS in isolated 
mitochondria of pancreatic cancer cells (Figure 4G), we monitored PANC-1 for 
autophagic induction following JCTH-4 insult. Indeed, autophagy was induced 
selectively in pancreatic cancer cells by JCTH-4 (Figure 6A-C). Increased ROS 
production triggered by JCTH-4-induced mitochondrial dysfunction is most likely 
responsible for selective autophagic induction in these pancreatic cancer cells, 
which provides additional evidence of a mitochondrial target by JCTH-4. 
Nevertheless, these cells ultimately die as a result of mitochondrial membrane 
permeabilization and the subsequent release of apoptogenic factors. 
In summary, the novel analogue of PST, JCTH-4, is effective in inducing 
apoptosis and autophagy selectively in pancreatic cancer cells by means of 
mitochondrial targeting. Furthermore, this compound was shown to be very 
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effective against one of the most aggressive and notoriously chemoresistant 
malignancies, surpassing its current standard chemotherapeutic agent in 
efficacy. Thus, the unprecedented activity of this compound presents a 
potentially safe and effective treatment for pancreatic cancer. 
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Summary 
 Breast cancer is one of the most common cancers amongst women in 
North America. Many current anti-cancer treatments, including ionizing radiation, 
induce apoptosis via DNA damage. Unfortunately, such treatments are 
unselective and produce similar effects in normal cells. We have reported 
selective induction of apoptosis in cancer cells by the natural compound 
pancratistatin (PST). Recently, a novel PST analogue, a C-1 acetoxymethyl 
derivative of 7-deoxypancratistatin (JCTH-4), was produced by de novo synthesis 
and exhibits comparable selective apoptosis inducing activity in several cancer 
cell lines. Recently, autophagy has been implicated in malignancies as both pro-
survival and pro-death mechanisms in response to chemotherapy. Tamoxifen 
(TAM) has invariably demonstrated induction of pro-survival autophagy in 
numerous cancers. In this study, the efficacy of JCTH-4 alone and in combination 
with TAM to induce cell death in human breast cancer (MCF7) and 
neuroblastoma (SH-SY5Y) cells was evaluated. TAM alone induced autophagy, 
but insignificant cell death whereas JCTH-4 alone caused significant induction of 
apoptosis with some induction of autophagy. Interestingly, the combinatory 
treatment yielded a drastic increase in apoptotic and autophagic induction. We 
monitored time-dependent morphological changes in MCF7 cells undergoing 
TAM-induced autophagy, JCTH-4-induced apoptosis and autophagy, and 
accelerated cell death with combinatorial treatment using time-lapse microscopy. 
We have demonstrated these compounds to induce apoptosis/autophagy by 
mitochondrial targeting in these cancer cells. Importantly, these treatments did 
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not affect the survival of noncancerous human fibroblasts. Thus, these results 
indicate that JCTH-4 in combination with TAM could be used as a safe and very 
potent anti-cancer therapy against breast cancer and neuroblastoma cells. 
 
Short Abstract  
 We have synthesized a novel synthetic analogue of pancratistatin with 
comparable anti-cancer activity; interestingly, combinatory treatment with 
tamoxifen yielded a drastic enhancement in apoptotic and autophagic induction 
by mitochondrial targeting with minimal effect on noncancerous fibroblasts. Thus, 
JCTH-4 in combination with tamoxifen could be used as a safe anti-cancer 
therapy. 
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Introduction 
 Apoptosis, or type I programmed cell death, is a physiological process that 
can operate extrinsically, via binding of a death ligand to a death receptor, or 
intrinsically. The intrinsic pathway of apoptosis is initiated by intracellular stress 
such as DNA damage and mitochondrial dysfunction; this ultimately leads to the 
permeabilization of the mitochondria, dissipation of mitochondrial membrane 
potential (MMP), release of apoptogenic factors from the mitochondrial 
intermembrane space, and subsequent execution of apoptosis1. 
 Autophagy is a process in which a cell breaks, degrades, and recycles its 
own intracellular components while maintaining plasma membrane integrity; it is 
triggered by different types of cellular stresses including oxidative stress, 
hypoxia, protein aggregates, nutrient deprivation, growth factor deprivation, and 
damaged organelles2. In the initial stages of this process, cytosolic material is 
engulfed by autophagosomes, double-membraned vesicles, which fuse to 
lysosomes to form autolysosomes. Post lysosomal fusion, cytosolic materials 
previously taken up by autophagosomes are degraded by lysosomal enzymes2.  
Extensive activation of this pathway yields extensive degradation of intracellular 
components which may lead to autophagic cell death or type II programmed cell 
death3. 
Evasion of cell death has been considered one of the hallmarks of 
cancer4. Cancer is a disease characterized by uncontrolled cell growth and 
proliferation5. In particular, neuroblastoma arises from developing nerve cells of 
the sympathetic nervous system from the neural crest6. It is the most common 
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solid tumor occurring in young children, accounting for approximately 9% of all 
childhood cancers7. Although much progress has been made to date, this 
disease remains problematic to both basic scientists and clinicians. On the other 
hand, breast cancer is the most common cancer amongst females8. Tamoxifen 
(TAM) has been frequently used for therapy in hormone–responsive breast 
cancers as an estrogen receptor (ER) antagonist9. Nonetheless, other reports 
provide evidence of additional independent mechanisms of apoptosis induction 
by TAM. In particular, TAM interacts with Complex I of the mitochondrial 
respiratory chain (MRC) at its flavin mononucleotide (FMN) site10.  
PST is a natural compound isolated from the Hymenocallis littoralis plant. 
Contrasting from many chemotherapeutics currently in use, it has been shown to 
induce apoptosis, in a non-genotoxic manner, selectively in various cancer cell 
types via mitochondrial targeting11-15. However, preclinical and clinical work has 
been hindered by its availability; it is present at very low amounts in its natural 
source and many complications burden its chemical synthesis. We have 
synthesized and screened synthetic analogues of 7-deoxypancratistatin and 
observed similar anti-cancer activity in a C-1 acetoxymethyl derivative, JC-TH-
acetate-4 (JCTH-4)16. We now have in hand a synthetic PST analogue with 
potent anti-cancer activity. Its synthesis has been standardized and can be 
scaled up to produce sufficient quantities for preclinical and clinical work. Since 
natural PST and TAM both target the mitochondria, it would be interesting to 
investigate the combined effect of a synthetic analogue of PST on human breast 
cancer and neuroblastoma cells in combination with TAM. 
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Herein, we report selective cytotoxicity of JCTH-4 in human 
neuroblastoma (SH-SY5Y) and breast adenocarcinoma (MCF7) cells. JCTH-4 
was able to induce apoptosis in both cell lines by mitochondrial targeting; JCTH-4 
caused dissipation of MMP and an increase in reactive oxygen species (ROS) 
production in isolated mitochondria from these cancer cells. Furthermore, 
autophagy was induced by JCTH-4 in MCF7 cells. Interestingly, the addition of 
TAM to JCTH-4 insult enhanced the aforementioned effects of JCTH-4 in SH-
SY5Y and MCF7 cells. Morphological changes induced by JCTH-4 and TAM 
alone and in combination in MCF7 cells were monitored via time-lapse 
microscopy of phase contrast or bright field pictures. Normal human fetal 
fibroblasts (NFF) exhibited a marked decrease in sensitivity to JCTH-4 both 
alone and in combination with TAM. Therefore, these observations suggest 
JCTH-4, alone and in with TAM, to be a safe and effect chemotherapeutic agent 
against breast cancer and neuroblastoma. 
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Materials and Methods 
1) Cell Culture 
1.1) Grow and culture SH-SY5Y human neuroblastoma cells (ATCC, Cat. No. 
CRL-2266, Manassas, VA, USA) with Dulbecco’s Modified Eagles Medium F-12 
HAM (Sigma-Aldrich, Mississauga, ON, Canada) supplemented with 2 mM L-
glutamine, 10 % fetal bovine serum (FBS) and 10 mg/ml gentamicin (Gibco BRL, 
VWR, Mississauga, ON, Canada). Maintain cells at 37˚ C and 5 % CO2. 
 
1.2) Grow and culture MCF7 human breast adenocarcinoma cells (ATCC, Cat. 
No. HTB-22, Manassas, VA, USA) in RPMI-1640 medium (Sigma-Aldrich 
Canada, Mississauga, ON, Canada) supplemented with 10% FBS standard 
(Thermo Scientific, Waltham, MA) and 10 mg/mL gentamicin (Gibco BRL, VWR, 
Mississauga, ON, Canada). Maintain cells at 37˚ C and 5 % CO2. 
 
1.3) Grow and culture the apparently normal human fetal fibroblast (NFF) cell line 
(Coriell Institute for Medical Research, Cat. No. AG04431B, Camden, NJ, USA) 
in Dulbecco’s Modified Eagle’s Medium, High Glucose (Thermo Scientific, 
Waltham, MA, USA) supplemented with 15 % FBS and 10 mg/mL gentamicin 
(Gibco BRL, VWR, Mississauga, ON, Canada). Maintain cells at 37˚ C and 5 % 
CO2.  
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2) Drug Preparation 
2.1) Weigh out tamoxifen (TAM) citrate salt (Sigma-Aldrich, Cat. No. T9262, 
Mississauga, ON, Canada) and dissolve it in DMSO to prepare a 10 mM stock 
solution. Store stock solution at -20˚ C until use. All vehicle controls used in this 
study contained DMSO at less than 0.5%.  
 
2.2) Repeat step 2.1 to prepare a 1 mM stock solution dissolved in DMSO of JC-
TH-acetate-4 (JCTH-4), produced by chemoenzymatic synthesis from 
bromobenzene as previously described16. Store stock solution at -20˚ C until use. 
All vehicle controls used in this study contained DMSO at less than 0.5%.  
 
3) Time-Lapse Microscopy 
3.1) Plate approximately 2.0 x 105 MCF7 cells in 35 mm glass bottom culture 
dishes (MatTek Corporation, Cat. No. P35G-014-C, Ashland, MA, USA) in sterile 
conditions of a class II biosafety cabinet and allow them to grow at 37˚ C and 5 % 
CO2. 
 
3.2) When cells reach 60 to 70 % confluence, treat them with 1 µM JCTH-4 using 
a 1 mM stock solution dissolved in DMSO and 10 µM TAM using a 10 mM stock 
solution dissolved in DMSO, alone and in combination in a class II biosafety 
cabinet. 
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3.3) After treatment of cells for 48 hours, place cells in a heated chamber at 37˚ 
C with 5 % CO2 on a stage of a Leica DMI6000 fluorescent microscope (Leica 
Microsystems, Wetzlar, Germany).  
 
3.4) Using LAS AF6000 software, set the microscope to take phase contrast or 
bright field micrographs at 400x magnification every 5 minutes for 18 hours. 
 
4) Nuclear Staining 
4.1) Plate approximately 2.0 x 105 MCF7 or SH-SY5Y cells in each well of a 6 
well clear bottom tissue culture plate in a class II biosafety cabinet and allow 
them to grow at 37˚ C and 5 % CO2. 
 
4.2) When cells reach 60 to 70 % confluence, treat them with 1 µM JCTH-4 using 
a 1 mM stock solution dissolved in DMSO and 10 µM TAM using a 10 mM stock 
solution dissolved in DMSO, both alone and in combination in a class II biosafety 
cabinet.  
 
4.3) Incubate cells with the aforementioned treatments at 37˚ C and 5 % CO2 for 
48 hours (SH-SY5Y cells) or 72 hours (MCF7 cells). After treatment and 
incubation of cells with drugs, directly add Hoechst 33342 dye (Molecular 
Probes, Eugene, OR, USA) to the media of the treated cells to a final 
concentration of 10 µM to stain the nuclei. 
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4.4) Incubate the cells with the Hoechst dye for 5 to 10 minutes protected from 
light. 
 
4.5) Place the plate on the stage of a Leica DM IRB inverted fluorescence 
microscope (Leica Microsystems, Wetzlar, Germany). 
 
4.6) Take fluorescent and phase micrographs at 400x magnification. 
 
5) Annexin V Binding Assay 
5.1) Plate approximately 5.0 x 105 MCF7, SH-SY5Y, or NFF cells in 10 mL tissue 
culture plates in a class II biosafety cabinet and allow them to grow at 37˚ C and 
5 % CO2. 
 
5.2) When cells reach 60 to 70 % confluence, treat them with 1 µM JCTH-4 using 
a 1 mM stock solution dissolved in DMSO and 10 µM TAM using a 10 mM stock 
solution dissolved in DMSO, both alone and in combination in a class II biosafety 
cabinet.  
 
5.3) Incubate cells with the aforementioned treatments at 37˚ C and 5 % CO2 for 
48 hours (SH-SY5Y cells) or 72 hours (MCF7 and NFF cells).  
 
5.4) Prepare Annexin V binding buffer in ddH2O with 10 mM HEPES, 10 mM 
NaOH, 140 mM NaCl, and 1 mM CaCl2 at pH 7.6 and store at 4˚ C until use. 
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5.5) After treatment and incubation of cells with drugs, remove the media from 
the plates containing suspended cells and place it into a separate 15 mL conical 
tube for each different treatment group labelled with the proper treatment. 
 
5.6) Detach adherent cells from the plates using trypsin. 
 
5.7) After the cells lifted from the plate as a result of the trypsin, aspirate the 
media placed in the 15 mL conical tube in step 5.4 and place it back in their 
original plates with the trypsin suspended cells.  
 
5.8) With the electronic pipette filler and serological pipettes, mix the media with 
the trypsin cell solution and place this mixture back into the corresponding 15 mL 
conical tubes. 
 
5.9) Centrifuge the cells at 600 x g for 5 minutes at 4˚ C, remove the supernatant 
from each tube, and resuspend cells in PBS.  
 
5.10) Centrifuge the cells at 600 x g for 5 minutes, remove the supernatant from 
each tube, and resuspend cells in labelled microfuge tubes with about 50 to 70 
µL of Annexin V binding buffer.  
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5.11) Add Annexin V AlexaFluor-488 (1:50) (Sigma-Aldrich, Mississauga, ON, 
Canada) and Hoechst dye to a final concentration of 10 µM and incubate for 15 
minutes protected from light.  
 
5.12) Following incubation, vortex one of the microfuge tubes, add 7 to 10 µL of 
the cell mixture to a microscope slide, place a coverslip overtop of the cell 
mixture on the microscope slide and take fluorescent micrographs, both Annexin 
V and Hoechst images for each view, at 400x magnification on a Leica DM IRB 
inverted fluorescence microscope (Leica Microsystems, Wetzlar, Germany). 
Repeat for each experimental sample in each of the remaining microfuge tubes. 
 
6) Water Soluble Tetrazolium Salt (WST-1) Assay for Cell Viability 
6.1) Trypsinize a confluent T75 flask or 10 cm tissue culture dish of MCF7, SH-
SY5Y, or NFF cells in a class II biosafety cabinet. 
 
6.2) After the cells have been lifted, add 5 to 10 mL of media to the trypsin and 
place the media cell suspension in a 15 mL conical tube. 
 
6.3) Centrifuge the cells at 600 x g for 5 minutes, place the tube back into the 
biosafety cabinet, remove the supernatant from each tube, and resuspend the 
cells in about 1 to 3 mL of media depending on the cell pellet size. 
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6.4) Place 10 µL of the cell suspension in a microfuge tube, add 10 µL of Trypan 
Blue dye (Sigma-Aldrich, Mississauga, ON, Canada), and mix with a 
micropipette. 
 
6.5) Load 10 µL of Trypan Blue suspended cells on a haemocytometer (Hausser 
Scientific, USA), count the cells, and calculate the concentration of cells of the 
cell suspension in the original 15 mL conical tube. 
 
6.6) Use this concentration to determine the volume of original cell suspension 
needed to create diluted cell suspensions with concentrations of 1.5 x 105 
cells/mL for MCF7 and SH-SY5Y and 5.0 x 104 for NFF cells needed for plating.  
 
6.7) Use the diluted cell suspensions to plate 15 x 103 MCF7 or SH-SY5Y 
cells/well or 5.0 x 103 NFF cells/well by adding 100 µL of the diluted cell 
suspensions to each well of a 96 well clear bottom tissue culture plate. Incubate 
the cells at 37˚ C and 5 % CO2 overnight. 
 
6.8) Treat the cells with 1 µM JCTH-4 and 10 µM TAM both alone and in 
combination in a class II biosafety cabinet for 72 hours for MCF7 and NFF cells, 
and for 48 hours for SH-SY5Y cells.  
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6.9) After treatment and incubation of drugs, add 10 µL of WST-1 reagent (Roche 
Applied Science, Indianapolis, IN, USA) to each well and incubate the plate for 4 
hours at 37˚ C and 5 % CO2. Take absorbance readings at 450 nm on a Wallac 
Victor3 TM 1420 Multilabel Counter (PerkinElmer, Woodbridge, ON, Canada) and 
express them as percentages of the solvent control groups. 
 
7) Tetramethylrhodamine Methyl Ester (TMRM) Staining 
7.1) Place a coverslip into each well of a 6 well clear bottom tissue culture plate 
and plate MCF7 cells in each well of a 6 well tissue culture plate in a class II 
biosafety cabinet. Allow them to grow at 37˚ C and 5 % CO2. 
 
7.2) When cells reach 60 to 70 % confluence, treat them with 1 µM JCTH-4 using 
a 1 mM stock solution dissolved in DMSO and 10 µM TAM using a 10 mM stock 
solution dissolved in DMSO, both alone and in combination in a class II biosafety 
cabinet.  
 
7.3) Incubate cells with the aforementioned treatments at 37˚ C and 5 % CO2 for 
72 hours.  
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7.4) After treatment and incubation of cells with drugs, directly add Hoechst 
33342 dye (Molecular Probes, Eugene, OR, USA) to the media of the treated 
cells to a final concentration of 10 µM to stain the nuclei as well as 
tetramethylrhodamine methyl ester (TMRM) (Gibco BRL, VWR, Mississauga, 
ON, Canada) at a final concentration of 200 nM. 
 
7.5) Incubate the cells with the dyes at 5 % CO2 and 37˚ C for 45 minutes 
protected from light. 
 
7.6) Pipette 8 µL of media or PBS onto a microscope slide and take a coverslip 
from the 6 well plate and place it on top of the media or PBS on the microscope 
slide with the cells facing downwards with tweezers.  
 
7.7) Take fluorescent micrographs, both Hoechst and TMRM micrographs for 
each view, with a Leica DM IRB inverted fluorescence microscope (Leica 
Microsystems, Wetzlar, Germany) at 400x magnification. 
 
8) Mitochondrial Isolation  
8.1) Prepare about 10 mL of hypotonic buffer (1 mM EDTA, 5 mM Tris–HCl, 210 
mM mannitol, 70 mM sucrose, 10 μM Leu-pep, 10 μM Pep-A, and 100 μM 
PMSF) and reaction buffer and keep both solutions on ice. 
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8.2) With about 8 to 10 confluent T75 tissue culture flasks of SH-SY5Y cells, 
trypsinize the cells, add media to neutralize the trypsin, collect the cell 
suspensions  in 50 mL conical tubes, and centrifuge the tubes at 600 x g for 5 
minutes at 4˚ C. 
 
8.3) Remove the supernatant and resuspend cell pellets in about 10 to 20 mL of 
cold PBS, centrifuge the tubes at 600 x g for 5 minutes at 4˚ C, and repeat this 
wash process once. 
 
8.4) Remove the supernatant and resuspend the cells in cold hypotonic buffer. 
Homogenize cells manually with a glass tissue grinder and centrifuge the cell 
lysate at 600 x g for 5 minutes at 4˚ C.  
 
8.5) Centrifuge the resultant supernatant at 15,000 x g for 15 minutes at 4˚ C. 
Remove the cytosolic supernatant and resuspend the mitochondrial pellet in cold 
reaction buffer. 
 
9) Amplex Red Assay 
9.1) After isolating mitochondria from cells, estimate the concentration of protein 
of the sample of isolated mitochondria using a standard curve of known 
concentrations of 1mg/mL BSA (Bovine Serum Albumin) with the BioRad protein 
assay (Bio-Rad Laboratories, Hercules, CA USA). 
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9.2) Using the estimated concentration of protein of the isolated mitochondria 
solution, calculate the volume of this solution to give 20 µg of protein. Pipette this 
volume into each well of an opaque 96-well plate to load 20 µg of protein/well. 
 
9.3) Fill each well in the plate to a total volume of 100 µL with reaction buffer, 
drug treatment (with a final concentration of 1 µM JCTH-4, and/or 10 µM TAM, or 
250 µM PQ (Sigma-Aldrich, Mississauga, ON, Canada) used as a positive 
control), Amplex Red reagent at a final concentration of 50 µM, and horseradish 
peroxidase (HRP) (Sigma-Aldrich, Mississauga, ON, Canada) in the ratio of 6 
U/200 µL.   
 
9.4) After a 2 hour incubation, take fluorescence readings at Ex. 560 nm and Em. 
590 nm on a spectrofluorometer (SpectraMax Gemini XPS, Molecular Devices, 
Sunnyvale, CA, USA).  
 
10) Cellular Lysate Preparation 
10.1) Grow MCF7 cells to 60 to 70 % confluence in 10 cm tissue culture plates. 
 
10.2)  Treat cells with 1 µM JCTH-4 and 10 µM TAM alone and in combination 
for 72 hours with about 10 to 15 plates per treatment group.  
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10.3) Prepare cell lysis buffer (10 mM Tris HCl at pH 7.2, 5 mM KCl, 1 mM 
MgCl2, 1 mM EGTA, 1% Triton-X-100; 10 μM Leu-pep, 10 μM Pep-A, and 100 
μM PMSF) and store at 4˚ C until use. 
 
10.4) Mechanically dislodge cells from the plate surfaces with a cell scraper and 
collect cells in labelled 50 mL conical tubes.  
 
10.5) Centrifuge the tubes at 600 x g for 5 minutes at 4˚ C, remove the 
supernatant and resuspend cell pellets in about 10 to 20 mL of cold PBS, 
centrifuge the tubes at 600 x g for 5 minutes at 4˚ C, and repeat this wash 
process once. 
 
10.6) Remove the supernatant and resuspend the cells in cold cell lysis buffer. 
Homogenize cells manually with a glass tissue grinder and centrifuge the cell 
lysate at 600 x g for 5 minutes at 4˚ C.  
 
10.7) Discard the pellets and store the cell lysates at -20˚ C until use. 
 
11) Western Blot Analyses 
11.1) Determine the protein concentration of cell lysates using the BioRad protein 
assay (Bio-Rad Laboratories, Hercules, CA USA). Subject the protein samples to 
SDS-PAGE and transfer protein to a nitrocellulose membrane. 
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11.2) After transfer, block membranes with a 5% w/v milk TBST (Tris-Buffered 
Saline Tween-20) solution for 1 hour.  
 
11.3) Probe membranes with an anti-LC3 antibody raised in rabbit (1:500) 
(Novus Biologicals, Cat. No. NB100-2220, Littleton, CO, USA), or an anti-β-Actin 
antibody raised in mouse (1:1000) (Santa Cruz Biotechnology, Inc., Cat. No. sc-
81178, Paso Robles, CA, USA) overnight at 4˚ C.  
 
11.4) Subject membranes to one 15 minute and two 5 minute washes in TBST 
and incubate with an anti-mouse (1:2000) or an anti-rabbit (1:2000) horseradish 
peroxidase-conjugated secondary antibody (Abcam, Cat. No. ab6728 & ab6802, 
Cambridge, MA, USA) for 1 hour at at 4˚ C.  
 
11.5) Subject membranes to three consecutive 5 minute washes in TBST and 
visualize protein bands with enhanced chemiluminescence reagent (Sigma-
Aldrich, CPS160, Mississauga, ON, Canada).  
 
11.6) Performed densitometry analyses using ImageJ software. 
 
12) Monodansylcadaverine (MDC) Staining 
12.1) Place a coverslip into each well of a 6 well clear bottom tissue culture plate 
and plate MCF7 cells in each well of a 6 well clear bottom tissue culture plate in a 
class II biosafety cabinet. Allow them to grow at 37˚ C and 5 % CO2. 
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12.2) When cells reach 60 to 70 % confluence, treat them with 1 µM JCTH-4 
using a 1 mM stock solution dissolved in DMSO and 10 µM TAM using a 10 mM 
stock solution dissolved in DMSO, both alone and in combination in a class II 
biosafety cabinet.  
 
12.3) Incubate cells with the aforementioned treatments at 37˚ C and 5 % CO2 
for 72 hours.  
 
12.4) After treatment and incubation of cells with drugs, directly add 
Monodansylcadaverine (MDC) (Sigma-Aldrich, Mississauga, ON, Canada) to a 
final concentration of 0.1 mM to each well for 15 min.  
 
12.5) Incubate the cells with the dye at 5 % CO2 and 37˚ C for 15 minutes 
protected from light. 
 
12.6) Pipette 30 µL of media or PBS onto a microscope slide and take a coverslip 
from the 6 well plate and place it on top of the media or PBS on the microscope 
slide with the cells facing downwards with tweezers.  
 
12.7) Take fluorescent MDC and phase micrographs, for each view, with a Leica 
DM IRB inverted fluorescence microscope (Leica Microsystems, Wetzlar, 
Germany) at 400x magnification.  
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Results 
Please refer to the Journal of Visualized Experiments for videos: 
Ma et al. 2012. J Vis Exp. 30;(63). pii: 3586. doi: 10.3791/3586 
 
Selective Induction of Apoptosis in Human Breast Adenocarcinoma and 
Neuroblastoma Cells by JCTH-4: Enhancement of Activity by TAM  
Selective induction of apoptosis was shown in various cancer cells by 
natural PST (Fig. 1a)11-13. Because of the low availability of PST, we have 
synthesized analogues of 7-deoxypancratistatin (JCTH-4) (Fig. 1b) and screened 
them for similar anti-cancer activity in human breast adenocarcinoma (MCF7) 
and neuroblastoma cells (SH-SY5Y). In the first phase of experiments, we 
wanted to monitor morphological changes over time following treatment with 
JCTH-4 and TAM alone and in combination in MCF7 cells. MCF7 cells were 
monitored for 18 hours, as seen in Video 1 produced by time-lapse microscopy 
with phase contrast pictures, with solvent treatment (control) for 48 hours; these 
cells exhibited no major changes in morphology. In contrast, after 48 hours of 1 
µM JCTH-4 treatment, these cells exhibited morphological changes associated 
with apoptosis such as shrinkage, blebbing, apoptotic body formation as seen in 
Video 2. On the other hand, TAM treatment alone in MCF7 cells produced a very 
distinct morphology including punctate inclusions indicative of autophagosomes 
associated with autophagy (Video 3). Very minimal apoptotic morphology was 
observed and cells generally exhibited healthy morphology comparable to the 
solvent control treated MCF7 cells. Interestingly, in the presence of TAM, the 
apoptotic induction by JCTH-4 was drastically enhanced as indicated by 
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increased apoptotic morphology in MCF7 cells after 48 hours as illustrated in 
Video 4.  
In the second phase of experiments we utilized fluorescent dyes to 
evaluate the induction of apoptosis. After 72 hours and 48 hours of 1 µM JCTH-4 
treatment in MCF7 and SH-SY5Y cells respectively, Hoechst dye was used and 
to monitor nuclear morphology. Results indicated condensed, brightly stained 
nuclei accompanied by apoptotic bodies in MCF7 and SH-SY5Y cells, indicative 
of apoptotic induction (Fig. 2a,b). TAM treatment alone yielded minimal apoptotic 
nuclear morphology in MCF7 and SH-SY5Y cells; nuclei were large, round, and 
dimly stained with Hoechst comparable to solvent control group (Fig. 2a,b). In 
agreement with Video 4, nuclei of MCF7 and SH-SY5Y cells displayed a marked 
increase in apoptotic morphology with the combination treatment after 72 hours 
(Fig. 2a,b).  
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Figure 1. Structural comparison of PST to a synthetic 7-deoxy analogue. (a) 
Chemical structure of pancratistatin (PST). (b) Chemical structure of JC-TH-
acetate-4 (JCTH-4). 
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Figure 2. JCTH-4 induces nuclear apoptotic morphology with enhanced 
activity with TAM. Nuclear morphology of (a) MCF7 and (b) SH-SY5Y cells 
treated for 72 and 48 hours respectively with the indicated concentrations of TAM 
and JCTH-4 stained with Hoechst dye. Control groups were treated with solvent 
(DMSO). Images were taken at 400x magnification on a fluorescent microscope. 
Scale bar= 15 µm.  
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 To verify apoptotic induction, cells were evaluated for phosphatidylserine 
externalization, a marker for apoptosis, via an Annexin V binding assay17. MCF7 
and SH-SY5Y cells treated for 72 and 48 hours respectively with 1 µM JCTH-4 
alone and in combination with 10 µM TAM were positive for Annexin V binding, 
indicated by the green fluorescence, confirming the  induction of apoptosis (Fig 
3a,b). No evident externalization of phosphatidylserine was observed in MCF7 
and SH-SY5Y cells treated with TAM alone, as well as in NFF cells treated with 
all the aforementioned treatments groups after 72 hours (Fig. 3c). Therefore, 
JCTH-4 alone and in combination with TAM selectively induces apoptosis in 
MCF7 and SH-SY5Y cells. 
 To quantify the effect of JCTH-4 alone and in combination with TAM, a 
WST-1 based colorimetric assay for cell viability, an indicator of active cell 
metabolism, was performed on MCF7 and NFF cells treated for 72 hours and 
SH-SY5Y cells treated for 48 hours. Compared to the solvent control groups, 1 
µM JCTH-4 decreased active cell metabolism by over 50%, while 10 µM TAM 
alone exhibited no significant difference in both MCF7 and SH-SY5Y cells (Fig 
4a,b). Interestingly in MCF7 and SH-SY5Y cells, the addition of TAM to JCTH-4 
insult resulted in a synergistic decrease in cell metabolism. NFF cells were 
drastically less sensitive to both JCTH-4 alone and JCTH-4 with TAM (Fig. 4c). 
Hence, JCTH-4 demonstrates selective synergistic activity with TAM in MCF7 
and SH-SY5Y cells. 
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Figure 3. JCTH-4 causes phosphatidylserine externalization alone and in 
combination with TAM selectively in cancer cells. Annexin V binding to 
externalized phosphatidylserine was evaluated to verify induction of apoptosis 
induction in (a) MCF7 (72 hours), (b) SH-SY5Y (48 hours), and (c) NFF (72 
hours) cells treated with JCTH-4 and TAM at the indicated concentrations. 
Control groups were treated with solvent (DMSO). Images were taken at 400x 
magnification on a fluorescent microscope. Scale bar= 15 µm. 
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Figure 4. TAM enhances viability decrease by JCTH-4 selectively in cancer 
cells. 96-well plates were seeded with (a) MCF7, (b) SH-SY5Y, and (c) NFF 
cells and treated with JCTH-4 and TAM at the indicated concentrations. MCF7 
and NFF cells were treated for 72 hours and SH-SY5Y were treated for 48 hours. 
Post drug treatment and incubation, WST-1 reagent was added to each well, and 
absorbance readings were taken at 450 nm and expressed as a percentage of 
the control (DMSO). Statistics were performed using GraphPad Prism version 
5.0. Values are expressed as mean ± SD from quadruplicates of 3 independent 
experiments. MCF7: *p<0.001,**p<0.0001 versus control; #p<0.05 versus 1 µM 
JCTH-4; †p<0.0001 versus 10 µM TAM. SH-SY5Y: *p<0.0005 versus control; 
#p<0.005 versus 1 µM JCTH-4; †p<0.005 versus 10 µM TAM. NFF: *p<0.005 
versus 10 µM TAM + 1 µM JCTH-4 in MCF7 cells; #p<0.01 versus 10 µM TAM + 
1 µM JCTH-4 in SH-SY5Y cells. 
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Mitochondrial Targeting of JCTH-4  
To see if JCTH-4 is targeting the mitochondria to induce apoptosis 
mitochondrial membrane potential in whole cells and ROS generation in isolated 
mitochondria was monitored. MCF7 cells were treated for 72 hours and stained 
with TMRM. 1 µM JCTH-4 decreased MMP, indicated by the loss of red 
fluorescence (Fig 5a). However, with the addition of 10 µM TAM, a greater 
dissipation of MMP was observed, while 10 µM TAM alone had no evident effect 
on MMP.  
As increases ROS generation have been associated to mitochondrial 
membrane permeabilization and apoptosis induction, the production of ROS was 
assessed with Amplex Red dye in isolated mitochondria from SH-SY5Y cells 
treated with 1 µM JCTH-4 and 10 µM TAM, alone and in combination18-20. 
Fluorescence readings were expressed as relative fluorescence units (RFU).  
Increases in ROS generation were observed with JCTH-4 and TAM alone (Fig 
5b). Interestingly, combination treatment yielded a greater increase in ROS 
production. A well-known inducer of ROS production in mitochondria, PQ, was 
utilized as a positive control.  
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Figure 5. JCTH-4 and TAM act on the mitochondria. (a) MCF7 cells were 
grown on coverslips and treated with the indicated concentrations of drugs for 72 
hours and stained with TMRM to evaluate MMP. Cells of the control group were 
treated with solvent (DMSO).  Images were captured at 400x magnification on a 
fluorescence microscope. Scale bar= 15 µm. (b)  Isolated mitochondria from SH-
SY5Y cells were treated with JCTH-4 and TAM at the indicated concentrations 
and ROS production was assessed with Amplex Red substrate in presence of 
horseradish peroxidase (HRP). The control group cells were treated with solvent 
(DMSO). Paraquat (PQ) was used at a concentration of 250 µM as a positive 
control. Fluorescence readings were obtained after 2 hours of treatment at Ex. 
560 nm and Em. 590 nm and expressed as relative fluorescence units (RFU). 
Statistics were obtained using GraphPad Prism version 5.0. Data is 
representative of 3 independent experiments with similar trends. Values are 
expressed as mean ± SD of quadruplicates of 1 independent experiment. 
*p<0.05, **p<0.005, ***p<0.001 versus control; #p<0.05 versus 1 µM JCTH-4; 
†p<0.05 versus 10 µM TAM; @p<0.05 versus 250 µM PQ.  
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Induction of Autophagy by JCTH-4 and TAM 
Autophagic induction has been associated to chemotherapeutic insult by 
many different compounds3. To evaluate the induction of autophagy, MDC 
staining was performed on MCF7 cells treated with 1 µM JCTH-4 and 10 µM 
TAM alone and in combination for 72 hours. Blue punctate fluorescence, 
indicative of autophagosomes, was present in MCF7 cells treated with JCTH-4 
and TAM alone and in combination (Fig 6a). Notably, the intensity of MDC 
staining was greatest with the combination treatment, followed by TAM alone, 
and JCTH-4 alone.   
During autophagy, microtubule-associated protein 1 light chain 3 (LC3) 
normally situated in the cytosol (LC3-I), is lipidated with 
phosphatidylethanolamine and subsequently localized to the autophagosomal 
membranes (LC3-II)2. To verify the induction of autophagy, levels of LC3-II were 
assessed in MCF7 cells treated for 72 hours via western blot analyses. 1 µM 
JCTH-4 slightly induced the conversion of LC3-I to LC3-II while 10 µM TAM 
produced a greater autophagic response (Fig. 6b). Interestingly, combination 
treatment resulted in the greatest induction of autophagy, yielding a LC3-II to 
LC3-I ratio greater than 3. Therefore, these results demonstrate autophagic 
induction in MCF7 cells by JCTH-4 and TAM alone and in combination, with the 
greatest response in cells with the combination treatment. 
 
 
 
 347 
 
 
Figure 6. TAM enhances autophagic induction of JCTH-4. (a) MCF7 cells 
were grown on coverslips and subjected to JCTH-4 and TAM insult at the 
indicated concentrations for 72 hours. Control group cells were treated with 
solvent (DMSO). Post treatment, MCF7 cells were stained with MDC to detect 
autophagic vacuoles. Images were captured at 400x magnification on a 
fluorescence microscope. Scale bar= 15 µm. (b) Western blot analyses were 
carried out for LC3 and β-Actin on cell lysates of MCF7 cells treated with the 
indicated concentrations of drugs for 72 hours. Densitometric analyses were 
executed using ImageJ software. Statistics were performed using GraphPad 
Prism version 5.0. Values are expressed as mean ± SD. *p<0.05, **p<0.005, 
***p<0.0005 versus control; #p<0.001 versus 1 µM JCTH-4; †p<0.001 versus 10 
µM TAM.  
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Discussion 
PST and similar compounds have been shown to have anti-cancer 
properties11-15,21. We have previously reported natural PST to destabilize the 
mitochondria selectively in cancer cells, which thereby induces apoptosis by the 
release of apoptogenic factors12,14. It is most likely that JCTH-4 acts through the 
same mechanism; JCTH-4 caused MMP collapse in MCF7 cells as seen with 
TMRM staining (Fig. 5a), and increased generation of ROS in isolated 
mitochondria from SH-SY5Y cells (Fig. 5b), indicative of mitochondrial 
dysfunction. Thus, induction of apoptosis by JCTH-4 is most probably through 
mitochondrial targeting in cancer cells. 
Numerous differences exist between noncancerous and cancer cells 
which could serve as the basis for cancer selectivity by JCTH-4. Cancer cells are 
highly dependent on glycolysis and less on mitochondria for energy production; 
this phenomenon is referred to as the Warburg effect22. Such metabolic activity in 
the cancer cells leads to high acidity in the cytosol. Consequently, the acidic 
cytosolic environment contributes cancer cell mitochondria hyperpolarization 
which has been linked to an enhanced ability to invade and evade apoptosis23. 
Hyperpolariztion of cancer cell mitochondria however, may render cancer cells 
vulnerable to JCTH-4; once taken into the cell, JCTH-4 may acquire a positive 
charge through enzymatic processing and may selectively be taken up into 
cancer cell mitochondria due to their hyperpolarized nature. Moreover, an array 
of mitochondria associated antiapoptotic proteins have been shown to be highly 
expressed in cancer cells that prohibit mitochondrial membrane permeabilization 
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and subsequent execution of apoptosis such as antiapoptic proteins of the Bcl-2 
family of proteins24-26. 
In the presence of various forms of cellular stress, autophagy is triggered 
as a pro-survival response, allowing cells to survive under unfavourable 
conditions2.  Over stimulation of this pathway however, can lead to extensive 
breakdown of vital intracellular components giving rise to autophagic cell death3.  
Both the pro-survival and pro-death autophagic responses have been associated 
to chemotherapeutic insult3.  Mitochondrial dysfunction by JCTH-4 leading to 
oxidative stress could trigger an automatic default autophagic response. Indeed 
we did observe some autophagic induction along with apoptosis with JCTH-4 
treatment (Fig. 2a,b 3a,b 6a,b). Although TAM has been well established as an 
ER antagonist in ER positive breast cancer cells, it has been recently shown to 
interact with the mitochondria, binding to the FMN site of Complex I10. 
Furthermore, TAM is a well-known inducer of autophagy across many cancer cell 
types3. Indeed, TAM did cause an increase in ROS generation in isolated 
mitochondria (Fig. 5b). However, such interaction proved to be insufficient to 
cause MMP collapse (Fig. 5a), but sufficient to induce a typical pro-survival 
autophagic response.  Extensive autophagic induction was observed when 
JCTH-4 and TAM were used in combination (Fig. 6a,b), which was accompanied 
by an enhanced cytotoxic response (Fig. 4a,b), suggestive of a pro-death 
autophagic response; nonetheless, the cancer cells eventually die from apoptosis 
as a result of mitochondrial permeabilization and apoptogenic factor release. 
Such sensitization by TAM to JCTH-4 insult may be attributed to the increase in 
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ROS generation by TAM. Because both TAM and JCTH-4 are able to generate 
oxidative stress, the combinatorial production of such stress with both 
compounds may lead to extensive autophagic induction giving rise to a 
detrimental autophagic response and/or extensive mitochondrial permeabilization 
and subsequent apoptosis.  This combined treatment does not affect viability of 
noncancerous fibroblasts (Fig. 4c). These findings indicate that JCTH-4 alone 
and in combination with TAM can be used efficiently to treat breast cancer and 
neuroblastoma without causing adverse effects on noncancerous cells. 
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Video Legends 
 
Please refer to the Journal of Visualized Experiments for videos: 
Ma et al. 2012. J Vis Exp. 30;(63). pii: 3586. doi: 10.3791/3586 
 
Video 1. Cellular morphology of MCF7 cells treated with solvent control. 
MCF7 cells were monitored between 48 and 66 hours post solvent control 
treatment (DMSO) using time-lapse microscopy with phase contrast pictures.  
Cells were maintained at 37˚ C and 5% CO2. Images were captured at 400x 
magnification. 
 
Video 2. Induction of apoptotic cellular morphology in MCF7 cells treated 
with JCTH-4. MCF7 cells were monitored between 48 and 66 hours post 
treatment with 1 µM JCTH-4 using time-lapse microscopy with phase contrast 
pictures.  Cells were maintained at 37˚ C and 5% CO2. Images were captured at 
400x magnification. 
 
Video 3. Induction of autophagic cellular morphology in MCF7 cells treated 
with TAM. MCF7 cells were monitored between 48 and 66 hours post treatment 
with 10 µM TAM using time-lapse microscopy with phase contrast pictures.  Cells 
were maintained at 37˚ C and 5% CO2. Images were captured at 400x 
magnification. 
 
Video 4. Enhanced apoptotic morphology by JCTH-4 with TAM in MCF7 
cells. MCF7 cells were monitored between 48 and 66 hours post treatment with 
both 1 µM JCTH-4 and 10 µM TAM using time-lapse microscopy with phase 
contrast pictures.  Cells were maintained at 37˚ C and 5% CO2. Images were 
captured at 400x magnification. 
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  Graduate, University of Toronto, Toronto, ON, Canada 
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INTERNATIONAL PROJECTS & STUDIES 
 
May 2011 Golden Future South Africa Project: Khayelitsha, South Africa 
 Educated students in HIV and AIDS awareness, overall 
health and wellness, life skills, and educational 
paths/opportunities via classroom workshops in schools in 
the impoverished community of Khayelitsha, South Africa 
 
July 2008 “Contemporary Molecular Approaches to the Study of Human 
Breast Cancer” Research Workshop: The St. John's Research 
Institute, Bangalore, India  
 Shadowed and worked with medical doctors, molecular 
biologists, and pathogolists, learning state of the art 
techniques in primary culture and molecular biology as 
approaches used to studying human breast cancer using 
actual patient specimens 
 Aided in establishing a research collaboration between 
The St. John’s Research Institute, Bangalore, India and 
the University of Windsor, Windsor ON, Canada 
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COMMUNITY/UNIVERSITY OF WINDSOR INVOLVEMENT 
 
2011 University of Windsor Faculty of Science Council 
 Graduate Student representative for the Dept. of Chemistry 
and Biochemistry for the Faculty of Science Council 
responsible for program review and academic policies 
regarding programs in the sciences 
 
2008 – 2010 University of Windsor Science Society Vice President of   
  Academic Affairs 
 Mentored undergraduate science students in course 
selection  
 Provided guidance regarding professional and grad school 
applications 
 Coordinator of 4 professor meet and greet sessions 
attended by professors from the entire Faculty of Science 
and science undergraduate students 
 
2007 – 2009 Canadian Cystic Fibrosis Foundation – Shinerama (Windsor) 
 Raised funds supporting cystic fibrosis research 
 
2007  University of Windsor Students’ Alliance (UWSA) Board of  
  Directors 
 Represented over 12,000 students at the University of 
Windsor managing an organization and a 6.2 million 
budget, a staff of 150, and several business operations 
 
2006 – 2008 University of Windsor Walksafe Volunteer Program 
  responsible for walking people safely around campus at 
night 
 
2006 – 2008 Chemistry and Biochemistry Association 
  assisted in organizing student social events 
 helped organize and put on fundraisers to support the 
Children’s World Education Foundation, a non-profit 
organization financially supporting the education of 
children of widowed mothers 
 
1999 – 2006 Windsor Figure Skating Club 
 Can Skate Program  volunteer assistant teaching children 
from ages 3 to 14 how to ice skate and perform basic to 
intermediate skating skills 
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ATHLETIC ACCOMPLSIHMENTS  
 
Figure Skating 
 
2006 BMO Skate Canada Junior Nationals - 8th in Novice Pairs, Moncton, NB 
2005 BMO Skate Canada Junior Nationals- 4th in Pre-Novice Pairs, Ste. Foy, QC 
2004 BMO Financial Group Skate Canada Sectionals- 3rd in Novice Men 
2003 BMO Skate Canada Junior Nationals- 3rd in Juvenile Pairs, Brampton, ON 
 
Swimming and Running 
 
2002 WECSSAA Junior Boys Swimming- team finished 1st overall 
2001 SWOSSAA Midget Boys Cross Country- team finished 2nd in midget boys 
2001 OFSAA Midget Boys Cross Country- team finished 22nd  
 
 
